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Abstract          
 
Given the high genetic diversity of HIV, identifying genotypic signatures and phenotypic 
characteristics common to all transmitted founder (T/F) variants, irrespective of subtype, 
could aid the design of vaccine immunogens specific for these motifs. Recently, two putative 
T/F phenotypes were identified: 1) high affinity interactions between T/F glycoprotein (gp) 
120 and the α4β7 integrin that might facilitate the binding and infection of CD4+ T cells in 
the gut and 2) enrichment of oligomannose type N-glycans on the surface of T/F gp120 that 
may be involved in binding to the dendritic cell-specific intercellular adhesion molecule-3 
(ICAM-3)-grabbing non-integrin (DC-SIGN), a C-type lectin expressed on dendritic cells. DC-
SIGN could facilitate the transfer of HIV from dendritic cells in the genital mucosa to CD4+ T 
cells in the lymph nodes and thus play an important role in transmission. As T/F variants 
seem to have distinct N-glycosylation patterns compared with variants found later in 
infection, this study suggests that T/F variants may carry an optimum arrangement of N-
glycans that enables interactions with α4β7 and DC-SIGN that are essential for successful 
transmission in the genital tract. We aimed to investigate the role of α4β7 and DC-SIGN in 
HIV subtype C sexual transmission using matched single genome amplification (SGA)-derived 
T/F and chronic infection envelope (env) clones from five CAPRISA 002 study participants. In 
order to compare α4β7 reactivity we transfected HEK293T cells with the cDNA of the 
integrins. However, due to sub-cloning strategy we were unable to transfect HEK293T cells 
and therefore we utilised HeLa and TZM-bl cells that endogenously express 47 instead. 
However, the Act-1 monoclonal antibody did not inhibit gp120-α4β7 interactions on HeLa or 
TZM-bl cells suggesting that binding of pseudovirus was non-specific. Pseudovirus produced 
in HEK293T cells may have had low α4β7 reactivity or α4β7 may not occur in its activated 
conformation on HeLa and TZM-bl cells. In order to test whether T/F variants were better 
transferred to CD4+ cells than the chronic infection controls a DC-SIGN mediated trans-
infection assay was utilised. In contrast to recent reports we found no difference between 
T/F and chronic infection variants if we controlled for the effect of Env entry efficiency. 
Using site-directed mutagenesis (SDM) we deleted the potential N-glycans (PNGs) at 
positions N386 and N392, believed to carry oligomannose type N-glycans and thought to be 
 xii 
 
involved in DC-SIGN binding. The deletion of both PNGs not only resulted in a decrease in 
DC-SIGN reactivity compared with wild-type (WT) for both T/F and chronic infection Env 
pseudotyped viruses but also lowered Env entry efficiency, suggesting that these PNGs are 
most likely important for Env structure and function. However, when only a single PNG was 
deleted the transfer of HIV to CD4+ cells was not affected, suggesting that the N-
glycosylation at one site is sufficient to support trans-infection. The deletion of the PNG at 
position N392 rendered the chronic infection Env clone non-functional suggesting that the 
effect of N-glycans could be clone specific. Therefore, instead of specific N-glycans 
interacting with DC-SIGN it is possible that the transfer of HIV to CD4+ cells requires an 
optimum arrangement of oligomannose type N-glycans. As the entry efficiency of the Env 
clones could play a role in determining the level of trans-infection in vivo, the presence of 
the PNGs at positions N386 and N392 could contribute to the overall success of 
transmission, explaining the conservation of these sites across HIV subtype C variants. 
Further study to confirm the role of the N-glycans at positions N386 and N392 in HIV 
transmission could provide invaluable information for the overall understanding of HIV 
transmission and the design of an HIV vaccine. 
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Chapter 1: Literature Review: HIV transmission 
 
1.1 Introduction 
 
Human immunodeficiency virus (HIV) is a ribonucleic acid (RNA) virus that targets and 
destroys CD4+ cells of the human immune system: CD4+ T cells, macrophages and dendritic 
cells (Dalgleish et al. 1984; Maddon et al. 1986; Duncan & Sattentau 2011; Loré et al. 2005). 
The UNAIDS 2012 Global Report estimated that ~34 million people are infected with HIV 
worldwide, ~23.5 million of those infected live in sub-Saharan Africa and ~5.6 million of 
those live in Southern Africa (Joint United Nations Programme on HIV/AIDS 2012). HIV type 
1, hereinafter referred to as “HIV”, occurs globally, subdivided into nine distinct subtypes: A, 
B, C, D, F, G, H, J and K (Hemelaar et al. 2006) with subtype C being the dominant subtype in 
Southern Africa (Van Harmelen et al. 1999). HIV type 2 is localised to West Africa (Clavel et 
al. 1987) and is less pathogenic (Levy 1995). Recombination between viral subtypes has 
resulted in the existence of mosaic viruses known as circulating recombinant forms (CRF) 
(Chow et al. 2013; Thomson et al. 2005). 
 
Env, the most variable HIV protein can differ by 25-35% within an infected individual (Shaw 
& Hunter 2012) and up to 50% between viral subtypes (Johnston & Fauci 2007; Gao et al. 
2005). This extensive genetic diversity enables the disguise of Env epitopes through N-
glycosylation, trimerisation and conformational flexibility (Quiñones-Kochs et al. 2002; 
Eggink et al. 2010; Liu et al. 2008). HIV’s high genetic diversity, the existence of multiple 
subtypes, the structural elasticity of viral proteins, especially Env and the ability of the virus 
to escape the immune response are major challenges to effective vaccine development. 
Antiretroviral (ARV) drugs were the first successful step in HIV management but drug 
resistance is a major shortcoming (Johnson et al. 2011; Marconi et al. 2008). 
 
As 80% of infections are as a result of a single HIV variant the low diversity at transmission 
could provide a brief window of opportunity to prevent HIV sexual transmission (Abrahams 
et al. 2009; Derdeyn et al. 2004; Keele et al. 2008; Haaland et al. 2009; Salazar-Gonzalez et 
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al. 2008). Identifying the transmission motif(s) that allow(s) these T/F variants to be 
selectively transmitted is pivotal to the design of vaccine immunogens that target these 
variants before they diversify, thereby preventing HIV infection. 
 
As T/F variants have fewer PNGs than those from chronic infection (Derdeyn et al. 2004; 
Chohan et al. 2005) and recently it was shown that the Env PNGs of T/F variants were 
enriched with oligomannose type N-glycans (Go et al. 2011), the N-glycosylation of Env 
could comprise the transmission motif. The binding between Env and α4β7 on CD4+ T cells 
and DC-SIGN on dendritic cells has been suggested to play a role in HIV transmission and 
these interactions are affected by gp120 N-glycosylation (Geijtenbeek, Kwon, et al. 2000; 
Feinberg et al. 2007; Hong et al. 2007; Eggink et al. 2010; Nawaz et al. 2011). The potential 
role of Env N-glycosylation in HIV transmission in relation to the receptors α4β7 and DC-
SIGN will be the focus of this review. 
 
1.2 The HIV transmission genetic bottleneck 
 
The UNAIDS in 2009 reported that sexual transmission is the leading cause of new HIV 
infections with ~80% of new infections worldwide being caused by homo- and hetero-sexual 
transmission (Joint United Nations Programme on HIV/AIDS 2009). The rate of sexual 
transmission across a healthy mucosa has been calculated to be a mere 0.02% per coital act 
(Wawer et al. 2005), suggesting that the immune system, in general is efficient at preventing 
HIV infection. Studies on sero-discordant couples (Gray et al. 2001; Wawer et al. 2005) and 
sex workers (Sagar et al. 2004) demonstrated that multiple exposures were required before 
infection occurred confirming that there are stringent physical and physiological barriers in 
place that HIV needs to breach before coming into contact with its target CD4+ cells. These 
barriers include the multi-layered stratified epithelium of the vagina (Haaland et al. 2009), 
mucous secretions containing antimicrobial peptides and defensins (Tjabringa et al. 2005), 
the dendrites of Langerhans cells that project into the lumen of the genital tract (de Witte et 
al. 2007), the presence of dendritic cells in the sub-mucosa expressing C-type lectin 
receptors (CLR) (Geijtenbeek, Torensma, et al. 2000) and the paucity of CD4+ T cells in the 
genital mucosa (Pudney et al. 2005). 
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When HIV transmission is successful, a genetic bottleneck is observed whereby a single 
variant from the diverse donor viral population initiates productive infection in the recipient 
in eight out of ten cases (Figure 1.1) (Abrahams et al. 2009; Derdeyn et al. 2004; Keele et al. 
2008; Salazar-Gonzalez et al. 2008; Haaland et al. 2009).  
 
 
Figure 1.1 Schematic representation of the HIV genetic bottleneck during sexual transmission. HIV 
quasispecies is deposited in the genital tract. Although more than one viral variant may cross the mucosal 
barrier only a single variant, termed the transmitted founder (T/F) variant, is successful in causing productive 
infection. The T/F population evolves over the course of infection, which includes the alteration of the N-
glycan repertoire on the surface of glycoprotein (gp) 120 to escape the humoral response. 
 
The integrity of the mucosa appears to be a major contributing factor and aetiology of the 
genetic bottleneck as sexually transmitted infections (STI) (Horbul et al. 2011; Haaland et al. 
2009), the phase of the menstrual cycle (Patton et al. 2000; Wira & Fahey 2008), certain 
contraceptives (Sagar et al. 2004) and microbicides (Dayal et al. 2003; Cone et al. 2006; 
Phillips et al. 2000) compromise the integrity of the mucosa and result in the transmission of 
multiple HIV variants (Abu-Raddad & Longini 2008; Abrahams et al. 2009; Sagar et al. 2004; 
Haaland et al. 2009). 
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The HIV genetic bottleneck results in the transmission of a single variant, the T/F virus, 
which evolves over time due to the high recombination frequency (Rhodes et al. 2003) and 
mutation rate of the virus (Abram et al. 2010). Although many studies have characterised 
the early stages of HIV infection, it was only with the advent of SGA that T/F variants were 
accurately identified and thus characterised (Keele et al. 2008; Salazar-Gonzalez et al. 2008; 
Lee et al. 2009).  
 
SGA involves limited dilutions of viral complimentary deoxyribonucleic acid (cDNA) followed 
by two rounds of polymerase chain reaction (PCR) in order to ensure the presence of a 
single template molecule and to prevent PCR induced recombination (Simmonds et al. 1990; 
Palmer et al. 2005). The ability to unambiguously identify the T/F variant has enabled 
studies to elucidate the identity of the transmission motif(s), a distinct characteristic(s) that 
facilitates viral movement across the genital mucosa and/or its evasion of the immune 
response. 
 
1.3 Genotypic signatures and phenotypic characteristics of T/F variants 
 
It is well established that T/F variants have a strong preference for the CCR5 co-receptor 
(Keele et al. 2008; Salazar-Gonzalez et al. 2009) used for viral attachment and entry into the 
host cell. The CCR5-Δ32 polymorphism is a well-defined CCR5 allelic variation where the 
deletion of 32 basepairs (bp) completely inhibits viral entry (Samson et al. 1996) so that 
homozygous CCR5-Δ32 individuals are resistant to infection by R5 tropic variants (Marmor 
et al. 2001). It was recently observed that subtype C T/F variants were more sensitive to the 
CCR5 antagonist Maraviroc than chronic infection variants when using cells with high levels 
of the CCR5 co-receptor (Parker et al. 2013), in contrast to earlier studies that found no 
difference (Wilen et al. 2011; Parrish et al. 2012). This suggests that restricted use of certain 
CCR5 conformations could be involved in HIV transmission. 
 
Potential transmission motifs in the CCR5 and CD4 binding sites, the signal peptide and the 
cytoplasmic domain of Env were recently identified (Gnanakaran et al. 2011). These include 
a histidine residue at position 12 within the signal peptide, previously shown to be 
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associated with transportation of the nascent peptide in the endoplasmic reticulum, 
expression, incorporation and infectivity of the viral particle (Asmal et al. 2011) and the 
absence of a PNG at position N415, previously shown to be associated with escape from 
broadly neutralizing antibodies (Gnanakaran et al. 2010). It was suggested that the presence 
of a histidine residue and/or the absence of a PNG at position 12 and N415, respectively 
may provide an advantage during transmission.  
 
T/F variants have been shown to preferentially infect CD4+ T cells and not macrophages 
(Salazar-Gonzalez et al. 2009; Hladik et al. 2007; Brenchley et al. 2004) and to have 
enhanced neutralization sensitivity (Derdeyn et al. 2004) although studies have contradicted 
the latter finding (Frost et al. 2005; Keele et al. 2008; Rusert et al. 2005). The discrepancies 
between findings thus far could be due to the challenges facing these types of studies which 
include sample size, subtype variation, behavioral risk profiles of participants and 
differences in demographics, cloning strategy (SGA approach), the generation of 
pseudovirus and/or infectious molecular clones (IMC) and the use of T/F variants with 
unmatched chronic infection controls. 
 
1.4 Overall structure and function of the HIV Envelope 
 
HIV is an RNA virus comprised of nine genes: two structural genes env and gag, an 
enzymatic gene pol and six accessory genes tat, rev, nef, vif, vpr and vpu which make up the 
~10 kb viral genome (Figure 1.2) (Varmus 1988; Frankel & Young 1998). 
 
The structural env is the focus of many studies as it encodes the viral Env that interacts with 
host cell receptors to allow for viral attachment and entry into target CD4+ cells (Kwong et 
al. 1998). Env comprises of gp160, the precursor gene product that is cleaved into two parts, 
gp120 and gp41 (Stein & Engleman 1990; Hallenberger et al. 1992). The gp160 precursor 
protein, although non-functional and requires cleavage by the host protease furin to gp120 
and gp41 (Moulard et al. 1999), can still be incorporated into infectious viral particles 
(Moore et al. 2006). 
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Figure 1.2 HIV genome and virion structure. The enzymatic (pol) and structural (gag and env) genes encode 
nine proteins: the protease (PR) the reverse transcriptase (RT), the integrase (IN) (Pol proteins); the matrix 
(MA), the capsid (CA), the nucleocapsid (NC) and p6 (Gag proteins); the surface/gp120 (SU) and the 
transmembrane gp41 (TM) (Env proteins). The six accessory genes vif, vpr, vpu, tat, rev and nef encode their 
own proteins. A 5’ and 3’ long terminal repeat (LTR) flanks the ~10 kb genome. The Gag and Env proteins make 
up the structural core and outer envelope of HIV, respectively and the three Pol proteins and three accessory 
proteins Vif, Vpr and Nef are incorporated within the viral particle. Tat and Rev are gene regulatory proteins 
expressed after integration into the host genome (Frankel & Young 1998). 
 
Gp120 and gp41 form heterodimers through non-covalent bonds (Staropoli et al. 2000) and 
trimerise to form the HIV Env spike (Liu et al. 2008; Zanetti et al. 2006; Zhu et al. 2006; 
Caffrey et al. 1998; Chen et al. 2005). Gp120 is the extracellular receptor binding domain of 
Env that initially interacts with the CD4 receptor and gp41 is the transmembrane domain 
that anchors gp120 to the viral membrane and mediates fusion between the viral and host 
cell membranes (Weissenhorn et al. 1997).  
 
The binding of gp120 to CD4 results in a conformational change that reveals a previously 
concealed co-receptor (CXCR4 or CCR5) binding site. The co-receptor binding event results 
in further conformational changes that allow gp41 to penetrate the host cell membrane and 
fuse the viral and host cell membranes (Checkley et al. 2011; Wilen et al. 2012; Liu et al. 
2008; Kwong et al. 1998; Myszka et al. 2000). After membrane fusion, the viral RNA is 
reverse transcribed and integrated into the host cell’s genome using the host’s genetic 
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machinery. The integrated provirus generates new viral progeny thereby allowing further 
propagation and proliferation of the virus (Figure 1.3).  
 
 
Figure 1.3 The HIV life cycle 1) Transcription of the integrated viral genome through transactivation of the 5’ 
long terminal repeat (LTR) promoter by Tat 2) Spliced viral RNA is transported to the cytoplasm 3) Gag and Pol 
proteins are localised to the cell membrane 4) Assembly and budding of the viral particle is initiated 5) Env and 
CD4 are translated in the endoplasmic reticulum 6) Env is transported to the cell surface 7) CD4 is endocytosed 
and degraded 8) Immature viral particles containing Env are released from the host cell surface 9) Immature 
viral particles undergo maturation 10) Mature viral particles bind to target cells via CD4 and a co-receptor 
(CCR5 or CXCR4) 11) Fusion of the host cell and viral membranes 12) The viral contents is released into the 
host cell 13) Viral RNA is transported to the nucleus of the host cell 14) The viral RNA is reverse transcribed 
into complementary DNA (cDNA) 15) The viral cDNA is integrated into the host chromosome and the cycle 
begins again (Frankel & Young 1998). 
 
1.5 Gp120, the receptor binding domain 
 
1.5.1 The structure of gp120 
 
The structure of gp120 has been extensively studied using enzymatic cleavage (Leonard et 
al. 1990), computer (Modrow et al. 1987) and oligomeric modelling (Kwong et al. 2000), X-
ray crystallography (Weissenhorn et al. 1997) and cryo-electron microscopy tomography 
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(Zhu et al. 2006; Liu et al. 2008; Zanetti et al. 2006). The structure of the second and third 
variable loops were only recently solved (McLellan et al. 2011) as gp120 is highly N-
glycosylated making it difficult to determine the complete structure. 
 
 
Figure 1.4 The structure of gp120 A) A schematic representation of the HIV glycoprotein (gp) 120 variable (V) 
and constant (C) regions. Gp120 carries an array of N-glycans ( oligomannose or hybrid or complex and 
unknown) believed to shield antigenic epitopes from neutralizing antibodies. Adapted from McCaffrey et al. 
(2003) and Leonard et al. (1990) B) A ribbon diagram representing the conformation of gp120 upon binding to 
CD4. The V1/V2, V3 and V4 loops, the V5 region and the four β-stranded bridging sheet are indicated (Kwong 
et al. 1998). 
 
Gp120 is comprised of five variable and five conserved regions (Starcich et al. 1986; 
Srinivasan et al. 1987; Willey et al. 1989). While the variable regions are highly elastic 
between isolates, the conserved regions show little or no variation (Schønning et al. 1996; 
Milich et al. 1993; Fenouillet et al. 1990). The variable regions, with the exception of 
variable region (V) five, are joined by nine disulphide bonds forming distinctive loops 
(Leonard et al. 1990; Chen et al. 2005) which are critical for Env assembly (Benham et al. 
2000). The variable regions are positioned externally on the surface of gp120 and the 
conserved regions (C) are concealed within the core (Chen et al. 2005; Modrow et al. 1987; 
Kwong et al. 1998) (Figure 1.4).  
 
The CD4 binding site lies at the interface of the inner and the outer domain (Kwong et al. 
1998; Wyatt et al. 1998) and upon CD4 binding a conformational change causes the 
rearrangement of two pairs of double stranded β sheets, one from the inner and one from 
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the outer domain, to form a bridging sheet (Kwong et al. 1998). The formation of a bridging 
sheet reveals a previously concealed co-receptor binding site and the gp41 transmembrane 
stalk (Wyatt et al. 1995). These events lead up to the fusion of the viral and host cell 
membranes (Weissenhorn et al. 1997). 
 
1.5.1.1 N-linked glycosylation 
 
N-linked glycosylation is the attachment of an oligosaccharide to the asparagine of an Asn-X-
Ser/Thr (NXT/S) sequon, where X is any amino acid but proline (Marshall 1974; Gavel & von 
Heijne 1990; Apweiler et al. 1999). N-glycans are flexibly attached to the surface of a 
glycoprotein and extend into the extracellular space as they are relatively large molecules. 
N-glycans are able to adopt a number of positions around the linkage to the asparagine 
residue similar to the way a human hand is able to rotate at its wrist, with the carbohydrate 
branches resembling the fingers (Schwarz & Aebi 2011). The N-glycan adopts a final 
equilibrium position based on steric and hydrophobic or hydrophilic interactions between 
other N-glycans and neighbouring amino acid side chains (Wormald & Dwek 1999).  
 
N-linked glycans are highly non-immunogenic and disguise antigenic epitopes on the surface 
of immunogenic species (Wyatt et al. 1998). An N-linked glycan can either be one of three 
types: 1) oligomannose, 2) complex, or 3) hybrid, varying in size and complexity (Schwarz & 
Aebi 2011).  
 
N-glycosylation occurs posttranslationally in the endoplasmic reticulum where initially 
oligomannose type N-glycans are added (Helenius et al. 2002; Kelleher & Gilmore 2006). The 
protein is then translocated to the Golgi apparatus where terminal N-glycosylation occurs 
which trims and modifies the oligomannose residues resulting in complex and/or hybrid 
types (Hallenberger et al. 1992; Moulard et al. 1999; Helenius et al. 2002). Glycoproteins 
with oligomannose type N-glycans do not undergo terminal N-glycosylation.  
 
Any NXT/S sequon is considered a PNG as it could potentially, but not necessarily carry an N-
linked glycan (Go et al. 2011). The likelihood of a PNG carrying an N-glycan can be 
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determined by mass spectrometry and enzymatic digestion using specific glycosidases (Go 
et al. 2013; Go et al. 2011). Petrsecu et al. (2004), Apweiler et al. (1999) and Kelleher and 
Gilmore (2006) observed PNG sites proximal to disulphide bonds were less likely to be 
occupied by N-glycans. 
 
N-glycosylation is essential for accurate protein folding, structural maintenance, adhesion to 
receptors and protein metabolism. Improper N-glycosylation of a protein may result in an 
incorrectly folded and non-functional protein (Fenouillet & Jones 1995; Fenouillet et al. 
1989) as observed when gp120 N-glycosylation was inhibited by producing virus in the 
absence of a signal peptide and in the presence of tunicamycin, an antibiotic that inhibits 
the synthesis of N-linked glycoproteins (Fenouillet et al. 1989). Likewise, pseudovirus 
produced in the presence of tunicamycin had incorrectly folded aggregates (Land et al. 
2003) and reduced infectivity (Montefiori et al. 1988).  
 
The HEK293T and CHO cell lines have been successfully used to produce functional gp120 
(Bonomelli et al. 2011; Scanlan et al. 2002; Leonard et al. 1990). This suggests that HEK293T 
and CHO cells have the correct functional machinery to ensure accurate gp120 processing 
and N-glycosylation. However, differences in N-glycosylation were observed by Go et al. 
(2013) between cell lines when gp120 produced in CHO cells carried oligomannose type N-
glycans at positions N386 and N392 while gp120 produced in HEK293T cells carried a 
combination of oligomannose and complex N-glycans at these positions. Raska et al. (2010) 
also demonstrated that the N-gycosylation of gp120 is highly dependent on cell type when 
they compared gp120 N-glycosyation in HepG2 (hepatocytes), Jurkat (T cells), Dakiki (B 
cells), HT 1080 (fibrosarcoma cells) HEK293T and CHO cells. It was shown that these 
differences were dependent on the metabolic state of the cells (Raska et al. 2010). 
 
1.5.1.2 N-linked glycosylation of gp120 
 
Gp120 carries a heterogeneous array of N-linked glycans to protect HIV against proteolytic 
degradation and to shield antigenic epitopes from antibody recognition (Sagar et al. 2006; 
Binley et al. 2010; Reitter et al. 1998). On average, gp120 carries 25 PNGs (Zhang et al. 
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2004). Although N-glycans serve to mask gp120 and thus prevent immune detection, they 
paradoxically also facilitate immune recognition as it was shown that HIV has an 
oligomannose patch that may render HIV susceptible to immune cells that express lectins 
(Bonomelli et al. 2011). Furthermore, the N-glycan composition of gp120 was observed to 
balance DC-SIGN mediated degradation of HIV with the facilitation of HIV infection 
(Van`Montfort et al. 2011). Env enriched for oligomannose N-glycans demonstrated 
enhanced DC-SIGN binding but enhanced endocytic degradation (Van`Montfort et al. 2011). 
 
1.5.2 Gp120 co-receptor binding and viral tropism 
 
For viral attachment and entry into a host cell, CD4 and a second chemokine co-receptor 
(CXCR4 or CCR5) are required (Deng et al. 1996; Zhang et al. 1999; Sattentau et al. 1986). 
The particular co-receptor used by HIV determines whether the virus is R5 (utilises CCR5 
only), X4 (utilises CXCR4 only) or dual tropic (utilises both CCR5 and CXCCR4). It has been 
well documented that T/F variants are R5 tropic (Keele et al. 2008; Salazar-Gonzalez et al. 
2008). 
 
Although the gp120 V3 loop is highly variable, numerous studies have verified that it carries 
the co-receptor binding site (Pastore et al. 2006; Polzer et al. 2001; Berger et al. 1999; 
Cocchi et al. 1996; Kwong et al. 2000; Speck et al. 1997; Delobel et al. 2013; Rizzuto 1998; 
Valenzuela et al. 1997). A study using two neutralizing antibodies (110-4 and N11-20) 
against the V3 loop of gp120 demonstrated viral entry inhibition (Valenzuela et al. 1997) 
and when the V3 loop of an R5 tropic variant was replaced with one from an X4 tropic 
variant, the former was able to infect cells carrying CXCR4 (Polzer et al. 2001; Speck et al. 
1997). Furthermore, the charge on the amino acid side chains (Delobel et al. 2013; Jensen & 
van  ’t Wout 2010) and the N-glycans (Zhang et al. 2004; Li et al. 2005) present on the V3 
loop have been shown to determine viral tropism of HIV variants and the conformation of 
the V3 loop was shown to change upon co-receptor binding (Kwong et al. 1998; Chen et al. 
2005; Zanetti et al. 2006). Together these findings corroborate the role of the V3 loop in co-
receptor binding. 
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1.6 Receptors that may play a role in HIV transmission 
 
1.6.1 Dendritic cells and the DC-SIGN lectin 
 
1.6.1.1 Dendritic cells 
 
Dendritic cells comprise of a number of cell types with myeloid and plasmacytoid the major 
subset. Dendritic cells  are antigen presenting cells (APC) that capture antigens in peripheral 
tissues, process them into peptides and migrate to the lymph nodes where they activate 
naïve CD4+ T cells upon presentation of the antigen peptide within the context of a major 
histocompatibility complex (MHC) class 2 molecule (Geijtenbeek, Kwon, et al. 2000; Kwon et 
al. 2002; Pope et al. 1995; Granelli-Piperno et al. 1999; Holl et al. 2010). HIV and other 
glycosylated pathogens have evolved a mechanism to subvert the immune function of 
dendritic cells and exploit the migratory nature of these sentinel cells to encounter naïve 
CD4+ T cells in the lymph nodes (Chehimi et al. 2003; Geijtenbeek et al. 2009). Glycosylated 
pathogens are captured by dendritic cells via one of several CLRs [mannose receptor, DC-
SIGN, dendritic cell immunoreceptor, dendritic cell-associated lectin-1 and macrophage 
galactose-type lectin (Geijtenbeek et al. 2004)]. The dendritic cell matures and migrates to 
the lymph nodes where it transfers the pathogen over to naïve CD4+ T cells for infection, a 
term referred to as trans-infection (Halary et al. 2002; Geijtenbeek, Kwon, et al. 2000).  
 
Two competing models of HIV trans-infection exist (Yu et al. 2008). The first suggests that 
HIV is captured by a CLR on the surface of a dendritic cell triggering the endocytosis of the 
virus which is packaged into an endosomal multivesicular body (MVB). The MVB is non-
endocytic and is released as an exosome which is able to bind to and infect a target CD4+ 
cell (Izquierdo-Useros et al. 2009). The second model suggests that dendritic cell trans-
infection occurs via surface-accessible HIV. As soluble CD4 inhibited the transfer of HIV from 
dendritic cells to CD4+ cells (Cavrois et al. 2007), it was suggested that HIV is not 
internalised by dendritic cells but is held on the surface until the dendritic cell encounters a 
CD4+ cell (Cavrois et al. 2007).  
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Figure 1.5 Existing models of HIV transfer from dendritic cells to CD4+ cells. Three models exist which may 
explain how HIV is transferred from dendritic cells to CD4+ cells via a carbohydrate binding lectin receptor 
(CLR) A) The endosomal multivesicular body (MVB)/exosome model B) The surface-accessible HIV model and 
C) A combination of the MVB/exosome and surface-accessible HIV model (Yu et al. 2008). 
 
Yu et al. (2008) suggested a combination of the two trans-infection models whereby HIV is 
captured by a CLR on the surface of a dendritic cell and internalised into a non-endocytic 
pocket-like invagination of the plasma membrane. The virus is not completely internalised 
and is therefore still susceptible to inhibition by soluble CD4 but remains more protected 
than cell free virus (Figure 1.5). 
 
 
Figure 1.6 Schematic representations of DC-SIGN mediated cis- and trans-infection of CD4+ cells. HIV is 
deposited on the cervicovaginal epithelium after coitus. HIV enters the sub-mucosal epithelium where 
immature dendritic cells bind HIV via a C-type lectin or an HIV attachment factor. Dendritic cells expressing DC-
SIGN, CD4 and a co-receptor are infected with HIV (cis-infection) while dendritic cells only expressing DC-SIGN 
mediate trans-infection of CD4+ cells. Dendritic cells capture HIV and migrate to the lymph nodes where they 
mature and encounter HIVs target cells; CD4+ T cells. Infected dendritic cells produce viral progeny that infect 
target cells or dendritic cells transfer bound HIV over to the CD4+ T cells thereby facilitating HIV dissemination 
(Wu & KewalRamani 2006). 
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Dendritic cells can be directly infected by HIV if they express CD4 and a co-receptor. 
Dendritic cells are infected by HIV in the genital mucosa, migrate to the lymph nodes and 
produce viral progeny that is released and is able to infect the reservoir of naïve CD4+ T cells 
(Turville et al. 2003) in a process referred to as cis-infection (Lee et al. 2001) (Figure 1.6). 
 
1.6.1.2 DC-SIGN 
 
DC-SIGN is a CLR endogenously expressed on myeloid and plasmacytoid dendritic cells, 
activated B cells and subsets of macrophages (Geijtenbeek, Torensma, et al. 2000; 
Rappocciolo et al. 2006). DC-SIGN is a tetrameric type II transmembrane protein (Figure 1.7) 
and its natural ligand is ICAM-3 expressed on CD4+ T cells (Geijtenbeek, Kwon, et al. 2000; 
Geijtenbeek et al. 2002; Curtis et al. 1992; Hong et al. 2007; Requena et al. 2008). 
 
 
Figure 1.7 Schematic representation of DC-SIGN. DC-SIGN is a C-type lectin receptor expressed on dendritic 
cells, made up of an N-terminal cytoplasmic domain, a transmembrane domain and an ectodomain. The 
ectodomain has two components: a repeat region making up the neck and the C-terminal carbohydrate 
binding domain (CRD) (Wu & KewalRamani 2006). 
 
DC-SIGN has a strong affinity for ICAM-3 (Geijtenbeek, Torensma, et al. 2000) and the highly 
N-glycosylated HIV gp120 (Geijtenbeek, Kwon, et al. 2000). Anti-DC-SIGN antibodies (AZN-
D1 and AZN-D2) inhibited DC-SIGN-ICAM-3 as well as DC-SIGN-gp120 interactions suggesting 
closely associated (Geijtenbeek, Kwon, et al. 2000) but not overlapping ICAM-3 and gp120 
binding sites (Geijtenbeek et al. 2002). DC-SIGN binds HIV gp120 oligomannose residues via 
the carbohydrate recognition domain (CRD) (Chung et al. 2010; Hong et al. 2002).  
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1.6.1.3 The role of DC-SIGN in HIV transmission 
 
As there is a paucity of CD4+ T cells in the vaginal mucosa (Pudney et al. 2005) and an 
abundance of CD4+ T cells in the lymph nodes (Garside et al. 1998) it would be 
advantageous for HIV to be selectively transferred from the vaginal mucosa to the lymph 
nodes. It has been suggested that upon sexual transmission, HIV is able to circumvent 
dendritic cell antigen presentation and can be transferred to the lymph nodes by dendritic 
cells via DC-SIGN to infect target CD4+ cells (Trumpfheller et al. 2003; Pope et al. 1995; 
Geijtenbeek, Kwon, et al. 2000; Kwon et al. 2002; Arrighi et al. 2004; Granelli-Piperno et al. 
1999).  
 
In vivo experiments have shown that HIV can be safely retained inside dendritic cells for as 
long as six days however, after 24 hours the variants transferred were shown to be viral 
progeny and not the original virus (Turville et al. 2004). HIV cell to cell spread is suggested to 
be the predominant way HIV is disseminated (Chen et al. 2007) and has been shown to be 
more efficient than cell free replication (Carr et al. 1999). Therefore, it has been suggested 
that T/F variants carry markers that make them more susceptible to DC-SIGN mediated 
transfer to target cells. 
 
As DC-SIGN has been shown to have a high affinity for oligomannose type N-glycans 
(Mitchell et al. 2001), it preferentially binds HIV variants enriched with this type of 
carbohydrate (Van`Montfort et al. 2011; Feinberg et al. 2001; Kwon et al. 2002; Curtis et al. 
1992; Feinberg et al. 2007). HIV has been shown to have an oligomannose N-glycan patch 
(Bonomelli et al. 2011) with numerous Env N-glycans resistant to oligomannose trimming 
(Leonard et al. 1990) resulting in an enriched oligomannose repertoire of N-glycans.  
 
Pseudovirus produced in HEK293T cells lacking the GnTI enzyme (HEK293T-/-GnTI) and 
therefore only carrying oligomannose type N-glycans demonstrated increased DC-SIGN 
binding to Raji-DC-SIGN cells as well as immature dendritic cells (Eggink et al. 2010; 
Van`Montfort et al. 2011). Pseudovirus produced in the presence of Kifunensine, an enzyme 
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that inhibits the trimming of oligomannose type N-glycans, similarly showed an increase in 
DC-SIGN binding (Eggink et al. 2010; Van`Montfort et al. 2011). Endoglycosidase digestion of 
oligomannose type N-glycans revealed that DC-SIGN-bound gp120 migrated further on an 
sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) than gp120 bound 
to CD4 (Lin et al. 2003), indicating that variants that bound DC-SIGN carried more 
oligomannose type N-glycans than those that bound to CD4.  
 
Furthermore, the lectins griffithsin, cyanovirin-N and scytovirin that bind oligomannose 
residues inhibited HIV binding to DC-SIGN and the transfer of HIV to CD4+ cells (Alexandre 
et al. 2012), supporting previous studies that gp120 oligomannose residues is important for 
DC-SIGN-mediated transfer of HIV to CD4+ cells. DC-SIGN has been suggested to be the 
principal CLR involved in capturing, internalising and transferring HIV from dendritic cells to 
naïve CD4+ T cells as it was demonstrated that approximately 30-50% of viral input was 
captured by DC-SIGN when immature monocyte-derived dendritic cells were used 
(Van`Montfort et al. 2007). Together these findings suggest that oligomannose type N-
glycans are essential for interactions with DC-SIGN and could comprise the transmission 
motif. In fact, Go et al. (2011) demonstrated that T/F variants carried more oligomannose 
type N-glycans than chronic infection controls. As T/F variants were observed to have 
shorter variable loops with fewer PNGs (Derdeyn et al. 2004; Chohan et al. 2005) and 
complex N-glycans were shown to occur in the variable loops while oligomannose type 
carbohydrate structures were located in the constant regions (Go et al. 2011; Leonard et al. 
1990), T/F variants may carry an optimal arrangement of oligomannose type N-glycans on 
the constant regions of gp120 to increase their affinity to DC-SIGN.  
 
T/F variants may be more efficient at engaging DC-SIGN, more efficient at being transferred 
to CD4+ cells and more efficient at productive infection compared with chronic infection 
variants due to an optimal arrangement of oligomannose N-glycans. T/F variants were 
demonstrated to bind to immature monocyte-derived dendritic cells 1.6-fold more 
efficiently than chronic infection variants (Parrish et al. 2013). This supports the suggestion 
that the enhanced binding of T/F viruses to DC-SIGN via oligomannose N-glycans could lead 
to enhanced DC-SIGN mediated trans-infection of CD4+ T cells.  
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1.6.2 The α4β7 integrin and the gut associated lymphoid tissue 
  
1.6.2.1 The α4β7 integrin 
 
The α4β7 integrin, a heterodimer consisting of the non-covalently bound α4 and β7 
integrins (Buck & Horwitz 1987), is highly expressed on CD4+ T cells of the genital mucosa 
(McKinnon et al. 2011; Kelly & Rank 1997) and gut (Cicala et al. 2009). Mucosal addressin 
cell adhesion molecule-1 (MAdCAM-1) is the natural ligand of α4β7 and is selectively 
expressed on the high endothelial venules (HEV) of Peyer’s patches, mesenteric lymph 
nodes and the venules of the lamina propria (Berlin et al. 1995). α4β7 mediates the 
migration of CD4+ T cells from Peyer’s patches and mesenteric lymph nodes to the lamina 
propria in response to the expression of MAdCAM-1 (Bargatze et al. 1995). 
 
1.6.2.2 The role of α4β7 in HIV sexual transmission 
 
The α4β7 binding site that mimics the integrin’s natural ligand binding site (Zeller et al. 
2001) is found within the V1/V2 loop on the apex of the gp120 trimer spike (Liu et al. 2008). 
The α4β7 binding site, a tripeptide (Leu-Asp-Val), is conserved across HIV subtypes A, B, C 
and D (Arthos et al. 2008). It has previously been shown that T/F variants carry gp120 with 
more compact and less N-glycosylated V1/V2 loops (Derdeyn et al. 2004; Chohan et al. 
2005) suggesting that the V1/V2 loop could be important in HIV transmission possibly due to 
the presence of the α4β7 binding site.  
 
When N-glycans were removed from the V1/V2 loop, α4β7 reactivity increased suggesting 
that the loss of N-glycans, such as on T/F variants could improve access to this site (Nawaz 
et al. 2011). This finding as well as the structural mimicry of the binding site to that of its 
natural ligand, the conservation of the binding site within gp120 and across HIV strains, the 
observation that viral variants had decreased replication when the α4β7 binding site domain 
was mutated (Arthos et al. 2008) and the fact that CD4+ T cells with high α4β7 levels are 
prone to highly productive infection (Cicala et al. 2009) all suggest that α4β7 may be 
important in HIV infection and transmission.  
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HIV replicates more efficiently in activated CD4+ T cells than naïve CD4+ T cells (Stevenson 
et al. 1990) and α4β7 expression was observed on activated cervical CCR5+ CD4+ T cells 
(McKinnon et al. 2011; Cicala et al. 2009). α4β7, CD4 and CCR5 are found in a complex on 
the cell membrane seen by confocal microscopy of stained cells from gut biopsies (Cicala et 
al. 2009). In this complex, it has been suggested that α4β7 is the most prominent receptor 
of the three receptors. CD4 at 7 nm is three times smaller than α4β7 (22 nm) (Figure 1.7) 
and the CCR5 binding site on gp120 is effectively hidden prior to the gp120-CD4 interaction 
(Weissenhorn et al. 1997).  
 
 
Figure 1.8 A schematic representation of α4β7 expressed alongside the CD4 receptor and CCR5 co-receptor. 
The α4 and β7 integrins are non-covalently bound to form the α4β7 heterodimer that acts as a homing 
molecule for CD4+ T cells. α4β7 is closely associated with CD4 (≤1.2 nm) while α4β7 (22 nm) is three times 
larger than CD4 (7 nm) and CCR5 is effectively hidden prior to CD4-gp120 interaction. α4β7 is suggested to be 
the prominent receptor seen by the gp120 trimer (12 nm) (Cicala et al. 2009). 
As it has been suggested that T/F viruses bind α4β7 better than CD4 (Nawaz et al. 2011), 
and α4β7 is not only found near the apex of the gp120 trimer spike (Liu et al. 2008) but is 
also a mere ~1.2 nm from CD4 (Cicala et al. 2009), α4β7 may concentrate virus on the 
surface of CD4+ T cells thereby facilitating CD4 binding and subsequent infection (Arthos et 
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al. 2008). Therefore, the R5 tropic nature of T/F variants may be as a result of the co-
expression of α4β7 and CCR5 on this subset of susceptible HIV target cells (Cicala et al. 
2009).  
 
The gp120-α4β7 interaction was shown to mediate the rapid activation of the lymphocyte 
function-associated antigen-1 (LFA-1) receptor that facilitates the formation of a virological 
synapse (Figure 1.9) suggesting that this interaction could facilitate cell to cell spread (Carr 
et al. 1999; Cicala et al. 2011). 
 
Not all gp120 molecules were observed to bind α4β7 with the same efficiency despite 
having conserved V2 loops (Nawaz et al. 2011), suggesting that another factor may play a 
role in mediating this interaction. The type of gp120 N-glycosylation seems to affect α4β7 
reactivity as pseudovirus produced in cells that cannot process oligomannose type N-glycans 
into larger complex N-glycans showed a 100-fold increase in α4β7 reactivity (Nawaz et al. 
2011). When the N-glycosylation on the V1/V2 loop was deleted by SDM, α4β7 reactivity 
increased (Nawaz et al. 2011). Similarly, the removal of N-glycans from chronic infection 
variants, known to be more heavily glycosylated than T/F variants (Derdeyn et al. 2004) 
resulted in an increase in α4β7 reactivity (Nawaz et al. 2011). This suggests that early viral 
isolates with less N-glycosylation, specifically in the V1/V2 loop, may have enhanced α4β7 
reactivity as the α4β7 binding site may be more accessible.  
 
Studies using non-human primates corroborated the role of α4β7 in HIV transmission as an 
anti-α4β7 monoclonal antibody potently inhibited simian immunodeficiency virus (SIV) 
binding and LFA-1 activation as well as decreased viral dissemination (Ansari et al. 2011). 
α4β7 CD4+ T cells were preferentially infected in rhesus macaques exposed to SIV (Wang et 
al. 2009) however recently it was demonstrated that blocking the α4β7 receptor with Act-1, 
that blocks α4β7-gp120 interactions (Lazarovits et al. 1984), had no effect on viral infectivity 
negating the previous suggestion that α4β7 was important in HIV transmission and infection 
(Parrish et al. 2012). This latest finding is contradictory to other studies (Arthos et al. 2008; 
Cicala et al. 2009; Nawaz et al. 2011) possibly do to the bigger sample size used and the use 
of IMCs rather than pseudovirus. The use of pseudovirus in previous studies limits α4β7 
reactivity to only gp120-α4β7 interactions and not the entire viral structure. 
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Figure 1.9 A schematic representation of the formation of a virological synapse A) An uninfected target cell 
expresses CD4, CCR5, α4β7 and an inactivated form of the lymphocyte function-associated antigen-1 (LFA-1) 
receptor. A nearby cell is infected by HIV and expresses ICAM-1, the natural ligand for LFA-1 B) The gp120 of a 
virus on the surface of the infected cell interacts with α4β7 on the surface of an uninfected cell which results in 
the activation of the LFA-1 receptor C) The activated form of the LFA-1 receptor interacts with ICAM-1 on the 
surface of the infected cell to form a virological synapse which allows gp120 to interact with CD4 and CCR5 to 
initiate the viral attachment and entry into the uninfected target cell (Cicala et al. 2011). 
 
1.6.2.3 The role of α4β7 in CD4+ T cell depletion in the gut during early infection 
 
It has been established that the gut is preferentially and profoundly affected early on during 
HIV infection with the near-complete depletion of CD4+ T cells in the gut-associated 
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lymphoid tissue (GALT) shown to be important in establishing acute infection (Guadalupe et 
al. 2003; Mehandru et al. 2007; Ansari et al. 2011). The gastro-intestinal tract forms the 
host-pathogen interface and so has an extensive immune system made up of the GALT 
which is extremely important in HIV dissemination (Figure 1.10). 
 
  
 
Figure 1.10 A schematic representation of the gastrointestinal associated lymphoid tissue (GALT). The GALT 
is the largest mass of lymphoid tissue and is found in the gastrointestinal tract. Peyer’s patches, mesenteric 
lymph nodes and the lamina propria are tissues that are highly relevant to HIV pathogenesis (Lycke 2012). 
 
Infected CD4+ T cells migrate from the genital mucosa, the site of infection, to Peyer’s 
patches and the mesenteric lymph nodes within days of sexual transmission (Mehandru et 
al. 2007). High levels of HIV replication are observed in the lamina propria which proves to 
be detrimental to the immune system and signals the onset of acute HIV infection and peak 
viremia (Mehandru et al. 2007). The α4β7 integrin has been implicated in the translocation 
of HIV from the site of infection, the genital mucosa to the gut to initiate the depletion of 
CD4+ T cells (Ansari et al. 2011).  
 
α4β7 has been shown to be the homing integrin that recruits CD4+ T cells from the Peyer’s 
patches and mesenteric lymph nodes to the lamina propria upon MAdCAM-1 expression 
(Berlin et al. 1995; Bargatze et al. 1995). Antibodies to the α4 sub-unit of α4β7 inhibit 
binding to Peyer’s patches (Holzmann & Weissman 1989) and blocking α4β7 with a non 
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CD4+ T cell depleting antibody, during acute infection of rhesus macaques with SIV, resulted 
in reduced plasma and GALT viral replication (Ansari et al. 2011) demonstrating the 
importance of viral replication in the gut to establish acute infection. The α4β7 integrin may 
therefore be the link between sexual transmission across the genital mucosa and the 
translocation of infected CD4+ T cells to the gut to initiate near complete depletion of GALT 
CD4+ T cells. 
 
1.7 Conclusion 
 
Understanding the mechanism behind the genetic bottleneck at HIV transmission will be 
invaluable to the design of novel anti-HIV drugs and vaccines. Transmission of only a single 
variant suggests that some viruses may carry a phenotypic marker or transmission motif, 
allowing the variant to breach the mucosal barrier, escape immune detection and result in 
clinical infection. A therapy designed to target the transmission motif(s) could effectively 
prevent the spread of HIV. Env has been extensively studied as the viral protein most likely 
to carry the transmission motif(s) as it engages in the CD4 receptor and co-receptor 
essential for viral attachment and entry into the host cell. 
 
Recently, it has been suggested that T/F variants carry gp120 with high affinity for the α4β7 
integrin (Nawaz et al. 2011) and are enriched with oligomannose type N-glycans (Go et al. 
2011). T/F variants enriched with oligomannose type N-glycans supports the argument that 
DC-SIGN, a C-type lectin expressed on dendritic cells, may be important in HIV transmission 
as DC-SIGN has been shown to preferentially bind oligomannose type N-glycans. Therefore 
it is possible that the N-glycosylation of T/F variants may allow for optimal binding to DC-
SIGN, enhanced migration to the lymph nodes and thus selective transmission to CD4+ T 
cells. Env N-glycosylation has also been shown to affect the interaction of HIV with α4β7. 
Therefore, T/F variants with high affinity for the α4β7 integrin may also be selectively 
transmitted, propagated and disseminated as the homing integrin facilitates HIV infection of 
CD4+ T cells as well as aid the migration of HIV from the genital mucosa to the gut where 
viral replication can occur unchecked.  
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Within the context that T/F variants carry more compact gp120 with fewer PNG sites, the 
dependence of gp120-α4β7 and gp120-DC-SIGN interactions on the presence of PNGs could 
suggest that Env N-glycosylation may play an important role in HIV transmission. Therefore 
elucidating the role of Env N-glycosylation in HIV transmission might be instrumental in 
designing a broadly acting vaccine that could protect against HIV infection. 
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Study rationale and research objectives 
 
The UNAIDS 2012 Global Report estimated that two thirds of the global population infected 
by HIV live in sub-Saharan Africa (Joint United Nations Programme on HIV/AIDS 2012) where 
HIV subtype C is the dominant subtype (Van Harmelen et al. 1999). Previously, studies have 
focused on subtypes A and B (Wilen et al. 2011; Parrish et al. 2013) and the data from these 
studies most likely cannot be extrapolated to subtype C due to inter-subtype differences. 
The use of unmatched T/F variants and chronic infection controls (Wilen et al. 2011) rather 
than longitudinal sampling, the comparison of non SGA-derived sequences (Derdeyn et al. 
2004) rather than SGA-derived sequences (Keele et al. 2008; Salazar-Gonzalez et al. 2009) 
and the use of pseudovirus (Wilen et al. 2011; Borggren et al. 2008) and not IMC (Parrish et 
al. 2012) may have contributed to the conflicting results thus far, making it difficult to 
identify transmission signatures.  
 
This study focuses on five CAPRISA 002 study participants with matched T/F env clones and 
chronic infection controls generated by SGA. This research seeks to first compare the α4β7 
and DC-SIGN reactivity of Env clones and then determine the importance of gp120 N-
glycosylation for these interactions. We hypothesise that, T/F variants carry gp120 that bind 
with higher efficiency to α4β7 and DC-SIGN compared to those found later in infection and 
that this affinity is dependent on the presence of N-glycans. 
 
Study objectives: 
 
1) Develop an α4β7 reactivity assay using transient transfections of mammalian cells to 
determine whether T/F env clones have a higher affinity for the α4β7 integrin than 
chronic infection controls and whether this is dependent on gp120 N-glycans. 
2) Determine whether T/F variants are preferentially trans-infected to CD4+ cells via 
the DC-SIGN CLR compared with those from chronic infection. 
3) Determine whether the removal of PNGs, believed to be oligomannose type N-
glycans, affect DC-SIGN mediated trans-infection of CD4+ cells. 
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Chapter 2: Methods 
 
2.1 Envelope clones 
 
HIV env clones were generated from five CAPRISA 002 study participants (CAP177, CAP239, 
CAP45, CAP206 and CAP210) at acute (2 to 5 weeks post-infection) and chronic (1.5 to 3 
years post-infection) stages of infection. 
 
Table 2.1 Characteristics of the env clones 
 
Participant 
ID (CAP) 
Clone 
ID 
Stage of 
infection 
Sampling 
(Weeks 
post 
infection) 
Fiebig 
stage 
The vector in which the env 
clone was received  
Received from 
177 A3 acute 2 I/II pcDNA
TM
3.1/V5-His TOPO
®
 NICD 
 47 chronic 172 N/A pcDNA
TM
3.1/V5-His TOPO
®
 NICD 
239 Ell acute 5 I/II pTARGET
TM
 L. Shuping 
 T35 chronic 173 N/A pcDNA
TM
3.1/V5-His TOPO
®
 NICD 
45 B5 acute 2 I/II pTARGET
TM
 L. Shuping 
 H5 chronic 108 N/A pTARGET
TM
 L. Shuping 
206 H1 acute 4 V pTARGET
TM
 L. Shuping 
 E12-3 chronic 173 N/A pcDNA
TM
3.1/V5-His TOPO
®
 NICD 
210 E8 acute 5 I/II pTARGET
TM
 G. Bandawe 
 E1 chronic 80 N/A pTARGET
TM
 L. Shuping 
 C7 chronic 80 N/A pTARGET
TM
 L. Shuping 
                            *Adapted from L. Shuping (unpublished data) 
 
Each study participant had one T/F and one chronic infection env clone besides CAP210 
which had two chronic infection env clones. The env clones were either received from P. 
Moore [National Institute for Communicable Diseases (NICD), South Africa] or cloned by G. 
Bandawe [Institute of Infectious Disease and Molecular Medicine (IIDMM), University of 
Cape Town (UCT), South Africa] or L. Shuping (Department of Molecular and Cell Biology, 
UCT, South Africa).  
 
The entire env gene including 5’ and 3’ flanking sequences were cloned into either the 
pcDNATM3.1/V5-His TOPO® [Invitrogen, United States of America (USA)] or pTARGETTM 
(Promega, USA) vector (Table 2.1). The env clones were derived from SGA and extensive 
sequence analysis confirmed that these participants were infected with a single variant 
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(Abrahams et al. 2009). As the env clone selected during acute infection was identical to the 
consensus sequence, it was assumed to represent the T/F variant. The chronic infection env 
control clones were chosen as they carried the same PNGs found on the consensus 
sequence. 
 
2.2 Sub-cloning and/or preparation of α4 and β7 cDNA clones 
 
The pCDM8_α4 (Kamata et al. 1995) and pCEP4_β7 (Erle et al. 1991) plasmid DNA was a 
generous gift from Prof D. Erle, University of California, San Francisco, California. 
 
2.2.1 Sub-cloning of α4 cDNA 
 
The pCDM8 (Invitrogen, USA) mammalian expression vector that the α4 cDNA was originally 
cloned into utilises the tyrosine transfer RNA (tRNA) suppressor and p3 plasmid system. In 
order to select pCDM8-containing cells E. coli K12 MC1061 [p3] competent cells which 
contain the p3 plasmid are required. The p3 plasmid contains antibiotic resistance genes 
interrupted by several non-sense mutations. A tRNA suppressor produced upon expression 
of the pCDM8 vector suppresses the non-sense mutations thereby initiating expression of 
the antibiotic resistance genes and allowing antibiotic selection of pCDM8 containing cells. 
As E. coli K12 MC1061 [p3] competent cells were not available and new customs laws 
restricted the import of certain competent cells into the country at that time, we were 
unable to make use of this system.  
 
2.2.1.1 PCR 
 
Consequently, we sub-cloned the human α4 cDNA into the pTARGETTM expression system 
(Promega, USA) using TA cloning. α4 was amplified by PCR with Phusion Hot Start II High 
Fidelity DNA Polymerase (Thermo Scientific, USA) (Parameters: 95 °C 2 minutes, 20 cycles of 
94 °C 20 seconds, 55 °C 20 seconds, 72 °C 8 minutes and 72 °C 5 minutes). The T7 forward 
(F) primer and the pCDM8 reverse (R) primer (Table 2.2) were used to amplify the 3 096 bp 
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human α4 cDNA (Accession number NP_034706) as these primer sequences were present in 
the pCDM8 vector. Each PCR reaction contained 200 µM of each of the dNTP’s, 1X Phusion 
Hot Start II High Fidelity DNA Polymerase buffer, 0.5 µM each oligonucleotide, 0.05 µg 
template plasmid DNA and 1 U Phusion Hot Start II High Fidelity DNA Polymerase in a total 
volume of 50 µL. PCR products were visualised by 1% agarose gel electrophoresis (Sambrook 
& Russell 2001) using a BioDoc-ItTM Imaging System (Ultra-Violet Products Ltd., Cambridge, 
United Kingdom) and the relevant bands were excised and gel purified using the Wizard® SV 
Gel and PCR clean up system (Promega, USA) as per manufacturer’s instructions. PCR 
products were A-tailed using Supertherm Taq DNA Polymerase (JMR Holdings, USA) 
(Parameters: 72 °C 10 minutes) and purified using the Wizard® SV Gel and PCR clean up 
system (Promega, USA) as per manufacturer’s instructions. Each A-tailed PCR reaction 
contained 160 µM dATPs, 1X Supertherm Taq DNA Polymerase buffer, 2 mM MgCl2, 40 µL 
gel-extracted PCR product and 0.375 U Supertherm Taq DNA Polymerase.  
 
2.2.1.2 Ligation and screening 
 
DNA ligations of the A-tailed PCR products and the pTARGETTM vector were performed using 
T4 DNA ligase (Fermentas, USA) in a 10 µL reaction at a molar ratio of 4:1 insert: vector. The 
ligation was done at 4 °C for 24 hours and competent E. coli JM109 cells were transformed 
as per manufacturer’s instructions (Promega, USA) and cultured at 30 °C overnight. 
Transformed cells were isolated on Luria agar plates (1% tryptone, 0.5% yeast extract, 1% 
NaCl, 1.5% agar) with 100 µg/ml ampicillin.  
 
Colony PCR was used to screen colonies for plasmids containing the insert in the correct 
orientation using Supertherm Taq DNA Polymerase (JMR Holdings, USA) (Parameters: 95 °C 
2 minutes, 20 cycles of 94 °C 20 seconds, 55 °C 20 seconds, 72 °C 5 minutes and 72 °C 5 
minutes). Each PCR reaction contained 200 µM each dNTP, 1X Supertherm Taq DNA 
Polymerase buffer, 2 mM MgCl2 and 0.375 U Supertherm Taq DNA Polymerase. The T7 F 
primer, found within the pTARGETTM vector sequence and the 12-1691 α4 R2 primer, 
designed from nucleotide (nt) 2 383 to nt 2 406 and synthesised by Pei-Yin Leibrich 
(Department of Molecular and Cell Biology, UCT, South Africa) (Table 2.2), were used to 
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amplify a ~2 400 bp DNA fragment. Small scale plasmid DNA isolation was performed on 
positive colonies using the Bioflux Miniprep system (Bioer Technology Co., Ltd) according to 
manufacturer’s instructions.  
 
2.2.1.3 DNA sequencing 
 
The α4 F1 primer designed from nt 646 to nt 669, the α4 R1 primer designed from nt 2 383 
to nt 2 406 and the α4 R2 primer designed from nt 3 082 to nt 3 097 were used together 
with the T7 F and pCDM8 R primers to sequence the entire α4 cDNA (Table 2.2). The Big 
Dye® Terminator v3.1 Cycle Sequencing kit (Applied Biosystems, USA) and Half-dye (Bioline, 
United Kingdom) was used in the sequencing reactions performed at the Central Analytical 
facility of the University of Stellenbosch, South Africa. 
 
Table 2.2 The primers that were used to sub-clone the α4 cDNA into the pTARGETTM 
vector, perform colony PCR on transformed colonies and to sequence positive 
pTARGETTM_α4 clones 
 
*Primer *Direction Sequence Size 
T7 F F 5’-TAA TAC GAC TCA CTA TAG GG-3’ 20 
12-1962 α4 F1 F 5’-CCA GGA TCA TCT TAC TGG ACT GGC-3’ 24 
12-0696 pCDM8 R R 5’-CCT CTA GAG TCG CGG CCG CGA CCT GCA G-3’ 28 
12-1691 α4 R1 R 5’-CAC CAT GCA CGT TTC AGG CTC ATT-3’ 24 
12-0786 α4 R2 R 5’-TTA ATC ATC ATT GCT TTT-3’ 16 
*F=forward, R=reverse 
 
2.2.2 Preparation of pCEP4_β7 
  
E. coli JM109 bacterial cells were transformed with pCEP4_β7 plasmid DNA before being 
cultured at 30 °C overnight. Transformed cells were isolated on Luria agar plates with 100 
µg/ml ampicillin and small scale plasmid DNA isolation was performed on colonies using the 
Bioflux Miniprep system (Bioer Technology Co., Ltd) according to manufacturer’s 
instructions. The pCEP F primer and a set of three designed primers were used to sequence 
the 2 767 bp β7 cDNA (Accession number NP_000880). The β7 F1 primer designed from nt 
557 to nt 578, the β7 F2 primer designed from nt 2 236 to nt 2 258, the β7 F3 primer 
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designed from nt 2 598 to nt 2 620, the β7 R1 primer designed from nt 2 379 to nt 2 397 and 
the β7 R2 primer designed from nt 24 to nt 45 were used (Table 2.3). 
 
Table 2.3 The primers that were used to sequence pCEP4_β7 clones 
 
*Primer *Direction Sequence Size 
12-0677 pCEP F F 5’-AGA GCT CGT TTA GTG AAC CG-3’ 20 
12-2941 β7 F1 F 5’-CCC ATT CTG TGC GCA TTG GTT T-3’ 22 
12-2942 β7 F2 F 5’-TAC CGG CTC TCG GTG GAA ATC TA-3’ 23 
13-1567 β7 F3 F 5’-CCA CCC AAG TAT ACA ATA AAG TC-3’ 23 
12-0893 β7 R1 R 5’-TCA GAG AGT GGG ACT GTC T-3’ 19 
13-1566 β7 R2 R 5’-GCT CAG GAC CAG CAG CAA AAC A-3’ 22 
*F=forward, R=reverse 
 
High quality plasmid DNA was prepared using the PureYield™ Plasmid Midiprep system 
(Promega, USA) for transfection and the concentration of plasmid DNA was determined 
spectrophotometrically using a Nanodrop 200 (Thermo Scientific, USA).  
 
2.2.3 Restriction enzyme digest to confirm pTARGETTM_α4 and pCEP4_β7 
 
pTARGETTM_α4 plasmid DNA was screened using Xho I and Sal l (Fermentas, USA) restriction 
enzymes and pCEP4_β7 plasmid DNA was screened using Kpn I and BamH I (Fermentas, 
USA) restriction enzymes. Restriction enzyme digests were performed using 1X restriction 
enzyme buffer, 500 ng plasmid DNA and 1 U restriction enzyme made up with nuclease free 
water to a total volume of 20 µL. The restriction enzyme reactions were incubated in a 37 °C 
water bath for 1 hour. The relevant insert and vector bands were visualised by 1% agarose 
gel electrophoresis. 
 
2.3 Protein expression 
 
2.3.1 Cell lines 
 
Several cell lines were used in this study, as well as cells isolated from human blood. 
HEK293T, CHO, CHO NL4-3 gp160, HeLa, TZM-bl, Raji-DC-SIGN and Raji-WT cell lines were 
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obtained from the National Institutes of Health (NIH) acquired immune deficiency syndrome 
(AIDS) Research and Reference Reagent Programme (ARP), USA.  
 
HEK293T is a human embryonic kidney derived cell line that is easily transfectable and 
commonly used to generate pseudovirus as HEK293T cells have the correct N-glycosylation 
machinery to accurately N-glycosylate HIV Env (Go et al. 2011; Go et al. 2013). The Chinese 
hamster ovary (CHO) cell line is frequently used in the expression of Env (Go et al. 2013; 
Crispin et al. 2006; Kamata et al. 1995; Scanlan et al. 2002). CHO NL4-3 gp160 is a positive 
control CHO cell line that stably expresses HIV gp160. 
 
HeLa is a cervical cancer derived cell line that endogenously expresses the α4 and β7 
integrins. Although no reference was available, HeLa whole cell lysates (Santa Cruz 
Biotechnology Inc., USA) are recommended as a positive control for Western blotting using 
antibodies specific for these integrins (http://datasheets.scbt.com/sc-365209.pdf, 
http://datasheets.scbt.com/sc-166031.pdf). The TZM-bl cell line is a HeLa derived cell line 
that is stably transfected with the CD4, CCR5 and CXCR4 receptors that are required for HIV 
attachment and entry. TZM-bl is an HIV reporter cell line as it carries a luciferase gene 
downstream of the viral LTR which is inducible by the HIV transactivator, Tat.  
 
HEK293T, CHO, CHO NL4-3 gp160, HeLa, and TZM-bl are adherent cell lines that were 
maintained in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% foetal 
calf serum (FCS) (Sigma Aldrich, USA), 100 U/mL penicillin and 100 U/mL streptomycin 
(Sigma Aldrich, USA). Cells were routinely passaged every 3 to 4 days by washing them with 
1X phosphate-buffered saline (PBS), lifting them with 0.25% Trypsin/0.1% EDTA (Lonza, 
South Africa) and transferring them to fresh 75 cm2 tissue culture flasks (T75) (Nest 
Biotechnology Co., Ltd).  
 
Raji is a Burkitt’s lymphoma derived B cell line. Raji-DC-SIGN cells are Raji-WT cells stably 
transfected to express the human DC-SIGN receptor (Wu et al. 2004). Raji-DC-SIGN and Raji-
WT are non-adherent cell lines that were maintained in Roswell Park Memorial Institute 
medium-1640 (RPMI) (Thermo Scientific, USA) supplemented with 10% FCS (Sigma Aldrich, 
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USA). Cells were routinely passaged every 5 to 6 days by replacing 10 mL cell culture with 10 
mL fresh RPMI with 10% FCS.  
 
All cell lines were routinely tested for Mycoplasma contamination as described previously 
(Lu et al. 1997). Slides were viewed on a Zeiss Axiovert 200 inverted fluorescent microscope 
(Carl Zeiss, Germany) with the assistance of S. Cooper (Department of Human Biology, UCT, 
South Africa).  
 
CD4+ T cells were isolated from human blood received from the Western Province Blood 
Transfusion Service (Pinelands, South Africa). Peripheral blood mononuclear cells (PBMC) 
were isolated using Ficoll and monocytes were removed using the adherence methodology. 
The remaining cells were induced with interleukin (IL) -2 (NIH ARP, USA) every 2 days for 6 
days in RPMI with 10% FCS and thereafter used for experiments. All cells were maintained at 
37 °C in 5% CO2. 
 
2.3.2 Comparison of PEI, PolyFect® and Electroporation for transfection of plasmid DNA 
into mammalian tissue culture cells 
 
Polyethylenimine (PEI) (Sigma Aldrich, USA), PolyFect® (QIAGEN, USA) and Electroporation 
(BIO-RAD, USA) were compared using two HIV env clones (CAP177_A3 and CAP206_E12-3) 
that were previously shown to have good expression using Western blot (Z. Woodman, 
unpublished data). A total of 7 µg plasmid DNA was introduced into 4X105 HEK293T cells in a 
6 well tissue culture dish with 22.5 µL PEI (1 mg/mL) and 21 µL PolyFect® (2 mg/mL) 
reagents, respectively in a final volume of 2 mL. The culture medium was changed 6 hours 
after transfection to remove the PEI-DNA complexes.  
 
The Electroporation of 4X105 HEK293T cells with 7 µg plasmid DNA (250 V for 25 ms, 
capacitance 2 000, resistance 1 500) in a total volume of 100 µL was performed at the 
IIDMM, UCT, South Africa. The Gene Pulser MXcell™ Electroporation System (BIO-RAD, USA) 
and a 96 well Electroporation plate were used. After Electroporation, the cells were diluted 
in 2 mL culture medium and plated into a 6 well tissue culture dish.  
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Cells transfected using PEI, PolyFect® and Electroporation were grown at 37 °C in 5% CO2 for 
48 hours. Transfected cells were centrifuged at 3 000 times gravitational (g) for 5 minutes at 
4 °C before lysed on ice with radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris, 150 
mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X 100) containing 0.1 g/mL 
phenylmethylsulfonyl fluoride (PMSF) protease inhibitor (Thermo Scientific, USA). Cell 
lysates were stored at -20 °C for up to a week until required. 
 
2.3.3 Transfection of HEK293T cells with pTARGETTM_α4 and pCEP4_β7 using PEI 
 
pTARGETTM_α4 (8 766 bp) and pCEP4_β7 (12 767 bp) plasmid DNA was transfected 
separately (Table 2.4 and Table 2.5) and co-transfected (Table 2.6) into 4X105 HEK293T cells 
in a 6 well tissue culture dish. 
 
 A ratio of 1 µg plasmid DNA to 3.5 µL 1 mg/mL PEI was used when increasing 
concentrations of plasmid DNA were transfected. In order to identify the optimal 
concentration of plasmid DNA for integrin expression, the amount of pTARGETTM_α4 
plasmid DNA was increased from 0.4 to 2 pmol while pCEP4_β7 plasmid DNA was increased 
from 0.2 to 2 pmol. The molar ratio of pTARGETTM_α4 to pCEP4_β7 plasmid DNA in co-
transfection experiments was 1:1. The total plasmid DNA concentration was not kept 
constant with the addition of pcDNATM3.1/V5-His TOPO® empty vector.  
 
The culture medium was changed 6 hours after transfection to remove the PEI-DNA 
complexes. Cells were grown at 37 °C in 5% CO2 for 48 hours in culture medium before the 
cells were either lysed with RIPA buffer containing PMSF for Western blot analysis or lifted 
with 1% EDTA in 1X PBS (Ca/Mg++ free) for flow cytometry analysis. A Bradford protein 
assay (BIO-RAD, USA) was used to determine the protein concentration of each sample and 
60 µg protein was loaded per well for SDS-PAGE and Western blot analysis. 
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Table 2.4 The relative molar amounts of pTARGETTM_α4 plasmid DNA that were used in 
transfections of HEK293T cells 
 
pTARGET
TM
_α4 (pmol) pTARGET
TM
_α4 (µg) pCEP4_β7 (µg) 
0.4 2.1 0 
0.8 4.2 0 
1.2 6.4 0 
1.6 8.6 0 
2 10.8 0 
 
Table 2.5 The relative molar amounts of pCEP4_β7 plasmid DNA that were used in 
transfections of HEK293T cells 
 
pCEP4_β7 (pmol) pTARGET
TM
_α4 (µg) pCEP4_β7 (µg) 
0.2 0 1.4 
0.4 0 2.96 
0.8 0 5.92 
1.2 0 8.9 
1.6 0 11.9 
2 0 14.9 
 
Table 2.6 The relative molar amounts of pTARGETTM_α4 and pCEP4_β7 plasmid DNA that 
were used in co-transfections of HEK293T cells 
 
pTARGET
TM
_α4 and pCEP4_β7 (pmol) pTARGET
TM
_α4 (µg) pCEP4_β7 (µg) 
0.1 0.53 0.74 
0.4 2.1 2.96 
0.8 4.2 5.92 
1 5.3 7.4 
 
2.3.4 Transfection of CHO cells with pTARGETTM_α4 and pCEP4_β7 using PEI and 
Electroporation 
 
CHO cells were co-transfected with pTARGETTM_α4 and pCEP4_β7 plasmid DNA as well as 
transfected individually with each integrin’s cDNA to test whether the cell type used for 
transfection may impact protein expression. The same PEI and Electroporation 
methodologies of transfection were used as before and total plasmid DNA was kept 
constant to control for the effect of high concentrations of plasmid DNA on the transfection 
efficiency. The α4β7 recombinant protein (5397-A3, R and D systems, England) was used as 
a positive control and pcDNATM3.1/V5-His TOPO® empty vector was used as a negative 
control. 
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Two HIV Env clones, CAP177_A3 (T/F) and CAP206_E12-3 (chronic) were electroporated into 
HEK293T and CHO cells to confirm the Electroporation methodology. The gp120 
recombinant protein (NIH ARP, USA) and the positive control cell line CHO NL4-3 gp160 (NIH 
ARP, USA) cell lysates (for the CHO transfections only) were used as positive controls. The 
pcDNATM3.1/V5-His TOPO® empty vector was used as a negative control. 
 
2.3.5 Using the pGL4 Luc reporter gene to determine transfection efficiency  
 
The luciferase reporter gene construct, pGL4 Luc (0.25 µg) and pTARGETTM_α4 or pCEP4_β7 
plasmid DNA (8 µg) were introduced into 4X105 HEK293T cells in a 6 well tissue culture dish 
using PEI as described. The culture medium was changed 6 hours after transfection to 
remove the PEI-DNA complexes and cells were grown at 37 °C in 5% CO2. pGL4 Luc (0.25 µg) 
was also co-transfected with increasing amounts (0.5 to 1.3 pmol) of pTARGETTM_α4 and 
pCEP4_β7 plasmid DNA added in a 1:1 molar ratio. Two HIV env clones, CAP177_A3 (T/F) 
and CAP206_E12-3 (chronic) (5 µg) that were previously shown to have high expression 
levels by Western blot were used as positive controls. Untransfected HEK293T cells and cells 
transfected with pcDNATM3.1/V5-His TOPO® empty vector were used as negative controls. 
Luciferase was read after 48 hours using 50 µL Brite-Glo lysis buffer with the Modulus™ 
Microplate Luminometer (Promega, USA). 
 
2.4 Protein detection 
 
2.4.1  PAGE and Western blot 
 
2.4.1.1 SDS-PAGE  
 
Cell lysates with equivalent total protein concentrations were mixed with 5X sample buffer 
(5% SDS, 20% glycerol, 0.1% bromophenol blue, 5% β-mercaptoethanol, pH 6.8) and boiled 
for 5 minutes. Samples were separated by SDS-PAGE using the mini PROTEANTM III system 
(BIO-RAD, USA) with 10% resolving (0.1% SDS, 375 mM Tris, pH 8.8) and 5% stacking (0.1% 
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SDS, 125 mM Tris, pH 6.8) gels in a Tris-glycine-SDS running buffer (25 mM Tris, 250 mM 
glycine, 0.1% SDS, pH 8.3) at 25 mA/gel. Gels were used for Western blotting as described 
below.  
2.4.1.2 Native PAGE 
 
Samples were mixed with sample buffer lacking SDS and β-mercaptoethanol (20% glycerol, 
125 mM Tris, 0.1% bromophenol blue, pH 6.8). Non-denaturing PAGE was performed in the 
same way as an SDS-PAGE, except SDS was excluded from the resolving gel, stacking gel and 
Tris-glycine-SDS running buffer. Gels were run at 25 mA/gel. 
 
2.4.1.3 Western blot 
 
After SDS-PAGE, protein was transferred to a polyvinylidene difluoride (PVDF) membrane 
(BIO-RAD, USA) in transfer buffer (20 mM Tris, 150 mM glycine, 20% methanol) at 10 V for 1 
hour using a semi-dry protein transfer system (Cleaver Scientific, USA). Gels were stained 
with Coomassie Blue [50% methanol, 10% acetic acid, 0.05% Brilliant Blue R-250, 40% 
distilled water (dH20)] and destained (70% dH20, 10% acetic acid, 20% methanol) to ensure 
complete transfer of the protein. After transfer, the membranes were incubated in blocking 
buffer overnight at 4 °C or shaking for 2 hours at room temperature (RT).  
 
Table 2.7 Primary and secondary antibodies used for the detection of the α4 and β7 
integrins 
  
Company *P/S Antibody 
Sigma Aldrich, USA Primary  Mouse anti-human integrin α4 WH0003676M1 
Sigma Aldrich, USA Primary  Mouse anti-human integrin β7 WH0003695M1 
Santa Cruz Biotechnology Inc., USA Primary Mouse anti-human integrin α4 sc-365209 
Santa Cruz Biotechnology Inc., USA Primary Mouse anti-human integrin β7 sc-166031 
NIH ARP Primary Mouse anti human integrin α4β7 Act-1 Cat#11718 
Santa Cruz Biotechnology Inc., USA Primary Mouse anti-human β-actin sc-47778 
Santa Cruz Biotechnology Inc., USA Primary Goat anti-mouse IgG-HRP conjugated sc-2005 
 
For protein detection, membranes were incubated for 1 hour with shaking in blocking buffer 
[Tris-buffered saline (TBS), 0.1% tween-20, 4% skim-milk] containing 1:100 dilution of the 
respective primary antibody (Table 2.7). The monoclonal antibody Act-1, raised against the 
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native human α4β7 integrin, was used to detect protein under non-reducing conditions. The 
membrane was washed four times for 15 minutes using blocking buffer before incubation 
with 1:2 000 dilution of the goat anti-mouse immunoglobulin G (IgG)-horseradish 
peroxidase (HRP) conjugated secondary antibody for 1 hour at RT with shaking and then 
washed as before with 1X TBS-T (TBS, 0.1% tween-20). The chemiluminescence system 
together with autoradiography was used for signal detection as per manufacturer’s 
instructions (KPL, USA). A recombinant human integrin α4β7 (R and D systems, England) 
(Figure 2.7) was used as a positive control at concentrations of up to 100 ng. A 1:2 000 
dilution of the mouse anti-human β-actin monoclonal antibody was used to ensure 
equivalent amounts of total protein were loaded. 
 
2.4.2 Flow cytometry 
 
HEK293T cells co-transfected with 1 pmol pTARGETTM_α4 and pCEP4_β7 plasmid DNA using 
the PEI transfection methodology were lifted with 1% EDTA in 1X PBS. Cells were 
centrifuged at 2 000 g for 5 minutes at RT, resuspended in 200 μL cold fluorescence-
activated cell sorting (FACS) buffer (1X PBS containing 2% FCS) and stained with 0.4 µg/mL 
Act-1 monoclonal antibody on ice for 1 hour. The cells were washed by centrifugation three 
times at 2 000 g for 5 minutes at 4 °C with cold FACS buffer. Cells were then incubated with 
7.7 µg/mL Cy3® goat anti-mouse IgG in cold FACS buffer on ice in the dark for 1 hour. The 
cells were washed three times, resuspended in 200 µL FACS buffer and data was acquired by 
E. Smit from the South African Tuberculosis Vaccine Initiative laboratory (IIDMM, UCT, South 
Africa) on a FACS FortessaTM flow cytometer (BD Biosciences, USA). Control samples of 
unstained cells and secondary antibody-only stained cells were included. HeLa and TZM-bl 
cells that endogenously express the α4 and β7 integrins were used as positive controls. Data 
was analysed by D. Bowers (IIDMM, UCT, South Africa) using FloJo software (v 8.8.2, Tree 
Star, Stanford, CA). 
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2.5 Binding assay 
 
2.5.1 Pseudovirus production 
 
Two HIV env clones, CAP45_B5 (T/F) and CAP177_47 (chronic), were used to produce 
pseudovirus for the subsequent binding assays. HIV backbone plasmid DNA, HIV pSG3Δenv 
(5 µg) (Accession number L02317), together with either env clone (2.5 µg) were introduced 
into 4X105 HEK293T cells in a 6 well tissue culture dish using the PEI transfection 
methodology as described. The culture medium was changed 6 hours after transfection to 
remove the PEI-DNA complexes and cells were grown at 37 °C in 5% CO2. Pseudovirus was 
harvested from the supernatants and clarified through a 0.2 µm filter prior to storage in 20% 
FCS at -80 °C. The amount of pseudovirus was quantified using a p24 enzyme-linked 
immunosorbent assay (ELISA). 
 
2.5.2 p24 ELISA 
 
Lyophilized sheep anti-HIV p24 gag, affinity purified, coating antibody (5.5 ng/mL) (Aalto Bio 
reagents #D7320) in 1X NaHCO3 (pH 8.5) buffer was used to coat high binding Porvair 96 
well plates (WhiteSci, USA) overnight at RT. The plates were washed three times with 1X TBS 
and blocked with 100 µL/well 5% bovine serum albumin (BSA) in 1X TBS for 1 hour at RT. 
The plates were washed nine times with 1X TBS and dried. Eight p24 standards (16, 8, 4, 2, 
1, 0.5, 0.25 and 0 ng/mL) were prepared using lyophilized recombinant HIV-p24 (Aalto Bio 
reagents #AG6054) diluted in 1% Empigen in 1 XTBS. Pseudovirus was inactivated with 
1.25% Empigen in 1X PBS for 1 hour before the p24 ELISA was performed.  
 
The inactivated pseudovirus samples were first diluted 1:50, 1:100, 1:200, 1:400 and 1:800 
in 1% Empigen in 1X TBS and then 100 µL/well was added to the plates. The p24 standards 
were added (100 µL/well) in triplicate before the plates were incubated for 3 hours at RT. 
Empty rows were filled with 1X TBS to minimize evaporation. The plates were washed nine 
times with 1X TBS and dried before incubation with 100 µL secondary conjugate EH12AP 
(Aalto Bio reagents #BC-1071-AP) diluted 1:64 000 in 1X TBS, 20% sheep serum, 0.05% 
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Tween. The plates were incubated for 1 hour at RT and then washed nine times with 0.1% 
Tween in 1X TBS and dried. The plates were washed an additional two times with 1X TROPIX 
buffer (Applied Biosystems, USA) and dried. TROPIX CPD Star/Sapphire II (Applied 
Biosystems, USA) was diluted 1:4 in 1X TROPIX buffer and 50 µL/well was added to the 
plates. The plates were incubated for 5 minutes before luminescence was measured on a 
Modulus™ Microplate Luminometer (Promega, USA).  
 
2.6 Sequencing the flanking regions of α4 in pTARGETTM_α4 
 
The sequence upstream and downstream of the α4 insert in the pTARGETTM vector was 
sequenced to determine whether the α4 cDNA insert was inserted into the vector in the 
correct orientation during sub-cloning. The α4 F2 primer designed from nt 2 877 to nt 2 900 
and the α4 R3 primer designed from nt 778 to nt 800 were synthesised and used to 
determine the sequence upstream of the α4 cDNA start codon and the sequence 
downstream of the α4 cDNA stop codon (Table 2.8). 
 
Table 2.8 The primers used to sequence the flanking regions of α4 in pTARGETTM_α4  
 
*Primer *Direction Sequence Size 
12-1692 α4 F2 F 5’-TGC GCA TGT TCT ACT GGA AGG ACT-3’ 24 
12-1963 α4 R3 R 5’-TCG GTA GTA TGC TGG CTC CGA AA-3’ 23 
*F=forward, R=reverse 
 
2.6.1 Binding of high and low concentrations of pseudovirus to α4β7 expressing HeLa 
cells in the presence and absence of increasing concentrations of Act-1  
 
One day before binding 8X105 HeLa cells, endogenously expressing α4 and β7, were plated 
in a 6 well tissue culture dish. HeLa cells were incubated with 0 nM, 33 nM, 66 nM or 99 nM 
Act-1 for 1 hour. Unbound Act-1 was removed when cells were washed twice with 1X PBS. 
Approximately 200 ng and 5 ng p24 CAP45_B5 (T/F) and CAP177_47 (chronic) pseudovirus 
was added to the HeLa cells in triplicate. Binding was allowed for 2.5 hours at 37 °C in 5% 
CO2. Unbound pseudovirus was removed and cells were washed by centrifugation three 
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times with 1X PBS at 2 000 g for 5 minutes at RT. Cells were lysed on ice at 4 °C with 300 µL 
RIPA buffer containing PMSF. The concentration of p24 in the cell lysates were determined 
by a P24 ELISA to measure the amount of pseudovirus bound to the cells.  
 
2.6.2 Binding of pseudovirus to TZM-bl cells in the presence and absence of Act-1  
 
TZM-bl cells were tested in the same binding assay as described with 33 nM Act-1. A day 
before binding, 8X105 TZM-bl cells were plated in a 6 well tissue culture dish and were 
incubated with 0 nM and 33 nM Act-1 for 1 hour. Unbound Act-1 was removed when cells 
were washed twice with 1X PBS. Approximately 200 ng p24 pseudovirus of all five T/F and 
chronic infection Env clones was added to the TZM-bl cells in triplicate. Binding was allowed 
for 2.5 hours at 37 °C in 5% CO2. Unbound pseudovirus was removed and cells were washed 
by centrifugation three times with 1X PBS at 2 000 g for 5 minutes at RT. Infection was read 
after 48 hours using 50 µL Brite-Glo lysis buffer with the Modulus™ Microplate 
Luminometer (Promega, USA). 
 
2.6.3 Binding of pseudovirus to CD4+ T cells isolated from blood in the presence and 
absence of Act-1 
 
Buffy packs of human blood from healthy donors were received from the Western Province 
Blood Transfusion Service, Cape Town, South Africa. Ficoll Histopaque®-1077 (Sigma Aldrich, 
USA) (15 mL) was added to Leucosep® (50 mL) tubes and centrifuged at 2 000 g for 1 minute 
at RT so that the Ficoll moved below the porous separation disc. The blood was diluted 2:3 
1X PBS:blood, added (30 mL) to the Leucosep® tubes and centrifuged at 3 000 g for 10 
minutes at RT. The porous disc insured that the interface between the Ficoll and the blood 
was not disturbed upon adding the blood.  
 
The plasma and PBMC layer had a lower density than the Ficoll and therefore remained 
above the Ficoll while the high density erythrocytes moved below the Ficoll layer. The 
plasma layer (~5 mL) on the surface was discarded and the PBMC layer seen as a thin white 
‘buffy’ layer was removed and washed twice with 1% FCS in 1X PBS. Cells were resuspended 
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in RPMI with 10% FCS and monocytes were allowed to adhere for 4 hours at 37 °C in 5% 
CO2. Thereafter the culture medium was removed and placed into a T75. The cells were 
induced with 10 U/mL IL-2 (NIH ARP, USA) every 2 days for 6 days in RPMI. On the seventh 
day cells were counted and 2.5X106 cells/mL were incubated with 0 nM and 33 nM Act-1 for 
1 hour at 37 °C in 5% CO2 (Parrish et al. 2012). Cells were washed twice with centrifugation 
at 3 000 g for 3 minutes at RT. Cells were incubated with 100 ng p24 CAP45_B5 (T/F) and 
CAP177_47 (chronic) pseudovirus and allowed to bind for 5 hours before unbound 
pseudovirus was removed and the cells were washed four times with RPMI at 3 000 g for 3 
minutes at RT. Cells were lysed with 1.25% Empigen in 1X PBS and a p24 ELISA was 
performed to measure the amount of bound pseudovirus.  
 
2.7 DC-SIGN mediated trans-infection 
 
2.7.1 Flow cytometry to determine DC-SIGN expression on Raji-DC-SIGN cells 
 
One million Raji-DC-SIGN cells were centrifuged at 2 000 g for 5 minutes at RT, resuspended 
in 200 μL cold FACS buffer (1X PBS containing 2% FCS) and stained with either 5 µg/mL 
PerCP-CyTM5.5 anti-human CD209 (DC-SIGN) antibody (BD PharmingenTM, San Jose, USA) or 
5 μg/mL PerCP-CyTM5.5 Mouse IgG2b, ĸ Isotype control (BD PharmingenTM, San Jose, USA) 
for 45 minutes at 4 °C in the dark. Cells were then washed four times with 1 mL cold FACS 
buffer and centrifuged at 2 000 g for 5 minutes at 4 °C. Cells were resuspended in 200 µL 
cold FACS buffer and D. Bowers (IIDMM, UCT, South Africa) acquired the data on a FACS 
CaliberTM flow cytometer (BD Biosciences, USA) and analysed the data using FloJo software 
(v 8.8.2, Tree Star, Stanford, CA). As a control the same procedure was performed on Raji-
WT cells not expressing DC-SIGN. 
 
2.7.2 DC-SIGN mediated trans-infection assay 
 
The DC-SIGN mediated HIV trans-infection assay was conducted as described previously 
(Alexandre et al. 2012). Pseudovirus was normalised on p24 values determined by a p24 
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ELISA and 7.5X104 Raji-DC-SIGN cells were incubated with 10 ng p24 pseudovirus in a rolling 
incubator at 37 °C for 2.5 hours. After incubation the Raji-DC-SIGN cells were washed three 
times with culture medium using centrifugation at 2 000 g for 5 minutes at RT. Raji-DC-SIGN 
cells were resuspended in culture medium and co-cultured in triplicate with 6X104 TZM-bl 
cells that were plated the day before. Infection was read after 48 hours using 50 µL Brite-
Glo lysis buffer (Promega, USA) with the Modulus™ Microplate Luminometer (Promega, 
USA). As a control for the presence of DC-SIGN, the same procedure was performed on Raji-
WT cells not expressing DC-SIGN. 
 
2.7.3 Site-directed mutagenesis 
 
CAP239_E11 (T/F) and CAP239_T35 (chronic) env clones were chosen to undergo SDM at 
two PNG sites. The PNGs (NXS/T) at position N386 and N392 (according to HXB2 numbering) 
were mutated by changing the codon corresponding to the asparagine to that of a 
glutamine (N386Q and N392Q), thereby abolishing N-glycosylation at these sites. Similarly, 
double mutants lacking both PNGs were generated (N386Q,N392Q). 
 
In total four single mutants (239_E11_N386Q, 239_T35_N386Q, 239_E11_N392Q, 
239_T35_N392Q) and two double mutants (239_E11_N386Q,N392Q and 
239_T35_N386Q,N392Q) were generated. Mutagenesis was performed using a PCR based 
methodology adapted from Quickchange® site-directed mutagenesis protocol (Stratagene La 
Jolla, CA, USA). Complementary oligonucleotides containing the desired mutation were 
designed using WATCUT (http://watcut.uwaterloo.ca/watcut designed by Michael Palmer, 
University of Waterloo, Canada) with restriction analysis and silent mutation analysis 
software.  
 
Restriction enzyme sites were introduced through silent mutations to facilitate screening. A 
BsaW I (New England Bio labs, USA) restriction enzyme site was introduced into both N386Q 
mutants and an Acl I (Fermentas, USA) restriction enzyme site was introduced into both 
N392Q mutants. The double mutants contained both restriction enzyme sites. The primers 
used in SDM are indicated in Table 2.9 with the asparagine to glutamine transition at the N-
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glycosylation sites at position N386 and N392 highlighted in bold and the introduced silent 
mutation incorporating a restriction enzyme recognition site underlined. 
 
Mutagenesis was performed with Phusion Hot Start II High-Fidelity DNA Polymerase 
(Thermo Scientific, USA) (Parameters: 94 °C 5 minutes, 20 cycles of 94 °C 30 seconds, 55 °C 
30 seconds and 72 °C 12 minutes followed by 72 °C 12 minutes). Aliquots of the PCR 
products were visualised by 1% agarose gel electrophoresis, while the remainder was Dpn I 
(Thermo Scientific, USA) digested overnight to fragment methylated template DNA. E. coli 
JM109 competent cells were transformed with the Dpn I digested PCR products and 
colonies were selected on Luria agar plates with 100 µg/ml ampicillin (Sigma Aldrich, USA). 
 
Table 2.9 The site-directed mutagenesis primers used in generating CAP239_E11 (T/F) and 
CAP239_T35 (chronic) N-glycan mutants 
 
*Primer *Direction *Sequence Size 
239_N386Q F F 5’-GAG GAG AAT TTT TCT ATT GCC AGA CAT CCG GTC TGT TTA ATG G-3’ 43 
239_N386Q R R 5’-CCA TTA AAC AGA CCG GAT GTC TGG CAA TAG AAA AAT TCT CCT C-3’ 43 
239_N392Q F F 5’-CTA TTG CAA TAC AT CAG GCC TGT TTC AGG GAA CGT TTA ATG GTA C-3’ 45 
239_N392Q R R 5’-GTA CCA TTA AAC GTT CCC TGA AAC AGG CCT GAT GTA TTG CAA TAG-3’ 45 
239_N386Q,N392Q F F 5’-CTA TTG CCA GAC ATC CGG TCT GTT TCA GGG AAC GTT TAA TGG TAC-3’ 45 
239_N386Q,N392Q R R 5’-GTA CCA TTA AAC GTT CCC TGA AAC AGA CCG GAT GTC TGG CAA TAG-3’ 45 
*F=forward, R=reverse 
*Restriction enzyme sites introduced by silent mutation are underlined and nucleotide changes are highlighted in bold 
 
Plasmid DNA was isolated from overnight cultures using the crude sodium chloride, tris, 
ethylenediaminetetraacetic acid, Triton X-100 (STET) boiling minilysate preparation 
methodology. Overnight cultures (2 mL) were centrifuged at 13 000 g for 2 minutes at RT. 
The supernatant was discarded and the cell pellet was resuspended in 250 µL STET buffer 
(8% Sucrose, 5% Triton X-100, 50 mM EDTA, 50 mM Tris pH 8.0) containing 1 mg/mL 
lysozyme. The samples were vortexed, boiled for 1 minute and centrifuged at 13 000 g for 8 
minutes at RT. The pellet was discarded and an equal volume of isopropanol was added. 
After an additional 13 000 g centrifugation for 8 minutes at RT the supernatant was 
discarded and the air dried pellet was resuspended in 30 µL nuclease free water.  
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The plasmid DNA was precipitated by using 1/10th volume 3 M sodium acetate (pH 5.2) and 
2.5X total volume cold absolute ethanol. After mixing very well, the plasmid DNA was 
incubated at -20 °C for 30 minutes before centrifugation at 13 000 g for 30 minutes at RT. 
The plasmid DNA pellet was washed with 1 mL 70% ethanol by centrifugation for 15 minutes 
at RT. The supernatant was discarded and the pellet was resuspended in nuclease free 
water. The STET prepared plasmid DNA was screened by restriction enzyme digestion for 
positive clones and visualised by 1% agarose gel electrophoresis where loading dye (0.25% 
bromophenol blue, 0.25% xylene cyanol, 30% glycerol) contained RNase. The same 
approach was used to generate the single and double N-glycan mutants however the single 
mutants were used as the template for the double mutant PCR reactions. A Bioflux Miniprep 
kit (Bioer Technology Co., Ltd) was used to isolate plasmid DNA for sequencing of the entire 
env, using primers listed in Table 2.10, thus confirming the presence of the mutations.  
 
Table 2.10 The primers used for sequencing env N-glycan mutants 
 
Primer *Direction Sequence Size 
For14 F 5’-TAT GGG ACC AAA GCC TAA AGC CAT GTG-3’ 27 
For16 F 5’-TTT AAT TGT GGA GGA GGA TTT TTC TA-3’ 26 
EF00 F 5’-GGG AAA GAG CAG AAG ACA GTG GCA ATG A-3’ 28 
EF200 F 5’-GGG ATA ACA TGA CCT GGA TGC AGT GGG-3’ 27 
EF260 F 5’-TTC AGC TAC CAC CGA TTG AGA GAC T-3’ 25 
EF15 R 5’-CTT GCT CTC CAC CTT CTT CTT C-3’ 22 
EF55 R 5’-GCC CCA GAC CGT GAG TTG CAA CAT ATG-3’ 27 
Rev15 R 5’-CTG CCA TTT AAC AGC AGT TGA GTT GA-3’ 26 
Rev19 R 5’-ACT TTT TGA CCA CTT GCC ACC CAT-5’ 24 
*F=forward, R=reverse 
 
2.7.4 DC-SIGN mediated trans-infection of N-glycan mutants 
 
The trans-infection assay was repeated as outlined above with WT env clones and CAP239 
T/F and chronic infection N-glycan SDM mutants.  
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2.7.5 DC-SIGN binding 
 
The DC-SIGN binding assay was performed as previously described (Van`Montfort et al. 
2011). Approximately 10 ng p24 pseudovirus was added to 1X106 Raji-DC-SIGN cells and 
incubated in a rolling incubator at 37 °C for 2.5 hours. After incubation the Raji-DC-SIGN 
cells were washed three times with culture medium using centrifugation at 2 000 g for 5 
minutes at RT. Cells were lysed in 130 µL 1% Empigen in 1X TBS and stored at 4 °C overnight. 
The amount of cell-bound pseudovirus was quantified using a p24 ELISA. As a control for the 
presence of DC-SIGN, the same assay was performed with Raji-WT cells not expressing DC-
SIGN. 
2.8 Statistical analysis 
 
All statistical analysis was performed on GraphPad Prism version 5.00 for Windows, 
GraphPad Software, La Jolla California USA, www.graphpad.com, analysed with in-built 
statistical software and represented graphically. A non-parametric Mann-Whitney two-
tailed t-tests was performed and the results are indicated as statistically significant with a * 
when p<0.05 and ** when p<0.01. 
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Chapter 3: Development of an α4β7 reactivity assay using 
transient integrin expression in mammalian cell lines 
 
3.1 Introduction 
 
The α4β7 integrin is a heterodimer consisting of the non-covalently attached α4 and β7 
integrins (Buck & Horwitz 1987). The α4β7 integrin is a homing receptor expressed on CD4+ 
T cells that mediates the migration of CD4+ T cells from gut inductive sites to the gut (Cicala 
et al. 2009). The α4β7 integrin binds to gp120 via a tripeptide in the V2 loop of HIV that is 
highly conserved across subtypes A, B, C and D (Arthos et al. 2008) suggesting that the 
gp120-α4β7 interaction provides a certain advantage (Arthos et al. 2008; Cicala et al. 2009). 
Although, the presence of CD4 and CCR5 is sufficient for HIV infection, α4β7, due to its size 
(22 nm), might act as an anchor, concentrating virus on the cell’s surface and enhancing viral 
attachment to CD4 (7 nm) and a co-receptor (Cicala et al. 2009).  
 
CD4, CCR5 and α4β7 form close complexes on the cell membrane (Cicala et al. 2009) and 
this proximity suggests that variants exhibiting optimal α4β7 reactivity may be able to 
engage the CD4 and CCR5 receptors better than those with low α4β7 reactivity. In fact, HIV 
variants with higher α4β7 reactivity were shown to bind CD4 better than those with lower 
reactivity (Cicala et al. 2009). Variants with high α4β7 reactivity should preferentially infect 
CCR5+ CD4+ T cells carrying α4β7, which may explain why T/F viruses seem to utilise CCR5 
exclusively (Keele et al. 2008). Subtype A and C T/F variants have been shown to bind α4β7 
better than chronic infection variants (Nawaz et al. 2011) although this finding was not 
supported by a recent study (Parrish et al. 2012).  
 
HIV T/F variants are distinct in that they are R5 tropic, have shorter variable loops (Chohan 
et al. 2005) and carry less N-linked glycans in the V2/V4 domains compared with chronic 
infection variants (Derdeyn et al. 2004). The introduction of N-glycans over the course of 
infection is a viral strategy used to evade humoral immune responses as the carbohydrate 
structures shield antibody epitopes from recognition (Binley et al. 2010; Reitter et al. 1998; 
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Sagar et al. 2006). The difference in T/F N-glycosylation compared to viruses found later in 
infection was predominantly observed in the V2 loop (Derdeyn et al. 2004), the α4β7 
binding site domain, where the presence of fewer N-glycans might facilitate T/F Env binding 
to α4β7. Nawaz et al. (2011) demonstrated that PNGs in the V1/V2 loop as well as the more 
distal C3/C4 domain influenced α4β7 reactivity but the authors concluded that this 
interference was due to changes in gp120 conformation and not due to steric hindrance. 
Overall, T/F variants might carry an optimal arrangement of N-glycans that facilitate 
enhanced α4β7 reactivity, suggesting that α4β7 may play a central role in HIV transmission. 
We hypothesise that T/F variants carry α4β7 binding sites with higher affinity for α4β7 
possibly due to the presence or absence of specific PNGs that allow them to interact with 
the α4β7 integrin more efficiently compared with their chronic infection counterparts.  
 
Decreased binding to α4β7 was associated with lower viral loads (Ansari et al. 2011) and 
variants with mutated α4β7 binding sites demonstrated reduced viral replication (Arthos et 
al. 2008). These findings support the hypothesis that α4β7 reactivity may be a distinguishing 
feature of T/F viruses. However, recently it was shown that the infectivity of subtype C T/F 
and chronic infection variants was not inhibited by blocking α4β7 with a monoclonal 
antibody (Parrish et al. 2012), suggesting that α4β7 might not play a role in HIV 
transmission. These studies did not utilise longitudinal samples to compare T/F with chronic 
infection variants and comparison of pseudovirus with IMC might have led to conflicting 
results with regard to gp120-α4β7 interactions. Therefore, this study aimed to investigate 
α4β7 reactivity by comparing HIV subtype C T/F with chronic infection variants from the 
same participants. 
 
3.2 Results 
 
3.2.1 Sub-cloning of α4 cDNA and preparation of pCEP4_β7 
 
Although other studies have utilised α4β7+ CD4+ T cells to measure α4β7 reactivity (Nawaz 
et al. 2011; Cicala et al. 2009), this project aimed to express α4β7 in a mammalian cell line in 
order to circumvent potential PBMC donor variation. Furthermore, in order to measure the 
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reactivity between α4β7 and trimeric Env, pseudovirus was generated carrying our subtype 
C T/F and chronic infection env clones. We planned to transiently express α4β7 in HEK293T 
cells and then compare the binding ability of Env pseudotyped variants. The integrin’s cDNA, 
in expression cassettes pCDM8_α4 and pCEP4_β7 were a gift from Prof D. Erle, University of 
California, USA (Kamata et al. 1995; Erle et al. 1991).  
 
The pCDM8 vector carrying the α4 cDNA utilised the tyrosine tRNA suppressor and p3 
plasmid system for plasmid selection. As this methodology was not set up in our lab and due 
to constraints on importing competent cells at the time we sub-cloned the α4 cDNA into the 
pTARGETTM expression vector using TA cloning. Primers were designed and synthesised to 
amplify the α4 cDNA (3 096 bp) using the pCDM8_α4 plasmid DNA as a template. The PCR 
product was A-tailed and ligated to pTARGETTM, a linear T-tailed vector specifically designed 
for TA cloning.  
 
 
Figure 3.1 Restriction enzyme digestion confirmed pTARGET
TM
_α4 plasmid DNA. A single and double 
restriction enzyme digest using the Xho I and Sal I restriction enzymes confirmed the presence of the α4 cDNA 
insert (3 096 bp) in the pTARGET
TM
 vector (5 670 bp), visualised by 1% agarose gel electrophoresis.  
 
In order to confirm that the PCR product of α4 was correctly cloned into the pTARGETTM 
vector, plasmid DNA extracted from colonies screened to carry the insert in the correct 
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orientation was digested with Xho I and Sal I. A single Xho I and Sal I restriction enzyme 
digest of pTARGETTM_α4 resulted in a 8 766 bp band that corresponded to the length of the 
linearized pTARGETTM_α4 plasmid DNA. A double Xho I and Sal I restriction enzyme digest of 
pTARGETTM_α4 resulted in two bands at 5 670 bp and at 3 096 bp that corresponded to the 
pTARGETTM vector and the α4 cDNA insert, respectively (Figure 3.1).  
 
The pCEP4_β7 plasmid DNA was transformed into E. coli JM109 competent cells and 
amplified using antibiotic selection. Single and double restriction enzyme digestions with 
Kpn I and BamH l were carried out to confirm that the correct plasmid DNA had been 
isolated. 
 
 
Figure 3.2 Restriction enzyme digests confirmed pCEP4_ β7 plasmid DNA. A single and double restriction 
enzyme digest using the Kpn I and BamH I restriction enzymes confirmed the presence of the β7 cDNA insert 
(2767 bp) in the pCEP4 vector (10 200 bp), visualised by 1% agarose gel electrophoresis.  
 
A single Kpn I restriction enzyme digest of pCEP4_β7 resulted in a ≥ 10 000 bp band that 
corresponded to the length of the linearized pCEP4_β7 plasmid DNA (12 967 bp). A single 
BamH I and a double Kpn I and BamH I restriction enzyme digest resulted in two bands at ≥ 
10 000 bp and at 2 767 bp that corresponded to the pCEP4 vector (10 200 bp) and the β7 
cDNA insert, respectively (Figure 3.2).  
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Single and double restriction enzyme digests visualised by agarose gel electrophoresis 
confirmed the presence of the α4 and β7 cDNA inserts in the pTARGETTM and pCEP4 vectors, 
respectively. 
 
3.2.2 Sequence analysis of the α4 and β7 integrin cDNAs 
 
Although, restriction enzyme digestion had confirmed pTARGETTM_α4 and pCEP4_β7 
plasmid DNA, we confirmed the sequence identity of both constructs by designing and 
synthesising primers to sequence the α4 and β7 inserts (Figure 3.3).  
 
 
Figure 3.3 DNA sequencing confirmed the identity of the α4 and β7 cDNAs cloned into the pTARGET
TM 
and 
pCEP4 vectors, respectively. The contigs were generated in ChromasPro using overlapping sequences from 
primers complimentary to the insert sequences. In order to indicate that the entire cDNA of α4 and β7 was 
cloned, only the 5’ and 3’ ends of both α4 and β7 are indicated aligned to the GenBank sequences accession 
numbers NP_000876 and NP_000880, respectively. Matched nucleotides are indicated with dots. The start of 
the open reading frames (methionine, M) of the integrins is indicated by a rectangular box in each alignment 
and the stop codon represented by a * is indicated by a rectangular box.  
 
Sequence analysis confirmed that the entire cDNA of both α4 and β7 were inserted into the 
pTARGETTM and pCEP4 vectors, respectively and matched 100% with the GenBank sequence 
[α4 (NP_000876) and β7 (NP_000880)] (Figure 3.3). 
 
3.2.3 Expression of α4β7 in mammalian cells 
 
3.2.3.1 Determining the optimum transfection methodology 
 
This study aimed to utilise HEK293T cells transiently co-transfected with α4 and β7 
expression vectors to measure the α4β7 reactivity of HIV T/F and chronic infection Env 
clones. In order to determine the transfection methodology that resulted in the most 
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optimal expression of α4β7, two HIV env clones, CAP177_A3 (T/F) and CAP206_E12-3 
(chronic) that were previously shown to have high expression levels by Western blot were 
used to compare the transfection of HEK293T cells using PEI, PolyFect® and Electroporation.  
 
Figure 3.4 Transfections with PEI and PolyFect
®
 resulted in high HIV env expression compared with 
Electroporation. A gp120 Western blot compared env expression using PEI, PolyFect
®
 and Electroporation 
transfection methodologies. CAP177_A3 (T/F) and CAP206_E12-3 (chronic) env clones were transfected into 
HEK293T cells. Equivalent total protein (60 µg) of cell lysates was loaded per well. A 1:3 000 dilution of the 
anti-gp120 antibody (Mouse antiserum to HIV gp120, NIH ARP) was used. The pcDNA
TM
3.1/V5-His TOPO
®
 
empty vector (pcDNA) was included to control for non-specific binding of antibodies. A gp120 soluble 
recombinant protein (50 ng) (120 kDa) was included to control for successful Western blotting and β-actin (42 
kDa) was included as a loading control. The exposure time for this Western blot was 5 minutes. The molecular 
weight marker is indicated. 
 
Western blot analysis revealed that both PEI and PolyFect® transfections resulted in high Env 
expression in HEK293T cells compared with Electroporation (Figure 3.4). Even though 
Electroporation was used to stably express α4 and β7 from pCDM8_α4 and pCEP4_β7 
plasmid DNA in K562 human erythroleukemia cells (Abitorabi et al. 1997), Electroporation 
did not result in high protein expression, but rather poor Env expression. In all the 
experimental samples a single band was visible corresponding to gp160 as it ran higher than 
the gp120 band in the positive control, indicating unprocessed HIV Env. It has been 
previously shown that cell-associated gp160 is present at much higher concentrations than 
gp120 in cell lysates (Pfeiffer et al. 2006; Asmal et al. 2011).  
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The PolyFect® CAP206_E12-3 sample showed higher expression than the corresponding PEI 
sample although the corresponding β-actin band suggested that more total protein was 
loaded in this lane. As PEI was more cost effective and there were no major variations 
between PEI and PolyFect®, PEI was used for the expression of α4 and β7. 
 
3.2.3.2 Transfection of HEK293T cells and Western blot analysis with different primary 
antibodies for the detection of α4β7 
 
HEK293T cells were both singly transfected as well as co-transfected with pTARGETTM_α4 
and pCEP4_β7 plasmid DNA using PEI (Figure 3.5).  
 
Figure 3.5 Western blot did not detect α4 or β7 integrins in transfected HEK293T cell lysates using antibodies 
from Sigma Aldrich, USA. pTARGET
TM
_α4 (1 pmol) and pCEP4_β7 plasmid DNA (1 pmol) was transfected 
separately transfected and co-transfected into HEK293T cells using PEI. Equivalent total protein (60 µg) of cell 
lysates was loaded per well A) A 1:100 dilution of the anti-α4 antibody (Sigma Aldrich, USA) was used to detect 
the expression of the α4 integrin and B) A 1:100 dilution of anti-β7 antibody (Sigma Aldrich, USA) was used to 
detect the expression of the β7 integrin in the transiently transfected HEK293T cells. Cells only (HEK293T) and 
pcDNA
TM
3.1/V5-His TOPO
®
 empty vector (pcDNA) were included to control for non-specific binding of 
antibodies. An α4β7 recombinant protein (100 ng) (150 kDa) was included to control for successful Western 
blotting and β-actin (42 kDa) was included as a loading control. The exposure time for both Western blots was 
8 minutes. The molecular weight marker is indicated. 
 
A Western blot using the anti-α4 antibody (Sigma Aldrich, USA) detected the positive 
recombinant protein at 150 kDa and cell lysates generated from transfection with 
pcDNATM3.1/V5-His TOPO® empty vector did not yield any bands as expected. However, cells 
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transfected with 1 pmol pTARGETTM_α4 and co-transfected with 1 pmol pTARGETTM_α4 and 
pCEP4_β7 showed no α4 expression even though the band corresponding to β-actin 
indicated comparable loading of samples (Figure 3.5A).  
 
A Western blot using the anti-β7 antibody (Sigma Aldrich, USA) did not detect the positive 
recombinant protein at 130 kDa, even when 100 ng recombinant protein was loaded. Cell 
lysates generated from transfection with pcDNATM3.1/V5-His TOPO® empty vector did not 
yield any bands as expected while cells transfected with 1 pmol pCEP4_ β7 and co-
transfected with 1 pmol pTARGETTM_α4 and pCEP4_ β7 showed no β7 expression even 
though the band corresponding to β-actin indicated comparable loading of samples (Figure 
3.5B). 
 
Transfections and Western blots were repeated and conditions were altered to optimise 
integrin detection but there was no improvement. As the anti-β7 antibody (Sigma Aldrich, 
USA) was unable to detect the commercially available α4β7 recombinant protein (R and D 
systems, England) an alternative antibody (Santa Cruz Biotechnology Inc., USA) was 
purchased. As it was possible that the anti-α4 antibody was not specific enough to detect 
low levels of integrin expression, a new commercially available antibody was purchased.  
 
When we acquired the second set of antibodies (Santa Cruz Biotechnology Inc., USA) the 
data sheet indicated that HeLa cell lysates could be used as a positive control in Western 
blotting as these cells endogenously express α4 and β7, although no supporting literature 
was found or could be supplied by Santa Cruz Biotechnology Inc. We included HeLa and 
TZM-bl (HeLa derived) cell lysates in subsequent Western blots as positive controls.  
 
HEK293T cells were separately transfected and co-transfected with increasing 
concentrations of pTARGETTM_α4 and pCEP4_β7 plasmid DNA and protein expression was 
detected using the newly purchased antibodies (Santa Cruz Biotechnology Inc., USA) (Figure 
3.6).  
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Figure 3.6 Western blot did not detect the α4 and β7 integrins in transfected HEK293T cell lysates using 
antibodies from Santa Cruz Biotechnology Inc., USA. Increasing amounts of pTARGET
TM
_α4 (0.4, 0.8, 1.6 and 2 
pmol) and pCEP4_β7 plasmid DNA (0.2, 0.4, 0.8, 1.4, 1.6 and 2 pmol) were transfected separately into 
HEK293T cells and increasing amounts of pTARGET
TM
_α4 (0.1, 0.4, 0.8 and 1pmol) and pCEP4_β7 plasmid DNA 
(0.1, 0.4, 0.8 and 1pmol) were co-transfected into HEK293T cells. A) A 1:100 dilution of anti-α4 antibody (Santa 
Cruz Biotechnology Inc., USA) was used to detect the expression of the α4 integrin and B) a 1:100 dilution of 
anti-β7 antibody (Santa Cruz Biotechnology Inc., USA) was used to detect the expression of the β7 integrin in 
the transiently transfected HEK293T cells and C) A 1:100 dilution of anti-α4 antibody (Santa Cruz Biotechnology 
Inc., USA) was used to detect the expression of the α4 integrin and D) A 1:100 dilution of anti-β7 antibody 
(Santa Cruz Biotechnology Inc., USA) was used to detect the expression of the β7 integrin in the transiently co-
transfected HEK293T cells. Equivalent total protein (60 µg) of cell lysates was loaded per well. Cells only 
(HEK293T) and pcDNA
TM
3.1/V5-His TOPO
®
 empty vector (pcDNA) were included to control for non-specific 
binding of antibodies. An α4β7 recombinant protein (100 ng) (150 kDa) and cells carrying endogenous α4β7 
(HeLa and TZM-bl) were included to control for successful Western blotting and β-actin (42 kDa) was included 
as a loading control. The exposure time for all the Western blots was 8 minutes. The molecular weight marker 
is indicated. 
 
A Western blot using the newly purchased anti-α4 antibody (Santa Cruz Biotechnology Inc., 
USA) detected the positive recombinant protein (100 ng) at 150 kDa and cell lysates 
generated from a transfection with pcDNATM3.1/V5-His TOPO® empty vector did not yield 
any bands as expected (Figure 3.6A and Figure 3.6C). Cells transfected with pTARGETTM_α4 
(0.4 to 2 pmol) and co-transfected with pTARGETTM_α4 and pCEP4_β7 (0.1 to 1 pmol) 
showed no α4 expression even though the bands corresponding to β-actin indicated 
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comparable loading of samples. Unexpectedly the HeLa and TZM-bl cell lysate samples were 
negative for α4 expression.  
 
A Western blot using the new anti-β7 antibody (Santa Cruz Biotechnology Inc., USA) did not 
detect the positive recombinant protein at 130 kDa, even when 100 ng recombinant protein 
was loaded (Figure 3.6B and Figure 3.6D). Cell lysates generated from transfection with 
pCEP4_ β7 (0.2 to 2 pmol) and co-transfection with pTARGETTM_α4 and pCEP4_β7 (0.1 to 1 
pmol) indicated a band that corresponded to the molecular weight of the β7 integrin (130 
kDa). This band was present in HEK293T cell lysates not transfected with the integrin 
plasmid DNA as well as cell lysates transfected with pcDNATM3.1/V5-His TOPO® empty 
vector. HEK293T cells do not endogenously express β7 (Qi et al. 2012) suggesting that the 
DNA band did not represent the β7 integrin but that the anti β7-antibody was binding to a 
non-specific protein that had a similar molecular weight to β7. The intensity of the 130 kDa 
band varied with the amount of transfected pCEP4_β7 plasmid DNA (Figure 3.6B) although 
it was not as expected as transfection with 1.4 pmol pCEP4_β7 resulted in lower expression 
than transfection with 0.2 pmol of plasmid DNA. The observed difference in expression was 
not due to loading inconsistent amounts of total protein as the intensity of β-actin was 
comparable between samples.  
 
This experiment was designed to determine the optimum concentration of plasmid DNA for 
integrin expression, and therefore the total plasmid DNA concentration was not kept 
constant with the addition of pcDNATM3.1/V5-His TOPO® empty vector. It is therefore 
possible that higher concentrations of plasmid DNA affected the transfection efficiency 
and/or cell viability.  
 
Dot blots of the α4β7 recombinant protein (R and D systems, England) were performed to 
determine the optimal concentration of antibody for integrin detection but the recombinant 
protein (100 ng) was not detected by the anti-β7 antibodies (Sigma Aldrich, USA and Santa 
Cruz Biotechnology Inc., USA) at the highest recommended dilution (1:100). Western blot 
parameters including transfer system (wet and dry), time taken to transfer (1 to 2 hours), 
time taken to block (1 to 48 hours), number of washes (2 to 8 15-minute washes), 
incubation time of primary and secondary antibodies (1 to 24 hours) and exposure time to 
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X-ray film (30 seconds to 30 minutes) were tested but neither α4 nor β7 was detected in 
HEK293T cell lysates after transfection (data not shown). 
 
To ensure that degradation of the plasmid DNA was not responsible for the lack of 
detectable cell-associated α4β7, plasmid DNA was retransformed, fresh plasmid DNA was 
prepared and the integrity and quality of the plasmid DNA was confirmed by Nanodrop 
260/230 and 260/280 ratios as well as agarose gel electrophoresis (data not shown). A 
second aliquot of the pCEP4_β7 plasmid DNA was obtained from Prof D. Erle but when this 
was used in HEK293T transfection no expression could be detected.  
 
In order to confirm the transfection efficiency of the PEI methodology, pTARGETTM_α4 and 
pCEP4_β7 plasmid DNA were co-transfected together with the pGL4 luciferase reporter 
gene (Figure 3.7). 
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Figure 3.7 The efficiency of the PEI transfection methodology was confirmed by a luciferase reporter gene. 
HEK293T cells were transfected with pGL4 Luc (1.2 pmol) and either 1.2 pmol pTARGET
TM
_α4 (α4) or pCEP4_β7 
(β7) or co-transfected with 0.5 and 1.3 pmol pTARGET
TM
_α4 and pCEP4_β7 (α4β7) plasmid DNA. The pGL4 Luc 
construct carrying a luciferase reporter gene was an indicator of how well the cells took up the plasmid DNA. A 
negative cells only (HEK293T) control was included. In order to control for the effect of the vector only, pGL4 
was co-transfected with pcDNA
TM
3.1/V5-His TOPO
®
 empty vector (pcDNA). Two HIV env clones previously 
shown to have good expression using Western blot (CAP177_A3 and CAP206_E12-3) were also transfected 
with pGL4 Luc. The degree of transfection efficiency is indicated by relative light units (RLU) on a log10 scale. 
 
Co-transfection with the pGL4 luciferase reporter gene indicated a 1000-fold increase in 
relative light units (RLU) compared to when HEK293T cells were mock transfected, indicating 
that irrespective of the construct being co-transfected, the transfection efficiency was 
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similar (Figure 3.7). The pcDNATM3.1/V5-His TOPO® empty vector and two HIV env clones, 
CAP177_A3 (T/F) and CAP206_E12-3 (chronic) that were previously shown to have high 
expression levels by Western blot (Figure 3.4) were used to compare the transfection 
efficiency of separately transfected and co-transfected pTARGETTM_α4 and pCEP4_β7 
plasmid DNA using PEI.  
 
Similar levels of luciferase activity were evident however, the cell lysates were not analysed 
by Western blot and it is therefore not possible to confirm that this level of transfection 
efficiency was sufficient for the detection of CAP177_A3, CAP206_E12-3 and the α4β7 
integrin. Previously, Western blots were carried out four times to determine the expression 
of the env clones and the integrin. The expression levels of the Env clones were constantly 
similar suggesting consistent transfection efficiencies across all experiments. 
 
3.2.3.3 Transfection of α4β7 in CHO cells 
 
In order to determine whether α4β7 expression was restricted in HEK293T cells, an 
alternative cell line was tested. CHO cells were both separately transfected and co-
transfected with pTARGETTM_α4 and pCEP4_β7 plasmid DNA using PEI and Electroporation. 
Western blots of CHO cell lysates after α4β7 PEI and Electroporation transfections did not 
indicate integrin expression (data not shown). Similar to what was seen with transfected 
HEK293T cells, the positive α4β7 recombinant protein was detected when the anti-α4 
antibody (Santa Cruz Biotechnology Inc., USA) was used but not the anti-β7 antibody (Santa 
Cruz Biotechnology Inc., USA). The pcDNATM3.1/V5-His TOPO® empty vector control was 
negative and β-actin indicated comparable loading of samples.  
 
In order to control for the ability to electroporate CHO cells, the CAP177_A3 and 
CAP206_E12-3 env clones were electroporated into HEK293T and CHO cells, as these clones 
were previously shown to have been expressed in electroporated HEK293T cells, although 
poorly (Figure 3.4). 
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Figure 3.8 Electroporation of HEK293T but not CHO cells resulted in HIV env expression A) HEK293T and B) 
CHO cells were transfected with CAP177_A3 (T/F) and CAP206_E12-3 (chronic) env clones using 
Electroporation. A 1:3 000 dilution of the anti-gp120 antibody was used (Mouse antiserum to HIV gp120, NIH 
ARP). Equivalent total protein (60 µg) cell lysates was loaded per well. The pcDNA
TM
3.1/V5-His TOPO
®
 empty 
vector (pcDNA) was included to control for non-specific binding of antibodies. A gp120 soluble recombinant 
protein (50 ng) (120 kDa) and CHO NL4-3 gp160 (CHO NL4-3) cell lysates (only in B) were included to control 
for successful Western blotting and β-actin (42 kDa) was included as a loading control. The exposure time for 
the first Western blot was 6 minutes and the second 5 minutes. The molecular weight marker is indicated. 
 
Western blot analysis revealed that the Electroporation of HEK293T (Figure 3.8A) but not 
CHO (Figure 3.8B) cells resulted in discernible cell-associated gp160 expression. CHO NL4-3 
gp160 (a CHO cell line stably expressing gp160) positive control cell line indicated a single 
band that corresponded to gp160 as it ran higher than the recombinant gp120 positive 
control (Figure 3.8B). The pcDNATM3.1/V5-His TOPO® empty vector control was negative and 
β-actin indicated comparable loading of samples in both Western blots. This result suggests 
that the electroporation of CHO cells was not successful as expression of the env clones was 
observed when HEK293T cells were transfected, validating our Electroporation protocol. As 
CHO cells seemed to be resistant to Electroporation we did not continue with the CHO cell 
line. 
 
3.2.3.4  Detection of α4β7 using flow cytometry 
 
Flow cytometry is a more sensitive detection system than Western blotting and therefore 
we utilised a fluorescently labelled secondary antibody to detect Act-1 stained 
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pTARGETTM_α4 and pCEP4_β7 PEI co-transfected HEK293T cells. Unstained cells and cells 
stained with secondary antibody only were used to determine background fluorescence. 
 
Figure 3.9 Flow cytometry did not detect α4β7 integrin on PEI co-transfected HEK293T cells. HEK293T cells 
were co-transfected with 1 pmol pTARGET
TM
_α4 and pCEP4_β7 plasmid DNA and stained for flow cytometry 
analysis A) Unstained transfected HEK293T cells to determine HEK293T-inherent cell fluorescence B) Cells 
stained with Cy3
®
 goat anti-mouse secondary antibody only to determine background fluorescence due to non-
specific antibody binding C) Cells stained with Act-1 and the Cy3
®
 goat anti-mouse antibody. 
 
HEK293T cells co-transfected with pTARGETTM_α4 and pCEP4_β7 plasmid DNA did not show 
α4β7 integrin expression as the fluorescent signal was no different compared to when cells 
were stained with secondary antibody only (Figure 3.9).  
 
As HeLa and TZM-bl cells endogenously express α4 and β7 they were included as positive 
controls. Flow cytometry indicated that 57.6% and 77.4% of the TZM-bl (Figure 3.10A to 
Figure 3.10C) and HeLa (Figure 3.10D to Figure 3.10F) cell populations, respectively were 
positive for the α4β7 integrin. No Isotype control antibody was available and so cells stained 
with secondary antibody only were used to take into account background fluorescence due 
to non-specific binding of the antibody. 
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Figure 3.10 Flow cytometry detected the α4β7 integrin on TZM-bl and HeLa cells. One million TZM-bl and 
HeLa cells were stained for flow cytometry analysis A) Unstained TZM-bl cells to determine TZM-bl-inherent 
cell fluorescence B) TZM-bl cells stained with Cy3
®
 goat ant-mouse secondary antibody only to determine 
background fluorescence due to non-specific antibody binding C) TZM-bl cells stained with Act-1 and Cy3
®
 goat 
anti-mouse antibodies D) Unstained HeLa cells to determine HeLa-inherent cell fluorescence E) HeLa cells 
stained with Cy3
®
 goat ant-mouse secondary antibody only to determine background fluorescence due to non-
specific antibody binding F) HeLa cells stained with Act-1 and Cy3
®
 goat anti-mouse antibodies. 
 
α4β7 was detected on HeLa and TZM-bl (HeLa derived) cells by flow cytometry but not by 
Western blot. We concluded that either the antibodies or Western blot technique as a 
whole was not sensitive enough to detect low levels of integrin expression especially noting 
that the α4 integrin was only detected when high amounts of recombinant protein were 
used with the lowest recommended dilution of antibody.  
 
As both flow cytometry and Western blot analysis could not detect α4β7 on transfected 
HEK293T cells, we were concerned that the inclusion of pCDM8 vector sequence in our α4 
cloning strategy might have affected expression of α4 and we thus sequenced the plasmid 
DNA flanking the α4 cDNA. 
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3.2.4 Determining the 5’ and 3’ flanking sequences of the α4 cDNA in the pTARGETTM 
vector 
 
Primers were designed to the 5’ and 3’ ends of the α4 cDNA insert in order to sequence the 
plasmid DNA flanking the α4 integrin in the pTARGETTM vector. Sequence analysis revealed 
that the α4 insert was inserted into the pTARGETTM vector in the incorrect orientation as the 
Xho I and Sma I restriction enzyme sites upstream and downstream of the pTARGETTM MCS, 
respectively were instead downstream and upstream of the α4 cDNA insert, respectively 
(Appendix A.1.1).  
 
The T7 F primer that occurs in the pCDM8 vector sequence upstream of the pCDM8 MCS 
was used to PCR out the α4 cDNA from pCDM8_α4 while the T7 F primer also occurs in the 
pTARGETTM vector sequence upstream of the pTARGETTM MCS and was used during colony 
PCR to determine whether the α4 cDNA was inserted into the pTARGETTM vector in the 
correct orientation. Therefore the choice of the T7 F primer for both cloning and colony PCR 
affected the ability to differentiate whether the α4 cDNA insert was cloned into pTARGETTM 
in the correct orientation. As our cloning strategy resulted in the selection of a clone with 
the α4 cDNA in the incorrect orientation, explaining the lack of expression in transiently 
transfected HEK293T cells, we altered the design of our α4β7 reactivity assay to utilise HeLa 
cells that endogenously express the integrin as shown by flow cytometry (Figure 3.10.D to 
Figure 10.F). 
 
3.2.5 α4β7 binding assay 
 
3.2.5.1 Binding of pseudovirus to HeLa cells that endogenously express α4β7 
 
In order to develop an assay to measure α4β7 reactivity, pseudovirus was bound to HeLa 
cells in the presence and absence of the Act-1 monoclonal antibody that was previously 
used to block gp120 binding to α4β7 (Arthos et al. 2008; Parrish et al. 2012). In order to 
 61 
 
optimise the assay, we only tested the reactivity of two HIV Env clones CAP45_B5 (T/F) 
CAP177_47 (chronic). A range of Act-1 concentrations were tested to confirm that the 
binding of pseudovirus to HeLa cells was specifically via α4β7.  
 
Previous DC-SIGN binding assays utilised low equivalent p24 concentrations of input 
pseudovirus (Alexandre et al. 2012) and so to ensure that this was not impacting the binding 
of pseudovirus to α4β7, binding was performed with both high (200 ng) and low (5 ng) p24 
concentrations of input pseudovirus (Figure 3.11). 
 
Figure 3.11 Act-1 does not consistently inhibit binding of pseudovirus to HeLa cells endogenously expressing 
α4β7. Pseudovirus equivalent to A) 200 ng and B) 5 ng p24 carrying Env clones CAP177_47 and CAP45_B5 was 
added to cells pre-incubated with 0 nM, 33 nM, 66 nM and 99 nM Act-1 monoclonal antibody. Bound 
pseudovirus was measured by a p24 ELISA. This data represents two independent experiments performed in 
triplicate. 
 
In the absence of Act-1, 2.5% and 1.4% of virus pseudotyped with the Env clones CAP177_47 
and CAP45_B5, respectively bound to HeLa cells when 200 ng p24 input pseudovirus was 
added (Figure 3.11A). This was lower than when 5 ng p24 input pseudovirus was added as 
11% and 1.6% of pseudovirus carrying Env clones CAP177_47 and CAP45_B5, respectively 
bound to HeLa cells (Figure 3.11B). The overall low binding of pseudovirus to HeLa cells 
suggests that either the levels of α4β7 were too low and too easily saturated to allow for 
high numbers of pseudovirus to bind to HeLa cells or the Env clones were not binding to the 
integrin efficiently.  
 
Pseudovirus carrying Env clone, CAP177_47 bound more efficiently to HeLa cells than those 
carrying CAP45_B5 Env clone at both concentrations of input virus, suggesting that 
pseudovirus binding to HeLa cells was clone specific. In fact, the binding of pseudovirus 
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carrying CAP45_B5 Env clone was not altered by changing the input concentration whereas 
that of CAP177_47 increased 4-fold. With an input of 200 ng p24 pseudovirus, CAP177_47 
had lower binding in the presence of 33 nM and 66 nM Act-1 (1.7% and 1.1%, respectively) 
although binding in the presence of 99 nM Act-1 (2.4%) was the same as binding in the 
absence of Act-1. This trend was similar when the viral input was decreased to 5 ng although 
the experimental error was higher due to low p24 values. 
 
CAP45_B5 binding did not follow the same trend and there was no obvious difference in 
binding in the absence or presence of increasing concentrations of Act-1. Therefore, there 
was no consistent inhibition of pseudovirus binding to HeLa cells endogenously expressing 
α4β7 in the presence of increasing concentrations of Act-1 and binding was never reduced 
by 100% even by the highest concentration of Act-1, suggesting that binding of pseudovirus 
to HeLa cells might not have been via α4β7. 
 
3.2.6 Infection of TZM-bl cells in the presence and absence of the Act-1  
 
The CD4 receptor and α4β7 are within 1.2 nm of each other as determined by co-
precipitation using a cross linking reagent with a spacer arm (Cicala et al. 2009). α4β7 (22 
nm) is three times larger than CD4 (7 nm) and both are located in close proximity to the 
CCR5 co-receptor (Cicala et al. 2009). TZM-bl is an HIV reporter cell line that is used to 
measure HIV infectivity and TZM-bl cells were shown to endogenously express the α4β7 
integrin using flow cytometry (Figure 3.10A to Figure 3.10.C). Due to the proximity of CD4 
and α4β7, incubation with Act-1 should result in the antibody binding to the integrin which 
should inhibit the binding of gp120 not only to α4β7 but also to CD4. This in turn should 
prevent viral entry measured by cell-associated luminescence, abrogating the need to use 
the p24 ELISA.  
 
The entry efficiency assay, using pseudovirus to directly infect TZM-bl cells was performed in 
the presence and absence of saturating concentration of Act-1 (33 nM) (Parrish et al. 2012). 
All 11 T/F and chronic infection env clones were tested for entry efficiency in the presence 
and absence of the Act-1 monoclonal antibody (Figure 3.12).  
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There was a wide range of entry efficiency ranging from 1.0% to 199.3% higher than 
background. The entry efficiency of the CAP206 T/F clone was below the cut off value for 
the assay (2X higher than background) (Fouda et al. 2013), suggesting that this clone was 
non-functional. However, the 100 ng of pseudovirus added in this assay was likely too low to 
detect the entry of CAP206 T/F clone as the addition of undiluted pseudovirus resulted in 
RLU values only 4-fold higher than background (Z. Woodman, unpublished results). 
Therefore, although this Env clone (CAP206 T/F) is able to mediate infection of TZM-bl cells, 
higher viral inoculum was required for this assay and therefore it was not included in the 
analysis. 
- + - + - + - + - + - + - + - + - + - + - + - +
0.0
500000.0
1000000.0
1500000.0
2000000.0
2500000.0 T/F
C
PSG3      177           239            45            206               210
+/- Act-1 (33 nM)
Lu
ci
fe
ra
se
 (
R
LU
)
 
Figure 3.12 Act-1 does not inhibit infection of TZM-bl cells. The five study participants T/F and chronic 
infection env clones, CAP177 (177), CAP239 (239), CAP45 (45), CAP206 (206) and CAP210 (210) were used to 
generate pseudovirus to infect TZM-bl cells in the presence and absence of 33 nM Act-1 monoclonal antibody. 
The T/F and chronic infection Env clones of each participant are represented by black and white bars, 
respectively. CAP210 has one T/F env clone and two chronic infection env clones. A pSG3.1Δenv (pSG3) was 
included as a negative control as pseudovirus was generated in the absence of an env clone. A non-parametric 
Mann-Whitney statistical test was performed. This data represents an average of three independent 
experiments performed in triplicate. 
 
There was no statistical difference between entry efficiency in the absence and presence of 
Act-1 for all nine Env clones from each of the four study participants, suggesting that 
pseudovirion entry into TZM-bl cells was independent of gp120-α4β7 interactions.  
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3.2.7 Infection of CD4+ T cells in the presence and absence of the Act-1 monoclonal 
antibody 
 
Previous studies utilised CD4+ T cells isolated from PBMC to demonstrate gp120-α4β7 
interactions (Nawaz et al. 2011; Cicala et al. 2009; Arthos et al. 2008; DeNucci et al. 2010). In 
order to determine whether the use of CD4+ T cells would allow us to detect the α4β7 
reactivity of our T/F and chronic infection Env clones PBMC isolated from human blood were 
activated with IL-2. 
 
CD4+ T cells incubated with retinoic acid, as used by Nawaz et al. (2011), Cicala et al. (2009), 
Arthos et al. (2008) and DeNucci et al. (2010), resulted in the activation of the α4β7 integrin 
(Iwata et al. 2004). However due to project time constraints cells were differentiated in the 
absence of retinoic acid and flow cytometry was not carried out to determine the level of 
α4β7 expression. However, although we anticipated that only a subset of cells would 
express the integrin (Cicala et al. 2009), we still wanted to determine whether Act-1 
inhibition could distinguish Env α4β7 reactivity.  
 
CD4+ T cells pre-incubated in the presence or absence of 33 nM Act-1 monoclonal antibody 
were incubated with CAP177_A3 (T/F) and CAP206_E12-3 (chronic) pseudovirus (100 ng). 
After washing, bound pseudovirus was measured by p24 ELISA. No binding of pseudovirus 
was detected suggesting that neither CD4 nor α4β7 was expressed on the surface of the 
differentiated PBMC and due to the lack of availability of Act-1 this experiment could not be 
repeated.  
 
3.3 Discussion 
 
We planned to test the α4β7 reactivity of five subtype C T/F and chronic infection Env clones 
by transiently expressing α4β7 in HEK293T cells. We decided to transiently express the 
integrin in a cell line as it is more cost effective and the use of CD4+ T cells from human 
blood introduces donor variation as seen by Cicala et al. (2009). By transiently expressing 
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α4β7 in a cell line, cell surface integrin expression between experiments could also be kept 
fairly constant.  
 
Abitorabi et al. (1997) stably expressed α4 and β7 from pCDM8_α4 and pCEP4_β7 plasmid 
DNA in K562 human erythroleukemia cells using Electroporation and Qi et al. (2012) 
transiently expressed α4 and β7 cloned into pcDNA3.1/Hygro (-) vectors in HEK293T cells for 
purification purposes. This suggests that transiently transfected cell lines are a good model 
to yield high levels of integrin expression. 
 
The integrins cDNA’s were received in two expression cassettes, pCDM8_α4 and pCEP4_β7, 
and we subsequently sub-cloned the α4 cDNA from the pCDM8 vector into the pTARGETTM 
vector. However, when we transfected HEK293T cells with the two constructs, we initially 
could not detect α4 nor β7 in our experimental samples nor the positive control, 
recombinant α4β7 protein (R and D systems, England). It was only after probing high 
amounts of recombinant protein with high concentrations of antibody that we could detect 
α4, suggesting that poor antibody binding in combination with low expression of our 
integrin was the problem. When we changed the detection system from Western blot to 
flow cytometry, we were able to detect α4β7 on HeLa and TZM-bl (HeLa derived) cells but 
not transfected HEK293T cells, suggesting that either our expression levels after transient 
transfection were below the detection limit of flow cytometry or there was no integrin 
expression.  
  
Information on the plasmid DNA sequences or the cloning methodology was not available 
when we received the cDNA’s of the integrins and we thus sequenced the inserts using 
vector based primers as well as internal primers designed to the integrin sequence. In order 
to save time, we also sub-cloned α4 cDNA into pTARGETTM by amplifying the entire insert 
using pCDM8 primers as this did not require α4 sequence information and would guarantee 
the sub-cloning of all sequences required for expression as the original constructs were 
previously used to express α4β7 (Abitorabi et al. 1997). However, when transient expression 
of α4β7 in HEK293T cells was not detected using neither Western blot nor flow cytometry, 
we considered the possibility that our cloning methodology had affected the expression of 
α4.  
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In order to determine the sequence of the plasmid DNA flanking the α4 insert, we designed 
reverse and forward primers to the 5’ and the 3’ ends of α4, respectively to sequence the 
upstream and downstream regions, respectively. Sequencing indicated that the α4 cDNA 
was cloned in the incorrect orientation downstream of the CMV promoter, explaining the 
lack of α4β7 expression. 
 
The lack of detection of β7 expression by Western blot was likely due to the poor binding of 
the β7 antibodies as the positive α4β7 recombinant control was never detected using either 
antibody. The addition of a C-terminal polyhistidine-tag (his-tag) could have aided the 
detection of the β7 integrin although, a his-tag has been shown to decrease the solubility of 
protein (Busso et al. 2003) which negatively impacts protein expression.  
 
Due to time constraints we did not repeat the sub-cloning of α4 nor add a his-tag to β7 but 
instead decided to utilise HeLa cells that endogenously express α4β7 in the reactivity assay. 
The premise for the assay was that Env pseudotyped viruses would bind to HeLa cells with 
differential efficiency due to differences in α4β7 reactivity and that addition of Act-1, would 
distinguish α4β7-Env binding from non-specific HeLa cell-pseudovirus interactions.  
 
Pseudovirus carrying CAP45_B5 (T/F) and CAP177_47(chronic) Env clones bound to HeLa 
cells but with low efficiency and saturating levels of Act-1 did not inhibit binding, suggesting 
that binding was non-specific. It is unlikely that poor binding was due to low levels of α4β7 
as flow cytometry confirmed that 77.4% of HeLa cells carried α4β7 on the cell surface, 
comparable to 50% of α4β7+ CD4+ T cells demonstrated by Nawaz et al. (2011). However, 
the ability of the Env clones to bind to α4β7 could have been affected by the activation state 
of the integrin as Arthos et al. (2008) indicated that gp120 bound α4β7 in its activated form. 
Furthermore, pseudovirus has been shown to bind to HeLa cells non-specifically (Mondor et 
al. 1998) and Nawaz et al. (2011) showed that gp120’s produced in HEK239T and HEK293F 
cells have low α4β7 reactivity. The authors suggest that cell specific post-translational 
differences might account for the altered reactivity of the Env clones. However, when we 
attempted to transiently express Env in CHO cells, we could not detect protein expression 
using Western blot. As we were unable to transiently transfect CHO cells using different 
transfection methodologies, we could not test whether pseudovirus generated in CHO cells 
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would have bound to HeLa cells endogenously expressing α4β7 and whether this binding 
was inhibited by Act-1. It is therefore possible that the HEK293T cell derived pseudovirus did 
not bind specifically to α4β7 but non-specifically to the HeLa cells. As the binding assay 
relied on a p24 ELISA with a limiting detection (0.5 ng/ml) we repeated the assay using TZM-
bl cells.  
 
Arthos et al. (2008) showed that the presence of Act-1 inhibited the binding of gp120 to 
α4β7 and consequently viral replication. If α4β7 was present on the surface of TZM-bl cells, 
the addition of Act-1 prior to adding pseudovirus should inhibit gp120-CD4 interactions and 
therefore viral replication. TZM-bl cells, a HeLa derived reporter gene cell line that was also 
confirmed to endogenously express α4β7 using flow cytometry, were infected with 
pseudovirus in the presence and absence of Act-1. Cell associated luciferase activity which is 
more sensitive than the p24 ELISA was used to quantify entry of pseudovirus into TZM-bl 
cells. If α4β7 (22 nm) was expressed on TZM-bl cells, Act-1 would inhibit pseudovirus 
binding to CD4 (7 nm) and consequently infection, which could be determined by cell 
associated luciferase. However, no difference in TZM-bl infection was observed in the 
presence and absence of Act-1.  
 
We cannot confirm the activation state of α4β7 on the surface of HeLa and TZM-bl cells and 
it is therefore possible that Env pseudotyped viruses were unable to bind due to incorrect 
integrin conformation. As retinoic acid results in the activation of α4β7 on CD4+ T cells 
(Cicala et al. 2009) it is possible that HeLa cells could have been treated similarly and tested 
with a monoclonal antibody (J19) that specifically recognizes the activated form of α4β7 (Qi 
et al. 2012). However, due to time constraints, this strategy was not tested. It is also 
possible that the close proximity of CD4 and α4β7 might be cell-specific so that HeLa cells do 
not support CD4 and α4β7 complex formation. Co-immunoprecipitation studies as outlined 
by Cicala et al. (2009) might indicate whether α4β7 is within 1.2 nm of CD4 and CCR5 on 
HeLa cells. Therefore, a α4β7 binding assay utilising transfected cell lines, although more 
cost effective might not have been the best choice unless we could confirm the activation 
state of the integrin. Furthermore, production of pseudovirus in HEK293T cells most likely 
altered the processing and N-glycosylation of Env so that they did not bind to α4β7, 
supporting a previous study (Nawaz et al. 2011). Production of pseudovirus in CHO cells and 
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binding to α4β7+ CD4+ T cells and retinoic-treated HeLa cells will confirm whether the 
experimental approach of this study is still feasible. 
 
We attempted to differentiate PBMC into CD4+ T cells that are known to express α4β7 
(DeNucci et al. 2010) but pseudovirus binding was not different in the presence and absence 
of Act-1 as seen with HeLa and TZM-bl cells. We however did not induce α4β7 expression 
using retinoic acid and thus the levels of integrin might also have been too low to accurately 
measure pseudovirus binding. Unfortunately we were unable to confirm the phenotype of 
CD4+ T cells with flow cytometry due to the lack of availability of the Act-1 antibody and 
therefore these experiments could not be repeated. 
 
3.4 Conclusion 
 
As integrin expression was detected on HeLa and TZM-bl cells these cell lines were used to 
compare the binding and entry of pseudoviruses carrying subtype C T/F and chronic 
infection Env clones in the presence and absence of the Act-1 antibody. However, 
pseudovirus binding and entry was not inhibited by Act-1, suggesting that viral-cell 
interactions in this system were not mediated by α4β7. This could have been due to the 
activation state of the integrin and/or the N-glycosylation profile of Env produced in 
HEK293T cells. The production of pseudovirus in an alternative cell line other than HEK293T 
and testing the activation state of the integrin using monoclonal antibodies able to 
distinguish the two forms will allow comparisons between subtype C HIV T/F and matched 
chronic infection env clones providing insight into the role of α4β7 reactivity in HIV 
transmission. 
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Chapter 4: Comparing the role of Env N-glycans of T/F and 
chronic infection variants in DC-SIGN mediated trans-
infection of CD4+ cells 
 
4.1 Introduction 
 
The N-glycans on gp120 assist HIV in evading antibody immune detection through masking 
antigenic epitopes. Furthermore, it has been suggested that the virus has evolved a 
mechanism whereby the N-glycans facilitate binding to dendritic cells in order to enhance 
HIV infection (Van`Montfort et al. 2011). Gp120 N-glycans are targets for the C-type lectin 
DC-SIGN expressed on dendritic cells of the genital mucosa and this lectin has been shown 
to facilitate HIV infection (Curtis et al. 1992; Geijtenbeek, Torensma, et al. 2000; Lee et al. 
2001). Upon antigen recognition, dendritic cells migrate to the lymph nodes where they 
present processed antigens to naïve CD4+ T cells. Therefore, HIV, once bound to DC-SIGN is 
transferred to the lymph nodes where it encounters abundant CD4+ T cells, allowing rapid 
viral replication. 
 
DC-SIGN preferentially binds oligomannose type N-glycans (Feinberg et al. 2007; 
Geijtenbeek, Torensma, et al. 2000; Mitchell et al. 2001; Van`Montfort et al. 2011), and it 
has recently been shown that subtype B and C T/F variants are enriched with oligomannose 
type N-glycans compared with viruses circulating during chronic infection (Go et al. 2011). 
Furthermore, earlier studies have indicated that a genetic bottleneck occurs at transmission 
and that the Envs of T/F variants are more compact with fewer N-glycans (Chohan et al. 
2005; Derdeyn et al. 2004), suggesting that variants could be preferentially selected due to 
their array of N-glycans.  
 
We hypothesise that T/F variants carry an optimum arrangement of oligomannose type N-
glycans that facilitates DC-SIGN mediated trans-infection which then allows for successful 
transmission in the genital tract. Furthermore, we suggest that the accumulation of Env 
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PNGs over the course of infection hinders the trans-infection capacity of variants circulating 
during chronic infection. 
 
In order to investigate whether DC-SIGN is able to mediate the trans-infection of subtype C 
HIV T/F variants better than viruses circulating during chronic infection, a DC-SIGN mediated 
trans-infection assay was optimized for pseudovirus carrying the Env clones of all five study 
participants. The env clones were generated from SGA-derived amplicons by L. Shuping. The 
T/F clones were carefully selected based on identity to consensus sequence and the chronic 
infection clones were selected based on consensus N-glycosylation patterns (Table 4.1). 
 
Table 4.1 Characteristics of the Env clones  
  
Participant 
ID (CAP) 
Clone 
ID 
Stage of infection Sampling (Weeks 
post infection) 
*Functionality (-fold 
entry efficiency) 
N386 N392 
177 A3 acute 2 *35 + - 
 47 chronic 172 19 + + 
239 Ell acute 5 50 + + 
 T35 chronic 173 5 + + 
45 B5 acute 2 10 + - 
 H5 chronic 108 *7 + - 
206 H1 acute 4 *10 + - 
 E12-3 chronic 173 35 - + 
210 E8 acute 5 120 + + 
 E1 chronic 80 128 + + 
 C7 chronic 80 37 + + 
*+: PNG present, -: no PNG present at positions N386 and N392                     
*Functionality of the env clones was determined by infecting TZM-bl cells with 100 ng pseudovirus normalised 
on p24 concentration except for CAP177_A3, CAP206_H1 and CAP45_H5 clones where the virus was not 
diluted. The -fold increase in entry efficiency above background was 2.6-, 1.2- and 1.1-fold, respectively for 
these clones when 100 ng of pseudovirus was used to infect TZM-bl cells (Adapted from L. Shuping, 
unpublished data). 
 
The entry efficiency of the Env clones varied from 1.1- to 128-fold higher than background 
when the equivalent of 100 ng p24 pseudovirus was used to infect TZM-bl cells. The entry 
efficiency of 100 ng p24 CAP177_A3, CAP45_H5 and CAP206_HI clones was below cut off for 
functionality for this assay (2X higher than background) (Fouda et al 2010) but when 
undiluted virus was tested, these Env clones were 35-, 7- and 10-fold higher than 
background, respectively indicating that they are functional but have poor entry efficiency.  
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The sequences flanking the Env clones with low entry efficiency were analysed for correct 
rev, vpu and env open reading frames, confirming that rev-vpu fusion was not the reason for 
reduced Env function (Kraus et al. 2010). As the CAP177_A3 env clone sequence was 
identical to the consensus of 20 SGA-derived sequences and CAP177_A3 was infected with a 
single variant, this clone should represent the T/F and therefore its low entry efficiency 
should be sufficient for productive HIV infection. However, as CAP206_H1 and CAP45_H5 
clones had one and two amino acid differences, respectively compared to consensus, it is 
possible that these mismatches altered Env structure and function. 
 
Go et al. (2011) and Go et al. (2013) used mass spectrometry to identify two PNGs, N386 
and N392 (numbered according to HXB2), that are believed to carry oligomannose N-
glycans. These sites not only differed between T/F and chronic infection variants with the 
latter carrying processed carbohydrates but have also been shown to be involved in DC-
SIGN binding (Hong et al. 2007). We therefore hypothesised that these sites might be 
essential for DC-SIGN mediated trans-infection and might comprise a motif involved in the 
selection of specific variants for transmission. In order to investigate the role of the 
oligomannose type N-glycans at PNGs N386 and N392 in subtype C DC-SIGN mediated trans-
infection of HIV, we generated N-glycan mutants of both T/F and chronic infection variants 
and compared their trans-infection capacity.  
 
4.2 Results 
 
4.2.1 DC-SIGN mediated transfer of T/F and chronic infection Env clones to CD4+ cells 
 
A Burkitt’s lymphoma cell line engineered to stably express DC-SIGN, Raji-DC-SIGN, was used 
for the trans-infection assay (Nabatov et al. 2006; Van`Montfort et al. 2007; Balzarini et al. 
2007; Liao et al. 2011; Eggink et al. 2010; Alexandre et al. 2012). 
 
Flow cytometry using a DC-SIGN specific antibody indicated that 24.8% of Raji-DC-SIGN cells 
expressed DC-SIGN (Figure 4.1D to Figure 4.1F) confirming the presence of the DC-SIGN 
receptor whereas Raji-WT cells did not express the lectin (Figure 4.1A to Figure 4.1C). 
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Figure 4.1 Flow cytometry confirmed DC-SIGN expression on Raji-DC-SIGN cells. One million Raji-DC-SIGN and 
Raji-WT cells were stained for flow cytometry analysis A) Unstained Raji-WT cells to determine Raji-WT-
inherent cell fluorescence B) A stained Isotype control (PerCP-Cy
TM
5.5 Mouse IgG2b, ĸ) of Raji-WT cells to 
determine background fluorescence due to non-specific antibody binding C) Raji-WT cells stained cells with 
PerCP-Cy
TM
5.5 anti-human CD209 (DC-SIGN) antibody D) Unstained Raji-DC-SIGN cells to determine Raji- DC-
SIGN-inherent cell fluorescence E) A stained Isotype control (PerCP-Cy
TM
5.5 Mouse IgG2b, ĸ) of Raji-DC-SIGN 
cells to determine background fluorescence due to non-specific antibody binding F) Raji-DC-SIGN cells stained 
cells with PerCP-Cy
TM
5.5 anti-human CD209 (DC-SIGN) antibody.  
 
Pseudovirus, normalised on p24 was added to Raji-DC-SIGN cells before being added to 
TZM-bl cells. The level of TZM-bl cell-associated luciferase activity was an indicator of how 
well the Raji-DC-SIGN cells were able to mediate trans-infection of the CCR5+ CXCR4+ CD4+ 
cell line. We hypothesised that pseudoviruses carrying the Env of T/F variants would be 
transferred more efficiently to CD4+ cells compared with those carrying the Env of chronic 
infection viruses if T/F variants are dependent on DC-SIGN mediated trans-infection for 
successful transmission in the genital tract.  
 
Raji-WT cells were unable to transfer pseudovirus to TZM-bl cells, indicating that DC-SIGN is 
required for trans-infection of CD4+ cells (data not shown). When trans-infection data was 
not normalised on entry efficiency, two participant’s (CAP45 and CAP210) T/F Env clones 
showed enhanced trans-infection compared with the chronic infection Env clones, two 
participant’s (CAP177 and CAP206) chronic infection Env clones showed enhanced trans-
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infection compared with the T/F Env clones and one participant (CAP239) showed no 
difference in trans-infection between the T/F and chronic infection Env clones (Figure 4.2A).  
 
Figure 4.2 There was no difference between the trans-infection of pseudovirus carrying the Env of T/F and 
chronic infection variants. T/F and chronic infection (C) Env clones from five subtype C study participants were 
tested for DC-SIGN mediated transfer to CD4+ cells. Participants CAP177, CAP239, CAP45, CAP206 and CAP210 
are indicated by 177, 239, 45, 206 and 210, respectively. Two chronic infection env clones were used for 
CAP210, indicated by 210(C1) and 210(C2) A) DC-SIGN mediated trans-infection data was not normalised to 
the entry efficiency of each clone and trans-infection data is represented in relative light units (RLU). This data 
represents one of two independent experiments performed in triplicate B) DC-SIGN mediated trans-infection 
data was normalised to the entry efficiency of each clone. Two independent experiments performed in 
triplicate were pooled and compared using a Mann Whitney statistical T test (p=0.8099). Horizontal lines 
represent the medians. Data is represented on a log10 scale. 
 
The trans-infection assay involves the transfer of pseudovirus from Raji-DC-SIGN cells to 
TZM-bl cells which are then infected. Therefore, the entry efficiency of the Env clones might 
skew the trans-infection assay if pseudovirus infected TZM-bl cells with varied efficiencies. 
In order to take into account the potential influence that Env entry efficiency might have on 
the trans-infection assay, the trans-infection data was normalised to the entry efficiency of 
the Env clones. When normalised trans-infection data of the Env clones of the T/F variants 
were compared to variants found later in infection, there was no significant difference 
between the two medians (p=0.8099) (Figure 4.2B).  
 
4.2.2 Site-directed mutagenesis of the T/F and chronic infection CAP239 env clones 
 
SDM was performed on the T/F (CAP239_E11) and chronic infection (CAP239_T35) env 
clones of participant CAP239 by mutating the asparagine (N) to a glutamine (Q) at positions 
N386 and N392 thereby preventing N-glycosylation at these sites. T/F and chronic infection 
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CAP239 env clones were mutated at both PNGs to generate single and double env N-glycan 
mutants (Figure 4.3). 
 
Figure 4.3 A graphical representation of the N-glycan mutants compared with WT. The WT CAP239 T/F and 
chronic infection env clones underwent mutagenesis at two PNGs, N386 and N392 (according to HXB2 
numbering) to generate single (N386Q and N392Q) and double (N386Q N392Q) N-glycan mutants. The black 
rectangle represents position 386 and the green rectangle represents position 392. An asparagine (N) to 
glutamine (Q) mutation resulted in the disruption of the PNG NXT/S sequon and thus prevented the 
attachment of an N-glycan ( ). 
 
Our laboratory compared the N-glycosylation of Env clones using Endoglycosidase H (Endo 
H) to remove oligomannose type N-glycans and SDS-PAGE. Preliminary data obtained by L. 
Shuping showed that partially purified CAP239 WT T/F gp120 protein treated with Endo H 
migrated further on an SDS-PAGE compared with the CAP239 WT chronic infection clone 
treated similarly (Lin et al. 2003). This suggested that the T/F clone carried more 
oligomannose type N-glycans than the chronic infection clone as Endo H treatment resulted 
in a greater shift in molecular weight. CAP239 env clones were selected to generate the Env 
N-glycan mutants and these were tested for DC-SIGN mediated trans-infection and 
compared with the WT Env clones. We hypothesised that if the oligomannose residues at 
positions N386 and N392 were essential for DC-SIGN binding then deletion of the sequons 
would reduce DC-SIGN mediated trans-infection of CD4+ cells. 
 
SDM primers were designed, synthesised and used to generate the respective single and 
double env N-glycan mutants. The sequences of the T/F and chronic infection CAP239 env 
clones were identical on either side of both PNGs so a single primer pair was used for each 
site to generate both T/F and chronic infection N-glycan mutants. Primers were designed to 
insert the recognition site for either the BSaW I or Acl I restriction enzyme by silent 
mutation alongside N386Q and N392Q, respectively.  
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Figure 4.4 DNA plasmid vector maps of wild-type, single and double N-glycan mutants. The restriction 
enzyme sites followed with a * indicates that the site was inserted by mutagenesis at position 1 423 for BsaW I 
and 1 433 for Acl I. No * indicates that the site was present in the wild-type (WT) sequence. Both envs are 
flanked by 5’ and 3’ sequences. The pTARGET
TM
_239_E11 (T/F) and pcDNA
TM
3.1/V5_HIS TOPO
®
_239_T35 
(chronic) env clones were inserted into mammalian expression vectors pTARGET
TM
 and pcDNA
TM
3.1/V5_HIS 
TOPO
®
, respectively. 
 
  
T/F                                           C 
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Restriction enzyme digestions were used to screen for the presence of the mutations and 
were visualised by agarose gel electrophoresis. The single mutants (N386Q and N392Q) 
were screened with their respective enzyme and the double mutants (N386Q,N392Q) with 
both restriction enzymes.  
 
 
Figure 4.5 Restriction enzyme digestion of wild-type env to and the N-glycan mutants to confirm site-
directed mutagenesis A) T/F and chronic infection (C) CAP239 wild-type (WT) env clones, single N386Q and 
double N386Q,N392Q N-glycan mutants either undigested (UD) or digested (D) with the BsaW I restriction 
enzyme and B) T/F and chronic infection (C) CAP239 WT env clones, single N392Q and double N386Q,N392Q 
N-glycan mutants either undigested (UD) or digested (D) with the Acl I restriction enzyme. 
 
A restriction enzyme digestion of the CAP239 WT T/F env clone with BsaW I generated DNA 
fragments with the molecular weight of 4 562 bp, 1 635 bp, 1 059 bp, 831bp and 147 bp. 
The deletion of the PNG at position N386 resulted in the loss of the 4 562 bp band with the 
concomitant appearance of a 3 078 bp and a 2 462 bp band instead of the expected 2 462 
bp and 2 100 bp bands (Figure 4.4). The appearance of the 3 078 bp band could be due to 
incomplete digestion at sites BsaW I (8 011) and BsaW I (7 864) resulting in a larger 
fragment comprising of the 831 bp, 147 bp and 2 100 bp fragments (Figure 4.5). 
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A restriction enzyme digestion of the CAP239 WT T/F env clone with Acl I generated DNA 
fragments with the molecular weight of 7 861 bp and 373 bp. The deletion of the PNG at 
position N392 resulted in the loss of the 7 861 bp band with the concomitant appearance of 
a 4 600 bp and a 3 800 bp band (Figure 4.5) instead of the expected 5 132 bp and 2 729 bp 
bands (Figure 4.4). However, incomplete digestion could not explain the difference between 
the expected and observed DNA banding patterns. 
 
A restriction enzyme digestion of the CAP239 WT chronic infection env clone with BsaW I 
generated DNA fragments with the molecular weight of 4 292 bp, 1 628 bp, 1 220 bp, 831 
bp and 147 bp. The deletion of the PNG at position N386 resulted in the loss of the 4 292 bp 
band with the concomitant appearance of a 2 702 bp and 1 600 bp band (Figure 4.5) instead 
of the expected 2 237 bp and 2 055 bp bands (Figure 4.4). Once again incomplete digestion 
could not explain the difference between expected and observed DNA banding patterns. 
 
A restriction enzyme digestion of the CAP239 WT chronic infection env clone with Acl I 
generated DNA fragments with the molecular weight of 7 745 bp and 373 bp. The deletion 
of the PNG at position N392 resulted in the loss of the 7 745 bp band with the concomitant 
appearance of a 5 145 bp and 2 600 bp band (Figure 4.5), confirming that the observed 
banding pattern matched that of the expected band sizes (Figure 4.4).  
 
The digestion of the CAP239 WT T/F and chronic infection double mutants with both BsaW I 
and Acl I generated the same banding patterns as their respective single mutants (Figure 
4.5) but as restriction enzyme digestion did not confirm that SDM was successful for CAP239 
WT T/F env clone and in order to confirm that spurious mutations were not introduced 
during PCR, all the putative PNG mutants were sequenced from the start to the stop codon 
of Env using a set of nine primers (Appendix A.2). The raw sequencing data was analysed 
using ChromasPro version 1.5 (http://www.technelysium.com.au/ChromasPro.html) and 
aligned to WT sequences using BioEdit Sequence Alignment Editor version 7.0.9 (Hall 1999) 
and the ClustalW multiple sequence alignment algorithm (Larkin et al. 2007). 
 
Sequence analysis confirmed that the glutamines at positions N386 and N392 were 
successfully introduced together with the silent restriction enzyme sites (Figure 4.6A). 
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Sequencing confirmed that mutagenesis did not result in the introduction of any spurious 
PCR-derived mutations as mutants were identical to the WT clonal sequences except where 
the intentional mutations were introduced. Therefore, the N-glycan Env mutants only 
differed from WT due to the absence of a single or double PNG (Figure 4.6B).  
 
 
Figure 4.6 Sequence alignment of the N-glycan env mutants relative to wild-type confirm deletion of PNGs A) 
DNA sequences of wild-type (WT) CAP239_E11 T/F and WT CAP239_T35 chronic infection (C) env clones were 
obtained from P. Moore, (NICD, South Africa) and were aligned to N-glycan mutant sequences using ClustalW. 
Identical nucleotides are indicated by dots. The codons for N386 and N392 are outlined by a rectangular box. 
AAT codes for an asparagine and is replaced by a CAG which codes for a glutamine in the respective mutants. 
The BSaW l restriction enzyme site (CGGT) inserted in the N386Q mutants is underlined in red and the Acl l 
restriction enzyme site (AACG) in the N392Q mutants are indicated in blue. Both double mutants (T/F 
N386Q,N392Q and C N386Q,N392Q) have both asparagine (AAT) to glutamine (CAG) mutations and carry both 
restriction enzyme sites B) Protein sequence alignment of the N-glycan mutants compared with WT env clones. 
The asparagine (N) to glutamine (Q) amino acid changes are outlined by a rectangular box at positions N386 
and N392. 
 
4.2.3 Entry efficiency of N-glycan mutants 
 
The deletion of one or two N-glycans on gp120 can impact the overall conformation of Env 
thereby affecting its function (Eggink et al. 2010; Fenouillet & Jones 1995; Fenouillet et al. 
1989; Land et al. 2003; Montefiori et al. 1988; Pal et al. 1989) and the entry efficiency of the 
virus (Liao et al. 2011). In order to ensure that the loss of either PNG had no effect on the 
entry efficiency of the N-glycan mutants relative to WT, the entry efficiency of the WT 
clones and the N-glycan mutants were compared. Pseudovirus, normalised on p24 was used 
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to infect TZM-bl cells and the level of TZM-bl cell-associated luciferase activity indicated 
entry efficiency of each virus (Figure 4.7). 
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Figure 4.7 The entry efficiency of N-glycan mutants differ when compared with wild-type. Single (N386Q and 
N392Q) and double (N386Q,N392Q) T/F and chronic infection (C) CAP239 N-glycan mutants were tested for 
entry efficiency. The level of entry efficiency was determined as a percentage of wild-type (WT) and error bars 
represent standard deviation. This data represents an average of two independent experiments performed in 
triplicate. 
 
The T/F N392Q mutant was the only N-glycan mutant that maintained similar entry 
efficiency to that of its respective WT Env clone. The other N-glycan mutants demonstrated 
a significant reduction in entry efficiency compared with WT (range: 75%-98% reduction) 
(Figure 4.7). Of the five N-glycan mutants with reduced entry efficiency compared with WT, 
one (chronic infection N392Q) was termed non-functional with this amount of input virus as 
RLU readings were only 1.5-fold higher than background (results not shown). The other four 
N-glycan mutants had RLU readings 14- to 156-fold higher than background (results not 
shown) and were thus above the 2-fold cut-off (Fouda et al. 2013). 
 
4.2.4 Trans-infection of N-glycan mutants 
 
In order to determine whether the loss of PNGs at positions N386 and N392 impacts the 
trans-infection of Env clones of T/F and chronic infection variants, pseudovirus carrying the 
N-glycan Env mutants were bound to Raji-DC-SIGN cells and then added to TZM-bl cells and 
luminescence, as a marker for infection, was measured (Figure 4.8A). As a result of the 
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reduction in the entry efficiency of the N-glycan Env mutants, the DC-SIGN mediated trans-
infection assay data was also normalised on the entry efficiency of the Env clones (Figure 
4.8B).  
 
Figure 4.8 Deletion of PNGs at N386 and N392 reduced DC-SIGN mediated trans-infection when compared 
with WT. Single (N386Q and N392Q) and double (N386Q,N392Q) T/F and chronic infection (C) CAP239 N-
glycan mutants were tested for DC-SIGN mediated trans-infection. The level of trans-infection was determined 
as a percentage of WT and error bars indicate standard deviation A) Trans-infection data was not normalised 
on the entry efficiency of each mutant B) Trans-infection data was normalised on the entry efficiency of each 
mutant. This data represents an average of two independent experiments performed in triplicate. 
 
When the cell-associated luciferase activity values were not normalised on entry efficiency, 
all the T/F and chronic infection single and double N-glycan mutants demonstrated 
reductions in HIV transfer from DC-SIGN expressing cells to CD4+ cells (Figure 4.8A). The 
chronic infection N392 N-glycan mutant had the lowest trans-infection values (1-fold above 
Raji-WT control cells), indicating that this clone was unlikely transferred to CD4+ T cells as it 
was non-functional.  
 
When cell-associated luciferase activity values were normalised on entry efficiency, the DC-
SIGN mediated trans-infection of the T/F and chronic infection single N-glycan mutants 
(N386Q and N392Q) were no longer reduced while the double N-glycan mutants 
(N386Q,N392Q) remained unchanged, suggesting that the removal of both PNGs abrogated 
transfer to CD4+ cells. The chronic infection N392 N-glycan mutant had an apparent 
increase in trans-infection when the data was normalised on entry efficiency similar to WT 
(Figure 4.8B), but this was likely due to the poor entry efficiency of this clone inflating the 
result. 
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4.2.5 DC-SIGN binding of N-glycan mutants 
 
Virus that binds DC-SIGN more efficiently is expected to be transferred more effectively to 
CD4+ cells (Parrish et al. 2013) and so a DC-SIGN binding assay was performed. Pseudovirus 
carrying the N-glycan mutants and their corresponding WT clones, normalised on p24 
concentration was added to Raji cells expressing DC-SIGN and the amount of bound virus 
was measured by a p24 ELISA.   
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Figure 4.9 Some of the N-glycan mutants have reduced binding to DC-SIGN compared with wild-type A) 
Single (N386Q and N392Q) and double (N386Q,N392Q) T/F and chronic infection (C) CAP239 mutants were 
tested for DC-SIGN binding using Raji-wild-type (WT) and Raji-DC-SIGN cells. The level of DC-SIGN binding of 
the N-glycan mutants was determined as a percentage of WT and error bars represent standard deviation. This 
data represents an average of two independent experiments performed in triplicate. 
 
Deletion of the PNG at position N392 of the chronic infection Env clone resulted in the 
greatest reduction in DC-SIGN binding, confirming that the loss of the PNG most likely 
altered Env conformation. Therefore, taken together this data suggests that removal of the 
PNG at position N392 rendered the chronic infection CAP239 N-glycan mutant non-
functional. The T/F and chronic infection double N-glycan mutants (N386Q,N392Q) 
demonstrated reductions in DC-SIGN binding compared with WT while the single N-glycan 
mutants demonstrated no differences (Figure 4.9). These results supported the normalised 
trans-infection data (Figure 4.8 B). 
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4.3 Discussion 
 
It is well established that binding to DC-SIGN is mediated by oligomannose type N-glycans 
on the surface of gp120 (Geijtenbeek et al. 2002; Geijtenbeek, Kwon, et al. 2000) and it was 
recently shown that subtype B and C T/F viruses are enriched with oligomannose type N-
glycans (Go et al. 2011). Therefore, dendritic cells expressing DC-SIGN could bind HIV within 
the genital tract and migrate to the lymph nodes where HIV could be transferred to CD4+ T 
cells via trans-infection (Curtis et al. 1992; Geijtenbeek, Torensma, et al. 2000; Lee et al. 
2001). Therefore, DC-SIGN may bind oligomannose type N-glycans on the surface of T/F 
viruses in the genital mucosa and facilitate the selective transmission, dissemination and 
expansion of these variants.  
 
In order to determine whether pseudovirus carrying the Env of T/F variants are transferred 
to CD4+ cells more efficiently than those carrying Env clones from chronic infection variants, 
five subtype C T/F and chronic infection matched env clones were compared in trans-
infection and DC-SIGN binding assays. 
 
Wilen et al. (2011) demonstrated that there was no difference in DC-SIGN mediated trans-
infection of 24 subtype B T/F and chronic infection variants while Parrish et al. (2013) 
demonstrated that subtype B (but not C) T/F variants displayed greater DC-SIGN mediated 
trans-infection compared with chronic infection variants. King et al. (2013) demonstrated 
that chronic infection variants displayed greater DC-SIGN mediated trans-infection than T/F 
variants whereas Borggren et al. (2008) showed that chronic infection variants displayed 
greater DC-SIGN mediated trans-infection than end-stage (AIDS) HIV variants.  
 
The conflicting results thus far could be due to differences in study design with some groups 
comparing IMC (Parrish et al. 2013), and others pseudovirus (Wilen et al. 2011; Borggren et 
al. 2008), or generating pseudovirus from PBMC (Borggren et al. 2008) or engineered cell 
lines (Wilen et al. 2011), or using DC-SIGN expressing primary cells (King et al. 2013) or 
stably transfected DC-SIGN cell lines (Borggren et al. 2008) for the trans-infection assay. 
Furthermore, these groups did not compare T/F and chronic infection variants from the 
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same participant and chronic infection ranged from 1 to 15 years (King et al. 2013; Wilen et 
al. 2011).  
 
We hypothesised that if T/F variants are dependent on DC-SIGN mediated trans-infection 
for successful transmission in the genital tract, they would be more easily transferred to 
CD4+ cells than the chronic infection variants. Raji-DC-SIGN cells used in the DC-SIGN 
mediated trans-infection assay were confirmed to express the DC-SIGN lectin (24%). Raji-WT 
control cells were shown not to express DC-SIGN and did not bind pseudovirus nor transfer 
pseudovirus to CD4+ cells compared with Raji cells expressing DC-SIGN, confirming the role 
of the lectin in gp120 binding and virus transfer. 
 
When the trans-infection of the Env clones were compared there was no trend between 
pseudoviruses carrying T/F and chronic infection Env clones, suggesting that T/F variants 
would not be preferentially transferred to CD4+ T cells compared to those found later in 
infection (Wilen et al. 2011). 
 
It is proposed that DC-SIGN mediated trans-infection is a two-step process in which DC-SIGN 
first binds to N-glycans on the surface of HIV, followed by the subsequent transfer of HIV to 
CD4+ T cells (Parrish et al. 2013). Assays used to measure trans-infection rely on the 
detection of infection of a reporter cell line, which can mask DC-SIGN reactivity, the actual 
role of DC-SIGN in the process. In order to investigate the efficacy of DC-SIGN reactivity of 
different Env clones many studies normalise trans-infection data on viral infectivity (Wilen 
et al. 2011; Borggren et al. 2008) or add equivalent TCID50 (median tissue culture infective 
dose) viral titres to dendritic cells (King et al. 2013) in order to take into account the impact 
that differences in Env entry efficiency could have on trans-infection results. Some studies 
however prefer to take into account the role that Env entry efficiency would have on DC-
SIGN mediated trans-infection as it more likely represents what happens in vivo (Parrish et 
al. 2013; Alexandre et al. 2012). We did not initially normalise our data on entry efficiency as 
we wanted to determine whether the poor trans-infection of certain clones could be due to 
poor infection of TZM-bl cells. 
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Previously in our laboratory it was shown that CAP177_A3, CAP45_H5 and CAP206_H1 had 
very low entry efficiency. As only pseudovirus equivalent to 100 ng p24 was tested for trans-
infection and unbound virus was removed before mixing with TZM-bl cells, the low trans-
infection of CAP177_A3 and CAP206_H1 is likely due to very low entry efficiency. However, 
CAP45_H5 Env clone had good trans-infection efficiency, suggesting that this clone might 
have enhanced reactivity with DC-SIGN that may rescue the low entry efficiency of this 
clone. Therefore, poor entry efficiency did not always translate into poor trans-infection. 
When trans-infection values were normalised on entry efficiency the T/F clones still did not 
have enhanced transfer compared to those from chronic infection, confirming that the 
transmitted founder variants did not have better DC-SIGN reactivity. 
 
One drawback to this study was the small sample size as this study focussed on only five 
participants. Furthermore, given the high genetic diversity at chronic infection, the selection 
of a single Env clone as a representative of the quasispecies has its limitations. Wilen et al. 
(2011) selected chronic infection clones randomly while Parrish et al. (2013) looked for 
clusters of recent clonal expansions identify an Env clone representative of chronic 
infection. Parker et al. (2012) selected certain chronic infection clones randomly and others 
from clusters of recent clonal expansions. Borggren et al. (2008) used seven matched 
participants similar to our five matched T/F and chronic infection participants. It is thus 
possible that wider sampling with an increased number of clones from chronic infection 
might reveal differences between T/F and chronic infection variants. However, although the 
sample size of this study was limited, selection of the clones was thorough and this 
approach is important to validate findings of larger, less detailed cohorts. 
 
In this study the chronic infection clones of each T/F-chronic infection pair were chosen 
based on identical N-glycan profiles compared with the consensus sequence, except for one 
of the chronic infection clones of CAP210. The two chronic infection CAP210 env clones 
performed similarly despite the one clone, CAP210_E1 having consensus N-glycosylation 
pattern with two amino acid mismatches and the other, CAP210_C7 differing by nine amino 
acids and one PNG compared to the consensus. This suggests that a single Env clone with an 
N-glycosylation profile identical to consensus might be sufficient when comparing DC-SIGN 
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binding and trans-infection although participants infected with viruses with higher diversity, 
additional clones might need to be tested.  
 
Hong et al. (2007) identified PNGs at positions N295, N386 and N392 of subtype B Envs that 
were involved in binding to DC-SIGN. As N295 was only found in the T/F clone of one study 
participant, CAP239, it is unlikely to be important in subtype C Env-DC-SIGN interactions. 
However, one or both PNGs at N386 and N392 were present in all five study participants 
suggesting that they might play an important role in subtype C gp120-DC-SIGN binding. 
Furthermore, recently, Go et al. (2011) determined that these sites carried oligomannose N-
glycans, carbohydrates shown to bind DC-SIGN (Geijtenbeek, Kwon, et al. 2000; 
Geijtenbeek, Torensma, et al. 2000). We therefore hypothesised that either one or both of 
these sites might play an important role in binding to DC-SIGN on dendritic cells. SDM was 
performed on the CAP239 T/F and chronic infection env clones to replace the NXS/T sequon 
with a QXS/T motif, thus preventing N-glycosylation at these sites. Sequence analysis 
indicated that the N-glycan Env mutants were identical to WT except for the asparagine to 
glutamine amino acid change. 
 
N-glycans are large, flexible molecules that project from the surface of the protein and 
move around in the extracellular space, fixed only at the point of attachment (an asparagine 
residue). An N-glycan adopts a final position based on steric, hydrophobic and hydrophilic 
interactions between neighbouring N-glycans and amino acid side chains (Petrescu et al. 
2004). The posttranslational removal of Env N-glycosylation by enzymatic treatment with 
glycosidases has shown no effect on the overall structure and function of Env (Fenouillet et 
al. 1990; Depetris et al. 2012) while the removal of Env N-glycosylation prior to protein 
processing has been shown to affect Env structure and function (Eggink et al. 2010; 
Fenouillet et al. 1989; Fenouillet & Jones 1995; Montefiori et al. 1988; Land et al. 2003; Pal 
et al. 1989). 
 
The entry efficiency of each N-glycan mutant was compared with its respective WT clone to 
determine whether the removal of one or both PNGs at position N386 and N392 affected 
the structure and function of the Env clone and therefore the infectivity of the 
corresponding pseudovirus. Hong et al. (2007) and van Montfort et al. (2011) showed no 
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differences in entry efficiency between WT and N-glycan mutants whereas Liao et al. (2011) 
showed that two N-glycan mutants had enhanced entry efficiency and one had reduced 
entry efficiency compared with WT. This study demonstrated a reduction in entry efficiency 
for all N-glycan mutants compared with WT, except for the T/F N392Q N-glycan mutant. 
While removal of the PNG at position N392 of the chronic infection clone resulted in loss of 
Env function, the entry efficiency of the T/F N392Q N-glycan mutant was not affected, 
suggesting that the effect of alterations in N-glycosylation are clone specific. Our results 
suggest that for 5/6 N-glycan mutants the structure and function of gp120 was altered when 
PNGs were deleted at positions N386 and N392. It has been shown that the N-glycan at 
position N386 is not essential for gp120 protein folding (Sanders et al. 2008) and therefore 
we anticipated that the removal of this PNG would not affect the entry efficiency of the 
pseudovirus. However, as the effect of PNG removal seems to be Env clone specific, 
functional dependence on certain N-glycans is likely due to overall differences in Env 
structure. 
 
To compare the N-glycan mutants to one another, the level of trans-infection was calculated 
relative to that of the WT Env clones. The loss of PNGs at positions N386 and N392 resulted 
in a reduction of trans-infection of both Env clones with the most marked reduction 
occurring when both sites were deleted. This suggests that these PNGs are important for 
DC-SIGN mediated trans-infection. In order to distinguish the extent to which DC-SIGN 
reactivity and Env entry efficiency might contribute to trans-infection, we normalised DC-
SIGN mediated trans-infection of Env clones with Env entry efficiency. Once the entry 
efficiency of the Env clones was taken into account, only the double mutants of both clones 
had reduced trans-infection, suggesting that the presence of one of these sites were 
required for interaction with DC-SIGN similar to WT levels. This result was corroborated 
when pseudovirus was tested for binding to DC-SIGN as only the double mutants had 
reduced binding compared to WT. The binding of the chronic infection N-glycan N392Q 
mutant to DC-SIGN although greatly reduced compared to WT, suggested that DC-SIGN 
might still bind to non-functional envelopes.  
 
Even though the loss of PNGs at either one or both sites lowered or abrogated the entry 
efficiency of the Env clones, the pseudovirus carrying these clones could still interact with 
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DC-SIGN and could be transferred to CD4+ cells if functional. In the case of functional single 
N-glycan mutants this suggested that although the structure of Env could no longer mediate 
entry as efficiently, this did not affect the ability of DC-SIGN to bind to gp120 and possibly 
transfer the virus to TZM-bl cells.  
 
Liao et al. (2011) observed that 5/7 single N-glycan mutants had similar DC-SIGN mediated 
trans-infection compared with WT while all three double N-glycan mutants and one triple N-
glycan mutant showed a reduction in DC-SIGN mediated trans-infection compared with WT. 
Similarly, when both PNGs at N386 and N392 were removed, there was a reduction in trans-
infection of the T/F and chronic infection mutants compared with their respective WT 
clones. This suggested that the presence of one of these sites could compensate for the 
absence of the other but when both are removed, trans-infection is reduced.  
 
The removal of a single N-glycan may be partially or completely masked by the presence of 
adjacent N-glycans while the removal of two or more N-glycans may produce more 
noticeable effects. The N-glycans at positions N386 and N392 are extremely close to one 
another and consequently the removal of one may be masked by the presence of the 
remaining so that differences in DC-SIGN mediated trans-infection are not detected. The 
reduction in DC-SIGN mediated trans-infection observed when both PNGs were removed 
suggests that our CAP239 WT clones carry N-glycans at positions N386 and N392 and are 
not only essential for Env function but also important for DC-SIGN binding. This suggestion is 
corroborated by the fact that all of the four other Env clones in this study have either one or 
both of these PNGs and Go et al. (2011) found that the PNGs at positions N386 and N392 
were conserved in the T/F env clones but not the chronic infection clones. Furthermore, 
when we analysed 103 unrelated subtype C sequences, the PNGs at positions N386 and 
N392 were conserved suggesting that these sites provide a replication or survival 
advantage.  
 
As it was determined that the PNGs at positions N386 and N392 carried oligomannose type 
N-glycans (Go et al. 2011) when pseudovirus was produced in HEK293T cells and we 
demonstrated that the deletion of both of these sites lowered DC-SIGN mediated trans-
infection when pseudovirus was generated in HEK293T cells then it is possible that 
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oligomannose type N-glycans could play an important role in HIV transmission. However Go 
et al. (2013) demonstrated that pseudovirus generated in CHO cells carry oligomannose N-
glycans at positions N386 and N392 while pseudovirus generated in HEK293T cells carry a 
combination of oligomannose and complex type N-glycans. Furthermore, DC-SIGN was 
shown to bind to complex N-glycans (Hong et al. 2007; Liao et al. 2011) in addition to 
oligomannose type N-glycans (Van`Montfort et al. 2011; Geijtenbeek, Kwon, et al. 2000; 
Geijtenbeek, Torensma, et al. 2000) and the PNG at position N386 contrary to Go et al. 
(2011) and consistent with Go et al. (2013) was demonstrated to carry a complex N-glycan 
(Liao et al. 2011). We can therefore not confidently assume, without mass spectrometry 
analysis, that our CAP239 WT T/F and chronic infection env clones carry oligomannose type 
N-glycans at N386 and N392 and therefore the reduction in DC-SIGN mediated trans-
infection was due to the removal of these types of N-glycans. 
  
Efficient binding between DC-SIGN and gp120 N-glycans should translate into enhanced DC-
SIGN mediated trans-infection of CD4+ cells (Borggren et al. 2008; Hong et al. 2007; Parrish 
et al. 2013). However van Montfort et al. (2011) and Alexandre et al. (2012) demonstrated 
that enhanced DC-SIGN binding does not correlate with enhanced DC-SIGN mediated trans-
infection of CD4+ cells. DC-SIGN binding of our N-glycan env mutants were tested and 
increased DC-SIGN mediated trans-infection normalised for Env entry efficiency was 
associated with increased DC-SIGN binding for all T/F and chronic infection N-glycan 
mutants with the exception of the chronic infection N392Q N-glycan mutant. The low entry 
efficiency of this mutant due to its lack of function inflated the normalised trans-infection 
data. The lack of correlation between DC-SIGN binding and trans-infection may be due to 
certain groups not normalising their trans-infection data (Alexandre et al. 2012) as Parrish et 
al. (2013) observed a correlation after normalisation although, care must be taken for clones 
with very low entry efficiency. 
 
Du et al. (2012) recently demonstrated that DC-SIGN binding and DC-SIGN mediated trans-
infection are directly correlated when using Raji-DC-SIGN expressing cells but not directly 
correlated when using immature monocyte-derived dendritic cells. Although DC-SIGN is the 
principle receptor involved in DC-SIGN mediated trans-infection of CD4+ cells (Alexandre et 
al. 2011; Balzarini et al. 2007), a number of complex interactions involving other receptor 
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ligand pairs and/or signalling molecules and pathways are likely to collectively orchestrate 
DC-SIGN mediated trans-infection of CD4+ T cells in vivo (Alexandre et al. 2011; 
Van`Montfort et al. 2011).  
 
Our assay utilised Raji cells expressing DC-SIGN as surrogate dendritic cells and TZM-bl cells 
expressing CD4, CCR5 and CXCR4 as surrogate CD4+ T cells. As we are only taking into 
account these specific receptors our assay may be missing as yet undiscovered key elements 
that are involved in DC-SIGN mediated trans-infection of CD4+ T cells in vivo. The direct 
correlation observed between DC-binding and DC-SIGN trans-infection (with exception of 
the chronic N392Q N-glycan mutant) is consistent with what Du et al. (2012) observed while 
using genetically engineered DC-SIGN expressing cells.  
 
Furthermore, Raji cells are a Burkitt’s lymphoma derived B cell line and a number of human 
B cell lines have shown to facilitate HIV transmission to CD4+ T cells (Bobardt et al. 2003; 
Jakubik et al. 2000; Moir et al. 2000). Although the use of Raji-DC-SIGN cells in DC-SIGN 
binding and DC-SIGN mediated trans-infection assays as an alternative for monocyte-
derived dendritic cells is well established (Geijtenbeek, Kwon, et al. 2000; Geijtenbeek, 
Torensma, et al. 2000; Geijtenbeek et al. 2002), the use of Raji cells may need to be re-
evaluated with respect to their B cell lineage.  
 
Upon N-glycan analysis of the CAP239 T/F and chronic infection env clones an equal number 
of PNGs were identified on both gp120 sequences however L. Shuping showed that the 
CAP239 WT T/F env clone treated with Endo H migrated further on a SDS-PAGE compared 
with the CAP239 WT chronic infection clone (unpublished data), suggesting that the T/F 
clone carries more oligomannose N-glycans than the chronic infection clone despite the 
equal number of PNGs. The reason there is no observable difference in DC-SIGN mediated 
trans-infection of T/F and chronic infection Env clones after the removal of two N-glycan 
sites comprising of the putative DC-SIGN binding site could be due to the fact that all chronic 
infection variants do not automatically lose the ability to be transferred to CD4+ cells by DC-
SIGN. Evolution over the course of infection most likely involves the random introduction of 
PNGs, some of which will abrogate DC-SIGN mediated trans-infection while others will have 
no impact.  
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Increasing the sample size and sampling at later time points might allow for the detection of 
variants that have DC-SIGN reactivity due to the accumulation of PNGS. This study has 
provided a detailed analysis of the trans-infection capacity of five paired subtype C Env 
clones and it has indicated that PNGs at positions N386 and N392 might be important for 
DC-SIGN interactions and further sampling might detect differences between T/F and 
chronic infection variants. 
 
4.4 Conclusion 
 
We hypothesised that T/F variants carry an optimum arrangement of oligomannose type N-
glycans if they are dependent on DC-SIGN mediated trans-infection for successful 
transmission in the genital tract. Five subtype C T/F and matched chronic infection Env 
clones demonstrated no difference in DC-SIGN mediated trans-infection of CD4+ cells 
consistent with previous findings. In order to determine whether PNGs at positions N386 
and N392 reported to carry oligomannose N-glycans influenced the DC-SIGN binding and 
DC-SIGN trans-infection of CD4+ cells, N-glycan mutants were generated. These mutations 
affected the ability of Env to mediate infection of TZM-bl cells, suggesting they play an 
important role in protein structure and function although the extent differed between 
clones. No difference in trans-infection was observed when only one of the PNGs was 
removed but the removal of both PNGs resulted in a reduction in DC-SIGN mediated trans-
infection when normalised for Env entry efficiency. The presence of one of the PNGs 
compensated for the absence of the other but when both were removed DC-SIGN mediated 
trans-infection was reduced. DC-SIGN binding correlated with DC-SIGN mediated trans-
infection with the exception of the single chronic infection N392Q N-glycan mutant that was 
non-functional. It can be concluded that the removal of both N-glycans at position N386 and 
N392 reduced DC-SIGN mediated trans-infection of CAP239 T/F and chronic infection env 
clones. 
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Chapter 5: Conclusion 
 
As T/F variants have distinct N-glycosylation patterns compared with chronic infection 
variants, this study suggested that T/F variants carry an optimum arrangement of N-glycans 
that enable interactions with α4β7 and DC-SIGN that are essential for successful 
transmission in the genital tract. The first objective of this study was to develop a reactivity 
assay to determine whether T/F env clones have a higher affinity for the α4β7 integrin than 
chronic infection controls. Due to experimental design error we utilised HeLa cells that 
endogenously express the α4β7 integrin to compare the binding and entry of pseudoviruses 
in the presence and absence of the Act-1 monoclonal antibody. Pseudovirus-HeLa cell 
interactions were not inhibited by Act-1, suggesting that α4β7 was not responsible for 
mediating these interactions, possibly due to the activation state of the integrin and/or the 
N-glycosylation profile of the Env clones. As we were not able to optimise the α4β7 
reactivity assay, we were not able to compare the binding of pseudovirus carrying T/F Env 
clones to that of the matched chronic infection controls and determine the role of Env N-
glycosylation in this process.  
 
The second objective was to determine whether T/F variants are preferentially transferred 
to CD4+ cells via the DC-SIGN CLR. There was no difference in DC-SIGN mediated trans-
infection of CD4+ cells of subtype C T/F and matched chronic infection env clones, although 
the small sample size could have influenced the outcome of the study.  
 
The third and final objective of this study was to determine whether the removal of PNGs, 
previously shown to carry oligomannose type N-glycans that interact with DC-SIGN affect 
the trans-infection of CD4+ cells. When N-glycan mutants were generated by deleting PNGs 
at positions N386 and N392, the entry efficiency and DC-SIGN binding of the mutants 
decreased in an Env clone specific manner, suggesting that N-glycans at the same site 
impact Env structure and function differently. When trans-infection data was normalised to 
entry efficiency there was no difference in trans-infection of the N-glycan mutants when 
only one of the PNGs was removed but the removal of both PNGs resulted in a reduction in 
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DC-SIGN mediated trans-infection. This would suggest that N-glycosylation at one site can 
compensate for the absence at another. However, as the removal of certain N-glycans 
affected Env entry efficiency, the presence and absence of PNGs could impact viral 
transmissibility as certain variants may not be able to replicate as well as others after 
transfer to CD4+ T cells.  
 
Future work could involve testing whether retinoic acid activates HeLa cell integrins and 
whether producing pseudovirus in CHO cells would be more beneficial than producing 
pseudovirus in HEK293T cells when testing α4β7 reactivity. The sample size will be 
expanded to include more chronic infection control clones in order to ensure sampling of all 
variants at this timepoint. The PNGs at positions N386 and N392 will also be deleted in 
additional Env clones and alternative N-glycans will be removed via site directed 
mutagenesis to determine whether these impact DC-SIGN interactions similar to that of the 
CAP239 Env. 
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Appendix 
 
A.1. Sequencing pTARGETTM_α4 and pCEP4_β7 
 
A.1.1 pTARGETTM_α4 
 
The pTARGETTM_α4 plasmid DNA was sequenced to confirm the presence of the entire α4 
cDNA inserted into the pTARGETTM vector in the correct orrientaton. 
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Sma I RE site        T7 F primer                                       ATG start codon of α4 cDNA  
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Figure A.1.1. Nucleotide sequence alignment demonstrates that the α4 cDNA was inserted into the 
pTARGETTM vector in the incorrect orrentation. The α4 cDNA nucleotide sequence (alpha4) 
(accesion number NP_034706) was aligned to a contig sequence (contig pTARGET_alpha4) 
generated by sequencing the pTARGETTM_α4 construct. The Sma I restriction enzyme site (RE), the 
T7 forward (T7 F) primer, the ATG start codon, the Xho I RE site and the TAA stop codon is indicated. 
Dots indicate 100% nucleotide matches. 
 
 
TAA stop codon of α4 cDNA 
Xho I RE site 
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Figure A.1.2. Protein sequence alignment confirms the α4 cDNA was inserted into the pTARGETTM 
vector in the incorrect orrientation. The α4 cDNA amino acid sequence (alpha4) (accesion number 
NP_034706) was aligned to a contig sequence (contig pTARGET_alpha4) generated by sequencing 
the pTARGETTM_α4 construct. A methionine (M) indicates the start codon and a * indicates the stop 
codon. Dots indicate 100% amino acid matches. 
 
A.1.2 pCEP4_β7 
 
The pCEP4_β7 plasmid DNA was sequenced to confirm the presence of the entire β7 cDNA 
in the pCEP4 vector. 
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ATG start codon of β7 cDNA            Transcriptional start 
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Figure A.1.3. Nucleotide sequence alignment confirms complete β7 cDNA in pCEP4 vector. The β7 
cDNA nucleotide sequence (beta7) (accesion number NP_000880) was aligned to a contig sequence 
(contig pCEP4_beta7) generated by sequencing the pCEP4_β7 construct. The transcriptional start, 
the ATG start codon and the TGA stop codon is indicated. Dots indicate 100% nucleotide matches. 
 
 
 
 
 
TGA stop codon of β7 cDNA 
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Figure A.1.4. Protein sequence alignment confirms complete β7 cDNA in pCEP4 vector. The β7 
cDNA amino acid sequence (beta7) (accesion number NP_000880) was aligned to a contig sequence 
(contig pCEP4_beta7) generated by sequencing the pCEP4_β7 construct. A methionine (M) indicates 
the start codon and a * indicates the stop codon. Dots indicate 100% amino acid matches. 
 
A.2. Sequencing the N-glycan Env mutants 
 
The entire envs of CAP239 T/F and chronic infection single and double N-glycan mutants 
were sequenced with a set of nine primers to ensure that mutagenesis was successful. A 
contig sequence was generated from sequence analysis and was aligned to either the WT 
CAP239 T/F or chronic infection env clone 
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Figure A.1.5. Sequence analysis confirms succesful site-directed mutagensis of the T/F N386Q 
single N-glycan mutant. The T/F WT sequence (239_E11) was aligned to a contig sequence 
(239_E11_N386Q) generated by sequencing the entire env of the T/F N386Q single N-glycan mutant 
A) Nucleotide sequence analysis shows an adenine (A) to cytosine (C) and a thymine (T) to guanine 
(G) mismatch indicating an asparagine (AAT) to glutamine (CAG) mutation. An adenine (A) to 
cytosine (C) and a cytosine (C) to a thymine (T) mismatch indicates the insertion of a BsaW I 
restriction enzyme site (CCGGT) B) Amino acid sequence analysis shows an asparagine (N) to 
glutamine (Q) mismatch indicating an NTS (PNG) to a QST (no PNG) sequon mutation. The BsaW I 
restriction enzyme site is silent as no other mismatches are present. A * indicates a stop codon and 
dots indicate 100% nucleotide/amino acid matches. 
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',"_"'_I'Im<> 
I I I I I I I I I I I I I I I I I I I I 
,,"_,, , C TGGC TGTGGT A T A T A A A A A T A T TC A T A A TG A T A GT A GG A GGT T TG A T A GGT T T A A G A A T A A T T T T TGC TGTGC T T TC T A T A A T A A A T A GGGT T A GGC A G 
',"_"'_I'Im<> 
I I I I I I I I I I I I I I I I I I I I 
,,"_,, , GG A T A C TC A CC T T TGTC A T T TC A G A TCC T TA CCCC A A A CCCG A GGGG A CCCG A C A GGC TCGG A A G A A TCG A A G A A G A A GGTGG A G A GC A A G A C A G A G A C A 
',"_"'_I'Im<> 
I I I I I I I I I I I I I I I I I I I I 
,,"_,, , G A TCC A T TCG A T T A GTG A A CGG A T TC T T A GCGC T TGCC TGGG A CG A CC TGCGG A GCC TGTGCC T T T TC A GC T A CC A CC A A T TG A G A G A C T TC A T A T TG A T 
',"_"'_I'Im<> 
I I I I I I I I I I I I I I I I I I I I 
,,"_,, , TGC A GTG A G A GC A GTGG A A C T TC TGGG A CGC A GCC T TC TC A GGGG A C T A C A G A GGGGGTGGG A A A TCC T T A A GT A TC TGGG A A A TC T TGTGC A A T A T TGG 
',"_"'_I'Im<> 
I I I I I I I I I I I I I I I I I I I I 
,,"_,, , GG A TC A G A GC T A A A A A A G A GTGC T A T TC A TC TGC T TG A T A CC A T A GC A A T A GC A GT A GC TGG A GG A GC A G A T A GG A T T A T A G A C T T A C T A C T A A G A A T T T 
',"_"'_I'Im<> 
''"-'" 
',"_"'_I'Im<> 
''"-'" 
I I I I I I I I I I I I 
GT A G A GC T A TC T A C A GC A T A CC T A G A A G A A T A A G A C A GGGC T T TG A A GC A GC T T TGC A A T A A _ 
',"_"'_I'Im<> GGCC T A A TGT A A G A G A A A G A A TG A G A CG A GC T A GTCC A GC A GC A G A A GG A GT A GG A GC A GCGTC TCG A G A T T T A G A T A G A C A TGGGGC A C T T A C A A CC A G 
''"-'" ',"_"'_I'Im<> C A A C A C A GCCC A C A A T A A TGC TG A T TGTGCC TGGC TGG A A GC A C A A G A GG A GG A A G A A GT A GGC T T TCC A GTC A G A CC TC A GGTGCC T T T A A G A CC A A TG 
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Figure A.1.6. Sequence analysis confirms succesful site-directed mutagensis of the T/F N392Q 
single N-glycan mutant. The T/F WT sequence (239_E11) was aligned to a contig sequence 
(239_E11_N392Q) generated by sequencing the entire env of the T/F N392Q single N-glycan mutant 
A) Nucleotide sequence analysis shows an adenine (A) to cytosine (C) and a thymine (T) to guanine 
(G) mismatch indicating an asparagine (AAT) to glutamine (CAG) mutation. An thymine (T) to an 
adenine (A) and an adenine (A) to guanine (G) mismatch indicates the insertion of a Acl I restriction 
enzyme site (AACGTT) B) Amino acid sequence analysis shows an asparagine (N) to glutamine (Q) 
mismatch indicating an NTS (PNG) to a QST (no PNG) sequon mutation. The Acl I restriction enzyme 
site is silent as no other mismatches are present. A * indicates a stop codon and dots indicate 100% 
nucleotide/amino acid matches. 
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• a _ • • • ~ • • _ 
I I I I I I I I I I I I I I I I I I I I 
A TG A G A GTG A GGGGG A C A C A G A GG A A T T A TCC A C A A TGGTGG A T A TGGGGC A TC T T A GGC T T T TGG A TGT T A A TG A T T TGT A A T A C A A GGGGC T TGTGGG 
I I I I I I I I I I I I I I I I I I I I 
TC A C A GTC T A T T A TGGGGT A CC A GT A TGG A A A G A TGC A A A A GC T A C T T T A T TC TGTGC A TC A G A TGC T A A A GC A T A TG A T A G A G A A GTGC A T A A TGT T G 
I I I I I I I I I I I I I I I I I I I I 
GGC T A C A C A TGCC TGTGT A CCC A C A G ' TCCC A A TCC A C A A G A A A TG A TGT TGGG A A A TGT A A C A G A G A A A T T T A A C A TGTGG A A A A A TG A C A TGGTGG A C 
I I I I I I I I I I I I I I I I I I I I 
C A G A TGC A T A A A G A T A T A A TC A GT T H TGGG A TC A A A GCC TC A A GCC A TGTGT A A A GT TG A CCCC A C TC TGTGTC A C T T T A A A C TGT A GT A C A A A T A T A 
I I I I I I I I I I I I I I I I I I I I 
C A A A GGC T A A TGT T A C A A GTG A A G A A' TG A G A A GT TGC TC T T TC A A T A T A A CC A C A G A A T T A A G A G A T A A G A A A C A G A A A GT A A A TGC A C T T T T T T A T AA 
I I I I I I I I I I I I I I I I I I I I 
A C T TG A T A T A GT A CC A A T T A A TG A G A GT TC T A GT TC T A GTG A GT A T A G A T TG A T A A A T TGT A A T A CC TC A GTC A T A A C A C A A GCC TGTCC A A A GGT A A C T 
I I I I I I I I I I I I I I I I I I I I 
T T TG A TCC A A T TCC T A T A C A T T A T TGTGC TCC A GC TGGT T A TGCG A T TC T A A A GTGT A A T A A T A A G A C A T TC A A TGG A GC A GG A CC A TGC A C T A A TGTC A 
I I I I I I I I I I I I I I I I I I I I 
GC A C A GT A C A A TGT A C A C A TGG A A T T H GCC A GTGGT A TC A A C TC A A C T A C TGT T A A A TGGT A GCC T A GC A G A A G A GG A T A T A A T A A T T A G A TC TC A A AA 
I I I I I I I I I I I I I I I I I I I I 
T A T A T T A G A C A A T A CC A A A A C A A T A A T A GT A C A TC TC A A GG A A GC TGT A G A G A T T A A C TGT A C A A G A CCC A A C A A T A A T A C A A GG A A A A GT A T A A G A A - A 
I I I I I I I I I I I I I I I I I I I I 
GG A CC A GG A C A A GC A T TC T A TGC A A C ' GG A G A C A T A A T A GG A A A T A T A A G A C A A GC A C A T TGT A A C A TC A GTG A A A G A A A A TGG A A TG A A A C T T T A C A AA 
I I I I I I I I I I I I I I I I I I I I 
GGGT A GGTG A C A A A T T A A G A A A A C A CT TCC T T A A T A A A A C A A T A A T A T T TGC A CC A GCC TC A GG A GGGG A CC T A G A G A T T A C A A C A C A T A TC T T T A A T - G 
I I I I I I I I I I I I I I I I I I I I 
T A G A GG A G A A T T T T TC T A T TGC A A T A CA TC A GGCC TGT T T A A TGGT A C A T T T A A TGGT A C A T A T A C A A A T A GT A C A A A T A GT A C T TC A A A TGC A A CC A - C 
I I I I I I I I I I I I I I I I I I I I 
A C A C TCCC A TGT A A A A T A A A A C A A A TT A T A A A C A TGTGGC A GG A GGT A GG A A G A GC A A TGT A TGCCCC TCCC A T TGC A GG A A A C A T A A C A TGT A A A TC AA 
I I I I I I I I I I I I I I I I I I I I 
A T A TC A C A GG A T TGC TC T TG A C A TGGG A TGGTGG A G A C A GT A A GG A G A A T A A G A C A A GGC A T A A TG A G A C A T TC A G A CC TGG A GG A GG A G A T A TG A G AGA 
I I I I I I I I I I I I I I I I I I I I 
T A A T TGG A G A A GTG A A T T A T A T A A A H T A A A GTGGT A G A A A T T A A GCC A T T A GG A GT A GC A CCC A C TG A TGC A A A A A GG A G A GTGGTGG A G A G A G A G A AA 
I I I I I I I I I I I I I I I I I I I I 
A G A GC A GTGGG A C T A GG A GC TGTGT TCC T TGGGT TC T TGGG A GCGGC A GG A A GC A C T A TGGGCGCGGCGTC A A T A A CGC TG A CGGT A C A GGCC A G A C A A T 
I I I I I I I I I I I I I I I I I I I I 
T A T TGTC TGGT A T A GTGC A A C A GC A A' GC A A T T TGC TG A GGGC T A T A G A GGCGC A A C A GC A T A TGT TGC A A C TC A C A GTC TGGGGC A T T A A GC A GC TCC A 
I I I I I I I I I I I I I I I I I I I I 
GGC A A G A GTCC TGGCC A T A G A A A G A H CC T A A A GG A TC A A C A GC TCC T A GG A A TGTGGGGC TGC TC TGG A A A A C TC A TC TGC A CC A C TGC TGTGTC T TGG 
I I I I I I I I I I I I I I I I I I I I 
A A C A C T A GT TGG A GT A A T A A A A C TC H GCGG A G A T T TGGG A T A A C A TG A CC TGG A TGG A GTGGG A T A G A G A A A T T A GT A A T T A C A C A A A C A C A A T A T A CC 
I I I I I I I I I I I I I I I I I I I I 
A GT TGC T TG A A G A A TC TC A A A A CC A GC A GG A A A A A A A TG A A A A GG A T T T A C T A GC A T TGG A C A GT TGG A A C A GTC TGTGG A A T TGGT T T A GC A T A A C A AA 
I I I I I I I I I I I I I I I I I I I I 
C TGGC TGTGGT A T A T A A A A A T A T TC A T A A TG A T A GT A GG A GGT T TG A T A GGT T T A A G A A T A A T T T T TGC TGTGC T T TC T A T A A T A A A T A GGGT T A GGC A G 
I I I I I I I I I I I I I I I I I I I I 
GG A T A C TC A CC T T TGTC A T T TC A G A TCC T T A CCCC A A A CCCG A GGGG A CCCG A C A GGC TCGG A A G A A TCG A A G A A G A A GGTGG A G A GC A A G A C A G A G A CA 
I I I I I I I I I I I I I I I I I I I I 
G A TCC A T TCG A T T A GTG A A CGG A T TCT T A GCGC T TGCC TGGG A CG A CC TGCGG A GCC TGTGCC T T T TC A GC T A CC A CC A A T TG A G A G A C T TC A T A T TG A T 
I I I I I I I I I I I I I I I I I I I I 
TGC A GTG A G A GC A GTGG A A C T TC TGGG A CGC A GCC T TC TC A GGGG A C T A C A G A GGGGGTGGG A A A TCC T T A A GT A TC TGGG A A A TC T TGTGC A A T A T TGG 
I I I I I I I I I I I I I I I I I I I I 
GG A TC A G A GC T A A A A A A G A GTGC T A TTC A TC TGC T TG A T A CC A T A GC A A T A GC A GT A GC TGG A GG A GC A G A T A GG A T T A T A G A C T T A C T A C T A A G A A T - T 
I I I I I I I I I I I I 
GT A G A GC T A TC T A C A GC A T A CC T A G H G A A T A A G A C A GGGC T T TG A A GC A GC T T TGC A A T A A _ 
',"_"'_""",,,."m<> GGCC T A A TGT A A G A G A A A G A A TG A G A CG A GC T A GTCC A GC A GC A G A A GG A GT A GG A GC A GCGTC TCG A G A T T T A G A T A G A C A TGGGGC A C T T A C A A CC A G 
''"-'" ',"_"'_""",,,."m<> C A A C A C A GCCC A C A A T A A TGC TG A T TGTGCC TGGC TGG A A GC A C A A G A GG A GG A A G A A GT A GGC T T TCC A GTC A G A CC TC A GGTGCC T T T A A G A CC A A - G 
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Figure A.1.7. Sequence analysis confirms succesful site-directed mutagensis of the T/F 
N386,N392Q double N-glycan mutant. The T/f WT sequence (239_E11) was aligned to a contig 
sequence (239_E11_N386Q,N392Q) generated by sequencing the entire env of the chronic infection 
N386Q,N392Q double N-glycan mutant A) Nucleotide sequence analysis shows two adenine (A) to 
cytosine (C) and thymine (T) to guanine (G) mismatches indicating two asparagine (AAT) to 
glutamine (CAG) mutations. An adenine (A) to cytosine (C) and a cytosine (C) to thymine (T) 
mismatch indicates the insertion of a BsaW I restriction enzyme site (CCGGT). A thymine (T) to an 
adenine (A) and an adenine (A) to a guanine (G) mismatch indicates the insertion of an Acl I 
restriction enzyme site (AACGTT) B) Amino acid sequence analysis shows two asparagine (N) to 
glutamine (Q) mismatches indicating two NTS (PNG) to a QST (no PNG) sequon mutations. The BsaW 
I and Acl I restriction enzyme sites are silent as no other mismatches are present. A * indicates a stop 
codon and dots indicate 100% nucleotide/amino acid matches. 
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• a _ • • • ~ • • _ 
I I I I I I I I I I I I I I I I I I I I 
' ,"_T" A TG A G A GTG A GGGGG A C A C A G A GG A A T T A TCC A C A A TGGTGG A T A TGGGGC A TC T T A GGC T T T TGG A TGT T A A TG A T T TGT A A T A C A A GGGGC T TGTGGG 
',"_T"_'''.''" 
I I I I I I I I I I I I I I I I I I I I 
',"_T" TC A C A GTC T A T T A TGGGGT A CC A GT A TGG AA A G A TGC A A A A GC T A C T T T A T TC TGTGC A TC A G A TGC T A A A GC A T A TG A T A G A G A A GTGC A T A A TGT T TG 
',"_T"_'''.''" 
I I I I I I I I I I I I I I I I I I I I 
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',"_T" C A G A TGC A TG A A G A T A T A A TC A GT T T A TGGG A TC A A A GCC TC A A GCC A TGTGT A A A GT TG A CCCC A C TC TGTGTC A C T T T A A A C TGTGTC A GTGC A A A T A 
',"_T"_'''.''" 
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',"_T" T A T A G A T TG A T A A A T TGT A A T A CC TC A GTCA T A A C A C A A GCC TGTCC A A A GGT A A C T T T TG A TCC A A T TCC T A T A C A T T A T TGTGC TCC A GC TGGT T A TG 
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',"_T" CG A T TC T A A A GTGT A A T A A T A A G A C A T TC AA TGG A A C A GG A CC A TGC A C T A A TGTC A GC A C A GT A C A A TGT A C A C A TGG A A T T A A GCC A GTGGT A TC A A C 
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',"_T" TC A A C T A C TGT T A A A TGGT A GCC T A GC A G AA G A GG A T A T A A T A A T T A G A TC TC A A A A T A T A TC A G A C A A T A CC A A A A C A A T A A T A GT A C A TC TC A A GG A A 
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',"_T" GC TGT A G A G A T T A GC TGT A C A A G A CCC A GCA A T A A T A C A A GG A A A A GT A T A A G A A T A GG A CC A GG A C A A GC A T TC T A TGC A A C A GG A GG A GT A A C A GG A A 
',"_T"_'''.''" 
I I I I I I I I I I I I I I I I I I I I 
',"_T" A T A T A A G A C A A GC A C A T TGT A GC A TC A GTGA A A G A A A A TGG A A TG A C A C T T T A C A A A A GGT A GGTG A C A A A T T A A G A A A A C A C T TCC T T A A T A A A A C A A T 
',"_T"_'''.''" 
I I I I I I I I I I I I I I I I I I I I 
',"_T" A A T A T T TGC A CC A GCC TC A GG A GGGG A CC TA G A G A T T A C A A C A C A T A TC T T T A A T TGT A G A GG A G A A T T T T TC T A T TGC A A T A C A TC A GGCC TGT T T A A T 
',"_T"_'''.''" 
I I I I I I I I I I I I I I I I I I I I 
',"_T" GGT A C A T T T A A TGGT A C A C A T A C A A A T A GT A C T TC A A A TGC A A CC A TC A C A C TCCC A TGC A A A A T A A A A C A A A T T A T A A A C A TGTGGC A GG A GGT A GG A A 
',"_T"_'''.''" 
I I I I I I I I I I I I I I I I I I I I 
',"_T" G A GC A A TGT A TGCCCC TCCC A T TGC A GG A AA C A T A A C A TGTC A A TC A A A T A TC A C A GG A T TGC TC T TG A C A TGGG A TGGTGG A G A C A T T A A TC A G A C A A G 
',"_T"_'''.''" 
I I I I I I I I I I I I I I I I I I I I 
',"_T" GC A T A A TG A G A C A T TC A G A CC TGG A GG A GGA G A T A TG A G A G A T A A T TGG A G A A GTG A A T T A T A T A A A T A T A A A GTGGT A G A A A T T A A GCC A T T A GG A GT A 
',"_T"_'''.''" 
I I I I I I I I I I I I I I I I I I I I 
',"_T" GC A CCC A C TG A TGC A A A A A GG A G A GTGGTGG A G A G A G A G A A A A G A GC A GTGGG A C T A GG A GC TGTGT TCC T TGGGT T T T TGGG A GCGGC A GG A A GC A C T A 
',"_T"_'''.''" 
I I I I I I I I I I I I I I I I I I I I 
',"_T" TGGGCGCGGCGTC A A T A A CGC TG A CGGT A CA GGCC A G A C A A T T A T TGTC TGGT A T A GTGC A A C A GC A A A GC A A T T TGC TG A GGGC T A T A G A GGCGC A A C A 
',"_T"_'''.''" 
I I I I I I I I I I I I I I I I I I I I 
',"_T" GC A T A TGT TGC A A C TC A C A GTC TGGGGC A TT A A GC A GC TCC A GGC A A G A GTCC TGGCC A T A G A A A G A T A CC T A A A GG A TC A A C A GC TCC T A GG A A TGTGG 
',"_T"_'''.''" 
I I I I I I I I I I I I I I I I I I I I 
',"_T" GGC TGC TC TGG A A A A C TC A TC TGC A CC A C TGC TGTGTCC TGG A A C A C T A GT TGG A GT A A T A A A A C TC A A GCGG A G A T T TGGG A T A A C A TG A CC TGG A TGG 
',"_T"_'''.''" 
I I I I I I I I I I I I I I I I I I I I 
',"_T" A GTGGG A T A G A G A A A T T A GT A A T T A C A C A AA C A T A A T A T A CC A GT TGC T TG A A G A A TC TC A A A A CC A GC A GG A A A A A A A TG A A A A GG A T T T A C T A GC A T T 
',"_T"_'''.''" 
I I I I I I I I I I I I I I I I I I I I 
',"_T" GG A C A GT TGG A A C A GTC TGTGG A A T TGGT TT A GC A T A A C A A A A TGGC TGTGGT A T A T A A A A A T A T TC A T A A TG A T A GT A GG A GGT T TG A T A GGT T T A A G A 
',"_T"_'''.''" 
I I I I I I I I I I I I I I I I I I I I 
',"_T" A T A A T T T T TGC TGTGC T T T C T A T A A T A A A TA GGGT T A GGC A GGG A T A C T C A CC T T TGTC A T T TC A G A TC CC T A CCCC A A A CCCG A GGGG A CCCG A C A GGC 
',"_T"_'''.''" 
I I I I I I I I I I I I I I I I I I I I 
',"_T" TCGG A A G A A TCG A A G A A G A A GGTGG A G A GCA A G A C A G A G A C A G A TCC A T TCG A T T A GTG A A CGG A T TC T T A GCGC T TGCC TGGG A CG A CC T A CGG A GCC T 
',"_T"_'''.''" 
I I I I I I I I I I I I I I I I I I I I 
',"_T" GTGCC T T T TC A GC T A CC A CC A A T TG A G A G A C T TC A T A T TG A T TGC A GTG A G A GC A GTGG A A C T T C TGGG A CGC A GCC T TC TC A GGGG A C T A C A G A GGGGG 
',"_T"_'''.''" 
I I I I I I I I I I I I I I I I I I I I 
',"_T" TGGG A A A TCC T T A A GT A TC TGGG A A A TC T TGT A C A A T A T TGGGG A TC A G A GC T A A A A A GG A GTGC T A T T C A TC TGC T TG A T A CC A T A GC A A T A GC A GT A G 
',"_T"_'''.''" 
I I I I I I I I I I I I I I I I I I I I 
',"_T" C TGG A GG A A C A G A T A GG A T T A T A G A CGT A CT A C T A A G A A T T TGT A G A GC T A TC T A C TGC A T A CC T A G A A G A A T A A G A C A GGGC T T TG A A A C A GC T T TGC A 
',"_T"_'''.''" 
',"_T" 
',"_T"_'''.''" 
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Figure A.1.8. Sequence analysis confirms succesful site-directed mutagensis of the chronic 
infection N386Q single N-glycan mutant. The chronic infection WT sequence (239_T35) was aligned 
to a contig sequence (239_T35_N386Q) generated by sequencing the entire env of the chronic 
infection N386Q single N-glycan mutant A) Nucleotide sequence analysis shows an adenine (A) to 
cytosine (C) and a thymine (T) to guanine (G) mismatch indicating an asparagine (AAT) to glutamine 
(CAG) mutation. An adenine (A) to cytosine (C) and a cytosine (C) to a thymine (T) mismatch 
indicates the insertion of a BsaW I restriction enzyme site (CCGGT) B) Amino acid sequence analysis 
shows an asparagine (N) to glutamine (Q) mismatch indicating an NTS (PNG) to a QST (no PNG) 
sequon mutation. The BsaW I restriction enzyme site is silent as no other mismatches are present. A 
* indicates a stop codon and dots indicate 100% nucleotide/amino acid matches. 
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Figure A.1.9. Sequence analysis confirms succesful site-directed mutagensis of the chronic 
infection N392Q single N-glycan mutant. The chronic infection WT sequence (239_T35) was aligned 
to a contig sequence (239_T35_N392Q) generated by sequencing the entire env of the chronic 
infection N392Q single N-glycan mutant A) Nucleotide sequence analysis shows an adenine (A) to 
cytosine (C) and a thymine (T) to guanine (G) mismatch indicating an asparagine (AAT) to glutamine 
(CAG) mutation. A thymine (T) to an adenine (A) and an adenine (A) to a guanine (G) mismatch 
indicates the insertion of an Acl I restriction enzyme site (AACGTT) B) Amino acid sequence analysis 
shows an asparagine (N) to glutamine (Q) mismatch indicating an NTS (PNG) to a QST (no PNG) 
sequon mutation. The Acl I restriction enzyme site is silent as no other mismatches are present. A * 
indicates a stop codon and dots indicate 100% nucleotide/amino acid matches. 
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Figure A.1.10. Sequence analysis confirms succesful site-directed mutagensis of the chronic 
infection N386,N392Q double N-glycan mutant. The chronic infection WT sequence (239_T35) was 
aligned to a contig sequence (239_T35_N386Q,N392Q) generated by sequencing the entire env of 
the chronic infection N386Q,N392Q double N-glycan mutant A) Nucleotide sequence analysis shows 
two adenine (A) to cytosine (C) and thymine (T) to guanine (G) mismatches indicating two asparagine 
(AAT) to glutamine (CAG) mutations. An adenine (A) to cytosine (C) and a cytosine (C) to thymine (T) 
mismatch indicates the insertion of a BsaW I restriction enzyme site (CCGGT). A thymine (T) to an 
adenine (A) and an adenine (A) to a guanine (G) mismatch indicates the insertion of an Acl I 
restriction enzyme site (AACGTT) B) Amino acid sequence analysis shows two asparagine (N) to 
glutamine (Q) mismatches indicating two NTS (PNG) to a QST (no PNG) sequon mutations. The BsaW 
I and Acl I restriction enzyme sites are silent as no other mismatches are present. A * indicates a stop 
codon and dots indicate 100% nucleotide/amino acid matches. 
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